About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
i
COLLOQUIUM ON PROTEOLYTIC PROCESSING AND PHYSIOLOGICAL REGULATION
NATIONAL ACADEMY OF SCIENCES WASHINGTON, D.C. 1999
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
ii
NATIONAL ACADEMY OF SCIENCES
Colloquium Series In 1991, the National Academy of Sciences inaugurated a series of scientific colloquia, five or six of which are scheduled each year under the guidance of the NAS Council’s Committee on Scientific Programs. Each colloquium addresses a scientific topic of broad and topical interest, cutting across two or more of the traditional disciplines. Typically two days long, colloquia are international in scope and bring together leading scientists in the field. Papers from colloquia are published in the Proceedings of the National Academy of Sciences (PNAS).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
PROTEOLYTIC PROCESSING AND PHYSIOLOGICAL REGULATION
Proteolytic Processing and Physiological Regulation
A COLLOQUIUM SPONSORED BY THE NATIONAL ACADEMY OF SCIENCES FEBRUARY 20–21, 1999 Saturday, February 20, 1999 Hans Neurath, University of Washington Welcome and introduction: Proteolytic enzymes, past and future David Agard, University of California, San Francisco Kinetic stability and folding of proteases: twin paradigms for protease pro regions Michael James, University of Alberta Structural basis and mechanism of zymogen activation David Matthews, Agouron Pharmaceuticals, Inc. Structure-assisted design of mechanism based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes Christopher Walsh, Harvard University Role of D, D-Peptidase in Vancomycin Resistance Earl Davie, University of Washington Introduction to Protease activated receptors Shaun Coughlin, University of California, San Francisco Thrombin signaling: Molecular mechanisms and roles in vivo Vishva Dixit, Genentech, Inc. Identification of components of the cell death pathway Wolfram Bode, Max-Planck-Institute for Biochemistry Structure of tryptase, a cage-like serine proteinase involved in asthma, allergic and inflammatory disorders Philip Beachy, Johns Hopkins University Hedgehog protein biogenesis and signaling Marc Kirschner, Harvard University The role of proteases in the regulation of cell cycle
iii
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
PROTEOLYTIC PROCESSING AND PHYSIOLOGICAL REGULATION
Sunday, February 21, 1999 C.S.Craik, University of California, San Francisco Introduction Arthur Horwich, Yale University Chaperone Rings in Protein Folding and Degradation Robert Huber, Max-Planck-Institute for Biochemistry Structure of the archaeal and yeast 20S proteasomes and of the eubacterial Analog HslV Sukanto Sinha, Athena Neurosciences Cellular mechanism of beta amyloid production and secretion Michael Brown, University of Texas Southwestern Medical Center A proteolytic system that controls cholesterol metabolism Michael Brown Introduction Charles Craik, University of California, San Francisco Reverse biochemistry-using protease inhibitors to dissect complex biochemical processes Christine Debouck, Smith-Kline and Beecham Pharmaceuticals From genomics to drugs—cathepsin K and osteoporosis James McKerrow, University of California, San Francisco Parasite proteases—windows on molecular evolution and targets for drug design Joshua Boger, Vertex Pharmaceuticals Recognizing a drug
iv
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
TABLE OF CONTENTS
v
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Table of Contents
Papers from a National Academy of Sciences Colloquium on Proteolytic Processing and Physiological Regulation
Proteolytic enzymes, past and future Hans Neurath
10962–10963
Caspase activation: The induced-proximity model Guy S.Salvesen and Vishva M.Dixit
10964–10967
Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors Amir R.Khan, Nina Khazanovich-Bernstein, Ernst M.Bergmann, and Michael N.G.James
10968–10975
The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study Michael Groll, Wolfgang Heinemeyer, Sibylle Jäger, Tobias Ullrich, Matthias Bochtler, Dieter H.Wolf, and Robert Huber
10976–10983
The structure of the human βII-tryptase tetramer: Fo(u)r better or worse Christian P.Sommerhoff, Wolfram Bode, Pedro J.B.Pereira, Milton T.Stubbs, Jörg Stürzebecher, Gerd P.Piechottka, Gabriele Matschiner, and Andreas Bergner
10984–10991
Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for Patched Naoyuki Fuse, Tapan Maiti, Baolin Wang, Jeffery A.Porter, Traci M.Tanaka Hall, Daniel J.Leahy, and Philip A.Beachy
10992–10999
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes D.A.Matthews, P.S.Dragovich, S.E.Webber, S.A.Fuhrman, A.K.Patick, L.S.Zalman, T.F.Hendrickson, R.A.Love, T.J.Prins, J.T.Marakovits, R.Zhou, J.Tikhe, C.E.Ford, J.W.Meador, R.A.Ferre, E.L.Brown, S.L.Binford, M.A.Brothers, D.M.DeLisle, and S.T.Worland
11000–11007
Kinetic stability as a mechanism for protease longevity Erin L.Cunningham, Sheila S.Jaswal, Julie L.Sohl, and David A.Agard
11008–11014
Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target Paul M.Selzer, Sabine Pingel, Ivy Hsieh, Bernhard Ugele, Victor J.Chan, Juan C.Engel, Matthew Bogyo, David G.Russell, Judy A.Sakanari, and James H.McKerrow
11015–11022
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
TABLE OF CONTENTS
vi
How the protease thrombin talks to cells Shaun R.Coughlin
11023–11027
VanX, a bacterial D-alanyl-D-alanine dipeptidase: Resistance, immunity, or survival function? Ivan A.D.Lessard and Christopher T.Walsh
11028–11032
Chaperone rings in protein folding and degradation Arthur L.Horwich, Eilika U.Weber-Ban, and Daniel Finley
11033–11040
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood Michael S.Brown and Joseph L.Goldstein
11041–11048
Cellular mechanisms of β-amyloid production and secretion Sukanto Sinha and Ivan Lieberburg
11049–11053
Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue Toshihiko Takeuchi, Marc A.Shuman, and Charles S.Craik
11054–11061
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
NATIONAL ACADEMY OF SCIENCES COLLOQUIA
vii
National Academy of Sciences Colloquia
BOUND REPRINTS AVAILABLE In 1991, the National Academy of Sciences (NAS) inaugurated a series of scientific colloquia, several of which are held each year under the auspices of the NAS Coun cil Committee on Scientific Programs. These colloquia address scientific topics of broad and topical interest that cut across two or more traditional disciplines. Typically two days long, these colloquia are international in scope and bring together leading scientists in the field. Papers presented at these colloquia are published in the Proceedings of the National Academy of Sciences (PNAS) and are available online (www.pnas.org). Because they have generated much interest, these papers are now available in the form of collected bound reprints, which may be ordered through the National Academy Press. Currently available are: Carbon Dioxide and Climate Change ($11) Held November 13–15, 1995 (Irvine, CA) Computational Biomolecular Science ($16) Held September 12–13, 1997 (Irvine, CA) Earthquake Prediction ($16) Held February 10–11, 1995 (Irvine, CA) Elliptic Curves and Modular Forms ($7) Held March 15–17, 1996 (Washington, DC) Genetic Engineering of Viruses and Viral Vectors ($21) Held June 9–11, 1996 (Irvine, CA) Genetics and the Origin of Species ($8) Held January 31-February 1, 1997 (Irvine, CA) Geology, Mineralogy, and Human Welfare ($11) Held November 8–9, 1998 (Irvine, CA) Neurobiology of Pain ($8) Held December 11–13, 1998 (Irvine, CA) Neuroimaging of Human Brain Function ($17) Held May 29–31, 1997 (Irvine, CA) Plants and Population: Is There Time? ($8) Held December 5–6, 1998 (Irvine, CA) Protecting Our Food Supply: The Value of Plant Genome Initiatives ($13) Held May 29–31, 1997 (Irvine, CA) Science, Technology, and the Economy ($12) Held November 20–22, 1995 (Irvine, CA) The Age of the Universe, Dark Matter, and Structure Formation ($13) Held March 21–23, 1997 (Irvine, CA)
Papers from future colloquia will be available for purchase after they appear in PNAS. Shipping and Handling Charges: In the U.S. and Canada please add $4.50 for the first reprint ordered and $0.95 for each additional reprint. Ordering Information: Telephone orders will be accepted only when charged to VISA, MasterCard, or American Express accounts. To order, call toll-free 1–800–624–6242 or order online at www.nap.edu and receive a 20% discount.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
PROTEOLYTIC ENZYMES, PAST AND FUTURE
10962
Proteolytic enzymes, past and future
This paper is the introduction to the following papers, which were presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation,” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. HANS NEURATH* Department of Biochemistry, Box 357350, University of Washington, Seattle, WA 98195 ABSTRACT Today’s knowledge is based on yesterday’s research, which, for me, started some 60 years ago. In the introduction to this colloquium, the past history of proteolytic enzymes is briefly reviewed against the background of simultaneously developing concepts and methodologies in protein chemistry. This history is followed by a sketch of more recent developments of the role of proteolytic enzymes in physiological regulation and an outlook of future trends apparent from current research. The history of proteolytic enzymes is intimately interwoven with that of protein chemistry. In the very early days, proteolytic enzymes were considered an impediment that had to be removed in the isolation of proteins generally. When I entered the field some 60 years ago, Northrop, Kunitz, and Herriott (1) had published the first edition of their treatise Crystalline Enzymes and demonstrated that, contrary to some prevailing notions, the crystalline proteolytic enzymes and protease inhibitors that they had isolated were chemical entities of constant solubility and hence obeyed the thermodynamic criteria of pure compounds. These compounds included pepsinogen, pepsin, and pepsin inhibitor, chymotrypsin, trypsin, their zymogens and inhibitors, carboxypeptidase, ribonuclease, hexokinase, diphtheria antitoxin, and a few others. Because these proteins were commercially unavailable, anyone interested in studying them had to isolate them the hard way. The field lay relatively dormant and awaited the development of more effective and specific methods of isolation, purification, and characterization of proteins, which came some 20 years later, including the methods of chromatography, gel electrophoresis, gel filtration, ultracentrifugation, amino acid analysis, and protein sequencing (2). In an effort to avoid the complexity of protein substrates, low molecular-weight synthetic peptides and their ester analogs were synthesized and found to simulate the specificity requirements of these proteases. Other landmarks included the discovery of natural and synthetic protease inhibitors such as disopropylfluoro phosphate, which introduced an organic phosphate label into the active site of serine proteases. Chemical characterization of active sites together with x-ray structure analysis of proteases showed that they can be grouped into families of common mechanism, similar structural features, and hence common evolutionary origin. They included the well known families of serine, cysteine, aspartic, and metallo endo- and exopeptidases. The number of proteases under investigation in the early days is minuscule compared with the current inventory of several thousand proteolytic enzymes that are coded by 2% of the structural gene pool (3). Interest in proteases was considerably stimulated by the recognition that, aside from their digestive action, proteases are involved in the regulation of a great many physiological processes. In many cases, regulation is mediated by the association of proteases with nonproteolytic domains that confer specificity to their interaction with receptor sites. The most studied among them are the proteases involved in blood coagulation, fibrinolysis, the complement system, and the processing of protein hormone precursors by specific convertases. A telling case of such an association is enterokinase, a protease that fulfills the simple but specific task of cleaving the amino-terminal hexapeptide during the activation of trypsinogen. Although enterokinase was discovered more than 50 years ago, it was only recently that its x-ray structure was elucidated by cloning and expressing the heavy chain (4). Surprisingly, it was found to be composed of a trypsin-like catalytic domain covalently bound to a series of nonprotease domains that also exist in unrelated proteins. One of these resembles the low density lipoprotein receptor, another resembles meprin, a third occurs in complement C1r, and yet another occurs in a macrophage receptor. The functional significance of these specific combinations is unknown. The term “limited proteolysis” was coined by Linderstrom-Lang to differentiate the restricted specificity of certain enzymes under certain conditions from the random proteolysis accompanying protein degradation. Proteolytic processing can be limited by the specificity of the protease, the accessibility of the susceptible peptide bond of the substrate, the obligatory activation of an enzyme precursor, the action of protease inhibitors, or a combination of these factors. By far the best characterized and perhaps most versatile proteolytic enzymes are the serine proteases. Together with their inhibitors, they regulate a great variety of physiological events. Whereas initially the different specificities of trypsin and chymotrypsin were exclusively ascribed to differences in the sequence and structure of the primary substrate-binding site (aspartic acid in trypsin vs. serine in chymotrypsin), this simple explanation had to be abandoned when Craik and coworkers (5) demonstrated that, in addition, two surface loops are changed, indicating that conformational changes at distant secondary binding sites are also required. It has also been shown that the introduction of a metal binding site by site-directed mutagenesis allows the interconversion of a protease belonging to the serine family into another that can be regulated like a zinc metallo protease (6, 7). However, the metal inhibits the serine protease but is essential for metalloprotease activity. A relative newcomer in the families of proteases are the caspases, which resemble each other in amino acid sequence, structure, and substrate specificity, as will be discussed in a paper to follow [G.S.Salvesen and V.M.Dixit (8)]. Another important recent advance is the isolation and characterization of proteasomes [R.Huber (9)]. One of the earliest and best understood cases of proteolytic processing is zymogen activation. It underlies a great variety of physiological regulations, particularly when coupled to consecutive activation reactions as in the cascades of blood
*To whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
PROTEOLYTIC ENZYMES, PAST AND FUTURE
10963
coagulation, fibrinolysis, the complement reaction, and others. The key point here is that a signal can be specifically and irreversibly amplified every time a downstream inactive enzyme precursor is activated. Recent work, to be presented in the paper to follow (8), has demonstrated a specific role of the pro segment of activation, which early on was regarded a throwaway piece but in certain cases can act as an intramolecular inhibitor and as an intramolecular chaperon that assures proper folding of the active enzyme (10). Certain generalizations have emerged from these and related investigations. If I may borrow a page from Nancy Thornberry (11), most proteases are synthesized as inactive precursors (zymogens) that require limited proteolysis for activation. Because proteolysis is irreversible under physiological conditions, the generation of the uncleaved precursor requires de novo synthesis. All active proteases, including those that activate zymogens, are regulated by specific inhibitors. However, some protease precursors can regulate their own activation, e.g., trypsinogen, whereas others, e.g., plasminogen, do not require peptide bond cleavage for their activation. Proteolytic processing, like all proteolytic reactions, requires unique combinations of primary, secondary, and tertiary structures to permit interaction with substrate so as to form the reactive enzyme-substrate intermediate. Let me now make a major leap in time and discuss in brief how we reached the current era of research on proteolytic enzymes and what we can expect in the millennium that we are about to enter. Two major factors have expanded our conceptual horizons and endowed us with experimental tools of previously unimaginable powers of resolution. One factor is the application of the newly emerging concepts and methodologies of molecular and cell biology, such as DNA cloning and sequencing, site-directed mutagenesis, gene amplification, gene knockouts, phage display, and the wealth of information yielded by genomics research generally. The other major impetus came from a group of newly developed concepts and experimental approaches to the structure and function of proteins by mass spectroscopy (12), multidimensional NMR, and the use of computers for the prediction of protein structure based on various types of algorithms. To these one might add the methods of combinatorial chemistry as applied to proteins to scan and identify protein ligands of physiological significance. Although we are still far from understanding the rules of the in vivo folding of nascent polypeptide chains, the challenge lies in deriving the function of a protein from its known chemical and biological parameters and in learning how to design proteins of predetermined physiological properties. All of these developments, singly and in combination, expand our horizons and the goals that we are setting for their application to biology and medicine. The importance of proteolytic enzymes to the understanding of vital biological tasks is perhaps best illustrated by current trends in the study of viral proteases (13). In every known instance, the timing, placement, and mode of action of the virus encoded protease are somehow adapted to the conditions under which it operates within the viral environment. Two examples follow: in herpes viruses such as cytomegalovirus, the structure of the protease reveals a catalytic triad of His/His/Ser instead of the conventional Asp/His/Ser of the mammalian serine proteases and a single beta barrel structure per monomer instead of two in the mammalian serine proteases (13). Analogously, in adeno viruses the cysteine protease contains a Glu/His/Cys catalytic triad characteristic of cysteine proteases, but the seven alpha helices and a single five-stranded beta sheet are not seen in the parent protease (papain). In either case, the examples given demonstrate the ability of the virus proteases to adapt themselves to the evolution of functions within the limits of compatible protein structures (13). Other rapidly expanding areas of biological research involving well known proteases include those of apoptosis, the mediation of thrombin signaling by protease activated receptors, proteolytic processing in cholesterol metabolism, in the cell cycle, and the many others included in this issue of the Proceedings. It is no coincidence that industry and academia are almost equally represented in this audience, because intense cooperation between both is essential if we are to reap the full benefits of the advances and discoveries in both basic and applied research. 1. Northrop, J.H., Kunitz, M. & Herriott, R.M. (1938) Crystalline Enzymes (Columbia Univ. Press, New York). 2. Neurath, H. (1995) Protein Sci. 4, 1939–1943. 3. Barrett, A.J., Rawlings, N.D. & Woessner, J.F. (1998) in Handbook of Proteolytic Enzymes (Academic, New York), pp. xiii–xxix. 4. Kitamoto, Y., Yuan, X., Wu, Q., McCourt, D.W. & Sadler, J.E. (1994) Proc. Natl. Acad. Sci. USA 91, 7588–7592. 5. Perona, J.J. & Craik, C.S. (1995) Protein Sci. 4, 337–360. 6. Higaki, J.N., Fletterick, R.J. & Craik, C.S. (1992) Trends Biochem. Sci. 17, 100–104. 7. Klemba, M., Gardner, K.H., Marino, S., Clarke, N.D. & Regan, L. (1995) Struct. Biol. 2, 368–373. 8. Salvesen, G.S. & Dixit, V.M. (1999) Proc. Natl. Acad. Sci. USA 96, 10964–10967. 9. Groll, M., Heinemeyer, W., Jäger, S., Ullrich, T., Bochtler, M., Wolf, D.H. & Huber, R. (1999) Proc. Natl. Acad. Sci. USA 96, 10976–10983. 10. Cunningham, E.L., Jaswal, S.S. & Agard, D.A. (1999) Proc. Natl. Acad. Sci. USA 96, 11008–11014. 11. Thornberry, N.A. & Lazebnik, Y. (1998) Science 281, 1312–1316. 12. Cohen, S.L. (1996) Structure (London) 4, 1013–1016. 13. Babé, L.M. & Craik, C.S. (1997) Cell 91, 427–430.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
CASPASE ACTIVATION: THE INDUCED-PROXIMITY MODEL
10964
Caspase activation: The induced-proximity model
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. GUY S. SALVESEN*† AND VlSHVA M. DlXIT‡ *Programs in Cell Death and Aging Research, Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037; and ‡Department of Molecular Oncology, Genentech Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 ABSTRACT Members of the caspase family of proteases transmit the events that lead to apoptosis of animal cells. Distinct members of the family are involved in both the initiation and execution phases of cell death, with the initiator caspases being recruited to multicomponent signaling complexes. Initiation of apoptotic events depends on the ability of the signaling complexes to generate an active protease. The mechanism of activation of the caspases that constitute the different apoptosissignaling complexes can be explained by an unusual property of the caspase zymogens to autoprocess to an active form. This autoprocessing depends on intrinsic activity that resides in the zymogens of the initiator caspases. We review evidence for a hypothesis—the induced-proximity model—that describes how the first proteolytic signal is produced after adapter-mediated clustering of initiator caspase zymogens. Apoptosis is a mechanism that regulates cell number and is vital throughout the life of all animals. Though several different types of biochemical events have been recognized as important in apoptosis, perhaps the most fundamental is the participation of members of a family of cysteine-dependent, Asp-specific proteases known as the caspases (1–3). Caspases cleave a number of cellular proteins, and the process is one of limited proteolysis in which a small number of cuts, usually only one, are made in interdomain regions. Sometimes cleavage results in activation of the protein, sometimes in inactivation, but never in degradation, because their substrate specificity distinguishes the caspases as among the most restricted of endopeptidases. Singularly important in this context is that caspase zymogens are themselves substrates for caspases, such that some are able to activate others in a hierarchical relationship (Fig. 1). Thus, pathways exist to transmit signals via sequential caspase activations, and this event has been most extensively examined in apoptosis. It is relatively easy to imagine that the caspases operating at the bottom of the pathway are activated by the ones above. Until recently, the questions of how the first caspase in a pathway became activated and how the first death signal was generated were perplexing issues. Now, several groups have focused on this issue (4–7) and have arrived at a consensus to describe the intriguing operation of the initiation of the proteolytic pathways that execute apoptosis. Though the basic hypothesis is supported, many issues remain to be explained, not the least of which is the nature of the mechanism that governs the process. This paper reviews the support for the hypothesis—the induced-proximity model—and its current limitations. Apoptosis Triggered by Death Receptors. One of the most intensively studied pathways to cell death results from ligation of transmembrane death receptors belonging to the tumor necrosis factor-R1 (TNF-R1) family. After engagement by specific ligands, these receptors transmit a lethal signal that results in classic apoptotic cell death (8, 9). Because simple transfection of death receptors is usually sufficient to sensitize cells to a death ligand, it follows that the components required to transduce this signal reside in many cells. Thus TNF-R1 family members serve as a conduit for the transfer of death signals into the cell’s interior after interaction with their extracellular cognate ligands. The TNF-R1/TNF pair itself presents a rather complex pathway with which to dissect apoptosis initiation, because this receptor/ligand pair can signal either apoptosis or an antagonistic NF- B-mediated survival pathway, depending on the cellular context. The TNF-R1 homologue Fas (CD95/Apo-1) has been the paradigm of choice, because addition of its cognate ligand, FasL, or even receptor agonist antibodies rapidly signals cell death (10). Because agonist Fas antibodies can trigger apoptosis, it was possible to use them to isolate the components of the death-inducing signaling complex (DISC) that forms after Fas ligation (4, 11). A combination of yeast two-hybrid and proteinsequence analysis revealed a seemingly simple DISC, comprising Fas itself, the adapter molecule FADD, and caspase-8 (Fig. 1). This discovery revealed a potential solution to the perplexing problem of how the first proteolytic signal was generated during apoptosis, because it implicated a caspase directly in the triggering event. Before this work, receptors were thought to signal either by altering the phosphorylation status of key signaling molecules or by functioning as ion channels. Death receptors, such as Fas, signal by direct recruitment and activation of a protease (caspase-8). How exactly does the recruited zymogen become active? To understand this process as a basis for formulating an adequate hypothesis, one must understand the unusual properties of caspase zymogens that set them apart from most other proteases. Because, unlike most other proteases, simple expression of caspase zymogens in Escherichia coli usually results in their activation (12, 13). This activation results from processing that is a consequence of intrinsic proteolytic activity residing in the caspase zymogens. It is not caused by E.coli proteases, as indicated by the fact that catalytically disabled C285A (caspase-1 numbering convention) mutants fail to undergo processing. Self-Processing of Caspase Zymogens. In common with other protease zymogens (14), with notable exceptions (see Table 1), generation of an active caspase usually requires limited proteolysis (Fig. 2). The activating cleavage takes place within a short segment that, in the zymogen, connects the large and small subunits of the catalytic domain with both subunits containing essential components of the catalytic machinery. The location of cleavage within this segment need not be precise in vitro (15); nevertheless, the highly conserved Asp-
†To
whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviations: TNF, tumor necrosis factor; DISC, death-inducing signaling complex; DED, death-effector domain.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
CASPASE ACTIVATION: THE INDUCED-PROXIMITY MODEL
10965
297 (caspase-1 numbering convention) directs cleavage specificity within this segment in vivo. Proteolytic processing that results in activation usually occurs at this Asp residue, such that most activated caspases can process their own and other caspase zymogens, given sufficient time and a high enough concentration in vitro (16–18). The extent to which this processing occurs in vivo, however, is regulated by the residues surrounding Asp-297. For example, the sequence surrounding Asp-297 in the downstream executioner caspases 3 and 7 fits the extended substrate specificity of the initiator caspases 8 and 9 remarkably well (19). With the notable exception of at least caspase-2 (20), distinctions in substrate specificity within the caspase family fit closely to the S4–S1 subsite preferences deduced from synthetic peptidic substrates (19).
FIG. 1. The framework of apoptosis. Death may be signaled by direct ligand-enforced clustering of receptors at the cell surface, which leads to the activation of the “initiator” caspase-8 (casp-8). This caspase then directly activates the “executioner” caspases 3 and 7 (and possibly 6), which are predominantly responsible for the limited proteolysis that characterizes apoptotic dismantling of the cell. Alternatively, irreparable damage to the genome caused by mutagens, pharmaceuticals that inhibit DNA repair, or ionizing radiation leads to the activation of another initiator, caspase-9 (28). The latter event requires the recruitment of pro-caspase-9 to proteins such as Apaf-1, which requires the proapoptotic factor cytochrome c (cyto C) to be released from mitochondria (29). Though other modulators probably regulate the apoptotic pathway in a cell-specific manner (30), this framework is considered common to most mammalian cells. Table 1. Zymogenicities of some caspases compared with two serine proteases Zymogenicity Protease Caspase-3 >10,000 Caspase-8 100 Caspase-9 10 Trypsin >10,000 2–10 tPA Zymogenicity is defined as the ratio of the activity of a processed protease to the activity of the zymogen on any given substrate (27). Data for trypsin and tissue plasminogen activator (tPA) are taken from ref. 27. The interesting range of zymogenicity values displayed by members of the caspase family is mirrored by members of the chymotrypsin family, with trypsin and tPA shown for comparison. Presumably, enzmes such as tPA and caspase-9 have down played the requirement for proteolysis as a mechanism of substantially increasing their activities, because allosteric regulators substitute this function: fibrin for tPA and Apaf-1 for caspase-9. In the case of tPA, specific side-chain interactions, absent in other members of the chymotrypsin family, allow activity of the zymogen. However, in the absence of a molecular structure of the caspase-8 and caspase-9 zymogens, little evidence is available to explain the high activity of the unprocessed protein. One clue is suggested by the structure of active caspases 1 and 3, each of which is composed of two catalytic units thought to arise from the dimerization of monomeric zymogens (reiewed in ref. 3). If activation of zymogens of the initiator caspases-8, 9, and CED3 operates by clustering, then the clustering phenomenon may be explained by adapter-driven homodimerization of monomers. However, as detailed in Future Directions, the molecular mechanisms are far from clear.
The Induced-Proximity Hypothesis. Interestingly, depending on expression conditions, one can obtain either processed active caspase or unprocessed zymogen from the same construct, at least for caspases 3, 7, and 9 (15, 21, 22). For example, short induction times (<30 min) yield unprocessed zymogens, but longer ones (>3 hours) yield fully processed enzymes. Significantly, even very short expression times and low inducer concentrations have failed to yield caspase-8 zymogens in our studies (G.S. and H.Stennicke, unpublished work). Caspase-8 processes itself extremely rapidly on heterologous expression in E.coli, suggesting that the zymogen must possess significant intrinsic proteolytic activity, allowing for autoprocessing. These observation are the basis for the inducedproximity hypothesis for the operation of the DISC, the assembly of which forces a locally high concentration of caspase-8 zymogens in a process mediated by recruited FADD (Fig. 3). This clustering of zymogens possessing intrinsic enzymatic activity would allow for processing in trans as well as activation of the first protease in the cascade. The hypothesis would need to be tested by asking whether the zymogen form of caspase-8 possessed reasonable enzymatic activity. Because such a test could not be made by expressing the wild-type precursor, a nonprocessable mutant was generated by replacing the two Asp cleavage sites within the large/small subunit linker segment with Ala. These replacements enabled the generation of a “frozen” zymogen that could be obtained in quantity after expression in E. coli. Significantly, the frozen zymogen retained the same specificity against caspase inhibitors and synthetic substrates but cleaved these substrates at 1% of the rate of an equivalent concentration of fully processed enzyme. The mechanistic origin of this rate differential is currently unknown, but, significantly, the zymogenicity of caspase-8, the ratio of its activity as a fully active enzyme to the activity of its unprocessed zymogen, was 100 (4). The importance of zymogenicity is detailed in Table 1. Testing the Hypothesis. The in vitro observations on the high zymogenicity of caspase-8 suggested that a test of the induced autoprocessing hypothesis was mandated, preferably in vivo. With this mandate in mind, we generated a caspase-8 construct in which the DED domains of the zymogen were replaced by a myristoylation signal, followed by three tandem repeats of a derivative FK506 binding protein (FKBP). The latter had been designed by Schreiber and colleagues (23) to act as an artificial mimic of natural cellular recruitment processes. Artificial oligomerization of proteins carrying the FKBP domains was induced by treatment with the cell penetrant FK1012, a dimeric form of FK506. Ectopic expression of the catalytically active chimera was tolerated fairly well by two human cell lines, even in the presence of monomeric FK506. However, on addition of dimeric FK1012, the cells underwent apoptosis by a mechanism that depended on the catalytic function of the chimeric caspase-8, because replacing the catalytic Cys by Ser failed to elicit the same effect. This technique, later termed the “artificial death switch” (24), has taken a prominent position in the exploration of apoptosis initiation. These data, the in vitro observations on the zymogenicity of pro-caspase-8, and the artificially induced death of cells harboring the chimeric FKBP-caspase-8 are fully consistent with the induced-proximity model. Indeed, since this original description, the postmitochondrial initiator caspase-9 (7) and the Caenorhabditis elegans caspase CED3 (25) have both been implicated in congruent
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
CASPASE ACTIVATION: THE INDUCED-PROXIMITY MODEL
10966
proximity activation mechanisms. Is this mechanism a common one for the basis of generating biochemical death signals? Possibly. However, a caveat must be added to the caspase-9 issue, because this caspase has a very low zymogenicity (22); in other words, it is almost as active before as it is after proteolytic processing! Thus, in the case of caspase-9, an alternative pathway may be used.
FIG. 2. Caspase activation by proteolysis. Caspases are synthesized as single-chain precursors that await activation within the cell. Activation usually proceeds in all caspases by cleavage at the conserved Asp-297 (caspase-1 numbering convention). After this activation, an as-yet undescribed conformational change is thought to occur, bringing the activity and specificity determinants (quarter circles in the linear precursor) into the correct alignment for catalysis. Frequently an N-terminal peptide is removed; however, the reason for this removal is obscure, because it is apparently not required for zymogen activation. In the example of caspase-8 shown in the figure, the N-peptide (sometimes called the prodomain) contains death-effector domains (DEDs) required for recruitment to the cytosolic face of death receptors. The crystal structures of caspases 1 and 3 reveal a dimer of small and large subunits in the active, processed state, and—it is assumed, though not specifically demonstrated—that this organization is the case for caspases in solution. The active sites in the putative dimer are shown as open circles. If the single-chain zymogens of caspases 8 and 9 are partly active, why are they not dangerous to healthy cells? They should cause a slow production of active executioner caspases. This question is most readily explained by the presence of endogenous caspase inhibitors, members of the IAP (inhibitor of apoptosis protein) family (31). Members of this family inhibit executioner caspases 3 and 7, and we propose that they present a barrier to caspase activity that must be exceeded before sufficient execution potential can be achieved. Thus, in the presence of IAPs, a little caspase activation is acceptable, because it would be rapidly saturated by the inhibitors. It is only when a sufficient concentration of activated executioner caspases builds up that apoptosis occurs. In this hypothesis, the IAPs regulate the apoptotic threshold.
FIG. 3. Model for the operation of the DISC. Assembly of the DISC occurs in a hierarchical manner. On ligation of Fas, its “death domain” (white circle) binds to a homologous domain in the adapter FADD, which in turn recruits the zymogen of caspase-8 by a homophilic interaction requiring the homologous DEDs (black circles). Immediately after recruitment, the zymogen is processed by an adjacent zymogen, resulting in proteolytic activation and origination of active caspase-8 as the initiating death signal. Activation is thought to result from cleavage at Asp-297 (caspase-1 numbering convention). Presumably, the active form of caspase-8 (designated as a dimer as seen in the structures of active caspases 1 and 3) releases itself from the adapter after proteolytic removal of the N-terminal DED, though it is not clear how the endogenous activated enzyme distributes in the cell. Future Directions. Notwithstanding the attractiveness of the induced-proximity model, there remain a number of open questions. For example, although the data support the hypothesis, the molecular mechanisms of the event(s) have not been explained, and there are a number of issues that need to be addressed in the near future. These issues are as follows. (i) Must the processed caspase-8 be released from the DISC to diffuse toward its downstream substrates? (ii) Does activation require dimerization, a consensus for the catalytic form of caspases 1 and 3 at least? (iii) Does processing occur in cis (intramolecular) or in trans (intermolecular)? (iv) Must the zymogens be specifically aligned within the recruitment complex, and how many zymogen molecules constitute an activation locus? (v) Is the minimal operative DISC as simple as the one depicted in Fig. 3, or are other proteins required (26)? These questions cut to the heart of uncertainties surrounding the fundamental activation mechanism of all the caspases, and each is (in principle) answerable by generating specific mutants and by using the artificial death-switch technique. Perhaps it is already possible to settle the issue of cis versus trans processing; in our hands, it is rarely possible to observe activation of caspase zymogens in the nanomolar range, but on artificial concentration toward the micromolar range, one observes processing and activation. This observation would imply a secondorder reaction, which is most easily understood in terms of trans processing. Indeed, this proposal makes sense, because it is much easier to regulate zymogen activation in trans than in cis. The answers to these questions will require the molecular structure of at least one caspase zymogen (preferably caspase-8). Their resolution will certainly lead to a better understanding of the molecular mechanism of the DISC, with the attendant possibilities of interfering therapeutically to either initiate or prevent the commitment step in deathreceptor-mediated apoptosis. This work was supported by grants from the National Heart, Lung, and Blood Institute, National Institute on Aging, and National Institute of Neurological Disorders and Stroke.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
CASPASE ACTIVATION: THE INDUCED-PROXIMITY MODEL
10967
1. Salvesen, G.S. & Dixit, V.M. (1997) Cell 91, 443–446. 2. Cohen, G.M. (1997) Biochem. J. 326, 1–16. 3. Thornberry, N.A. & Lazebnik, Y. (1998) Science 281, 1312–1316. 4. Muzio, M., Stockwell, B.R., Stennicke, H.R., Salvesen, G.S. & Dixit, V.M. (1998) J. Biol. Chem. 273, 2926–2930. 5. Martin, D.A., Siegel, R.M., Zheng, L. & Lenardo, M.J. (1998) J. Biol. Chem. 273, 4345–4349. 6. Yang, X., Chang, H.Y. & Baltimore, D. (1998) Mol. Cell 1, 319–325. 7. Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T. & Alnemri, E.S. (1998) Mol. Cell 1, 949–957. 8. Ashkenazi, A. & Dixit, V.M. (1998) Science 281, 1305–1308. 9. Ware, C.F., Santee, S. & Glass, A. (1998) in The Cytokine Handbook (Academic, London), 3rd Ed., pp. 549–592. 10. Nagata, S. & Goldstein, P. (1995) Science 267, 1449–1456. 11. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V. & Wallach, D. (1996) Cell 85, 803–815. 12. Orth, K., O’Rourke, K., Salvesen, G.S. & Dixit, V.M. (1996) J. Biol Chem. 271, 20977–20980. 13. Stennicke, H.R. & Salvesen, G.S. (1997) J. Biol. Chem. 272, 25719–25723. 14. Neurath, H. (1989) Trends Biochem. Sci. 14, 268–271. 15. Zhou, Q. & Salvesen, G.S. (1997) Biochem. J. 324, 361–364. 16. Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G. & Alnemri, E.S. (1996) Proc. Natl. Acad. Sci. USA 93, 14486–14491. 17. Muzio, M., Salvesen, G.S. & Dixit, V.M. (1997) J. Biol. Chem. 272, 2952–2956. 18. Slee, E.A., Harte, M.T., Kluck, R.M., Wolf, B.B., Casiano, C.A., Newmeyer, D.D., Wang, H.G., Reed, J.C., Nicholson, D.W., Alnemri, E.S., et al. (1999) J. Cell Biol. 144, 281–292. 19. Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M., Timkey, T., Garcia-Calvo, M., Houtzager, V.M., Nordstrom, P.A., Roy, S., Vaillancourt, J.P., et al. (1997) J. Biol. Chem. 272, 17907–17911. 20. Talanian, R.V., Quinlan, C., Trautz, S., Hackett, M.C., Mankovich, J.A., Banach, D., Ghayur, T., Brady, K.D. & Wong, W.W. (1997) J. Biol Chem. 272, 9677–9682. 21. Stennicke, H.R., Jurgensmeier, J.M., Shin, H., Deveraux, Q., Wolf, B.B., Yang, X., Zhou, Q., Ellerby, H.M., Ellerby, L.M., Bredesen, D., et al. (1998) J. Biol. Chem. 273, 27084–27090. 22. Stennicke, H.R., Deveraux, Q.L., Humke, E.W., Reed, J.C., Dixit, V.M. & Salvesen, G.S. (1999) J. Biol Chem. 274, 8359–8362. 23. Spencer, D.M., Belshaw, P.J., Chen, L., Ho, S.N., Randazzo, F., Crabtree, G.R. & Schreiber, S.L. (1996) Curr. Biol. 6, 839–847. 24. MacCorkle, R.A., Freeman, K.W. & Spencer, D.M. (1998) Proc. Natl. Acad. Sci. USA 95, 3655–3660. 25. Yang, X., Chang, H.Y. & Baltimore, D. (1998) Science 281, 1355–1357. 26. Imai, Y., Kinura, T., Murakami, A., Yajima, N,, Sakamaki, K. & Yonehara, S. (1999) Nature (London) 398, 777–785. 27. Tachias, K. & Madison, E.L. (1996) J. Biol. Chem. 271, 28749– 28752. 28. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S. & Wang, X. (1997) Cell 91, 479–489. 29. Zou, H., Henzel, W.J., Liu, X., Lutschg, A. & Wang, X. (1997) Cell 90, 405–413. 30. Green, D.R. & Reed, J.C. (1998) Science 281, 1309–1312. 31. Deveraux, Q., Takahashi, R., Salvesen, G.S. & Reed, J.C. (1997) Nature (London) 388, 300–304.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10968
Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. AMIR R. KHAN*, NINA KHAZANOVICH-BERNSTEIN, ERNST M. BERGMANN, AND MICHAEL N. G. JAMES† Medical Research Council Group in Protein Structure and Function, Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada ABSTRACT The three-dimensional structures of the inactive protein precursors (zymogens) of the serine, cysteine, aspartic, and metalloprotease classes of proteolytic enzymes are known. Comparisons of these structures with those of the mature, active proteases reveal that, in general, the preformed, active conformations of the residues involved in catalysis are rendered sterically inaccessible to substrates by the residues of the zymogens’ N-terminal extensions or prosegments. The prosegments interact in nonsubstrate-like fashions with the residues of the active sites in most of the cases. The gastric aspartic proteases have a well-characterized zymogen conversion pathway. Structures of human progastricsin, the inactive intermediate 2, and active human pepsin are known and have been used to define the conversion pathway. The structure of the zymogen precursor of plasmepsin II, the malarial aspartic protease, shows a new twist on the mode of inactivation used by the gastric zymogens. The prosegment of proplasmepsin disrupts the active conformation of the two catalytic aspartic acid residues by inducing a major reorientation of the two domains of the mature protease. The picornaviral 2A and 3C proteases have a chymotrypsin-like tertiary structure but with a cysteine nucleophile. These enzymes cleave themselves from the viral polyprotein in cis (intramolecular cleavage) and carry out trans cleavages of other scissile peptides important for the virus life cycle. Although the structure of the precursor viral polyprotein is unknown, it probably resembles the organization of the proenzymes of the bacterial serine proteases, subtilisin, and α-lytic protease. Cleavage of the prosegment is known to occur in cis for these precursor molecules. Zymogens of proteolytic enzymes consist of the intact protease with an N-terminal extension. Conversion of the inactive zymogen to the mature, active protease requires limited proteolysis usually of a single peptide bond (1). Molecular rearrangements accompany the proteolytic removal of the prosegment of the zymogen, eventually leading to the mature protease. The prosegments of the zymogens range in size from two residues for some of the granzymes to more than 150 residues for a-lytic protease, a bacterial serine protease (2). The conversion of zymogens to the respective active enzymes is achieved by several different mechanisms (3). The active serine proteases of the chymotrypsin family result from limited proteolysis of the zymogens by convertases. For example, the cascade of the blood-clotting enzymes (4) involves the conversion of inactive forms (e.g., prothrombin) to active forms of the enzyme (thrombin) by a highly specific catalytic cleavage by another of the clotting enzymes (factor Xa). On the other hand, simply changing the pH of the solution in which the gastric aspartic protease zymogens are dissolved from 6.5 to 3.0 (an increase in [H+] of 3,100-fold) is sufficient to bring about the conversion (5). In a similar fashion, the zymogens of the papain-like cysteine proteases are converted to the active enzymes in a pH-regulated fashion. The in vitro activation of propapain is consistent with an initial intramolecular cleavage event (6). The conversion of procarboxypeptidase is initiated by trypsin cleavage of the Arg-99p-Ala-1 bond at the prosegment to mature enzyme junction (7). Prostromelysin-1 can be converted to the active form by other proteolytic enzymes, heat, or the presence of organomercurial agents (8). There are some generalities regarding zymogen conversion that one can make in light of the three-dimensional structures of both the zymogens and the respective active enzymes (3). First, the residues that constitute the active sites of the protease portions of the zymogens have virtually identical conformations to those of the mature, active proteases. The major exceptions are the serine proteases of the chymotrypsin family. The activation process involves the formation of an ion pair between the newly formed N-terminal residue Ile-16 NH3+ and the β-carboxylate of Asp-194 (9), which triggers the conformational changes that form the oxyanion binding pocket and the active conformation of the S1 specificity pocket [the nomenclature of Schechter and Berger (10) is used throughout this manuscript]. Second, the preformed active sites of the protease portions of zymogens are generally not accessible to substrates because residues of the prosegments sterically block the approach to the active sites. This statement does not hold for the chymotrypsin-like serine proteases as the active sites of these zymogens are able to bind protein inhibitors that induce conformational changes that form the oxyanion hole in spite of the ion pair involving Asp-194 and Ile-16 being absent (11). Proteolysis of the portion of the prosegments that interact with the active site residues is prevented in several different ways. In prostromelysin the prosegment passes through the active site in the reverse polypeptide direction (N→C) relative to substrates or transition state mimics (12). A reverse orientation of the prosegment blocking the active site in the cysteine protease zymogens also has been observed in the structures of rat procathepsin B (13) and human procathepsin L (14). The region of the prosegment of the gastric aspartic proteases interacting with the catalytic residues Asp-32 and Asp-215 (porcine pepsin numbering) most intimately, includes a highly conserved lysine at position 36p (the residue numbers of the prosegment are followed by p). The εNH3+ group of Lys-36p forms an ion pair with each of the two active site carboxylate groups (15).
Conversion of Gastric Aspartic Protease Zymogens The molecular structures of human progastricsin (16), activation intermediate 2 of human gastricsin (17), and a structural
*Present address: Department of Molecular and Cellular Biology, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138. †To whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviation: HPV, human polio virus.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10969
homolog to mature, human gastricsin, human pepsin 3 (18) allow one to construct a reasonably detailed view of the pathway followed in the conversion of the inactive zymogen to the active protease. Fig. 1 shows stereo ribbon diagrams of each of these three molecular structures. Fig. 2 shows a diagrammatic view of the conversion pathway. This pathway is a general pathway for the gastric aspartic proteases but the individual enzymes differ in detail.
FIG. 1. Structures on the conversion pathway of the aspartic protease zymogen progastricsin. The structure of human gastricsin is not known; the human pepsin structure therefore has been used as a model for gastricsin. This figure, as well as Figs. 3–6 have been prepared with BOBSCRIPT (19) and RASTER 3D (20). (A) The structure of human progastricsin (16) represented in stereo. The residues of the prosegment (Ala-1p to Leu-43p) are in green, those of the gastricsin portion of the zymogen are in blue except for those regions that undergo large conformational changes, Ser-1 to Ala-13, Phe-71 to Thr-81 and Tyr-125 to Ala-136, which are represented in mauve. The promature junction is Leu-43p-Ser-1, the peptide bond cleaved intramolecularly is Phe-26p to Leu-27p. The side chains of Asp-32 and Asp-217 are represented in red. (B) Stereo view of the molecular structure of intermediate 2 on the activation pathway of human gastricsin (17). The color scheme used is the same as in A. The residues missing on this figure, Leu-22p to Phe-26p and Ser-1, are disordered in the structure, and there is no interpret able electron density for them on the maps. The water molecule bound between the two carboxyl groups of Asp-32 and Asp-217 is shown as a red sphere. The final step in the conversion involves the dissociation of the peptide Ala-1p to Phe-26p from gastricsin with the N-terminal residues of gastricsin, Ser-1 (N-ter) to Ala-13, replacing the N-terminal β-strand of the prosegment. (C) The structure of human pepsin (18) shown as a model of human gastricsin. The regions of gastricsin that undergo large conformational changes from their positions in progastricsin are shown in pink, and the active site aspartates with the bound catalytic H2O molecule are colored red. Reproduced with permission from ref. 3.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10970
FIG. 2. A diagrammatic representation of the conversion pathway of progastricsin to gastricsin. The prosegment of progastricsin (I), A1p to L43p, has three helical segments and a net positive charge forming several ion pair interactions and electrostatic stabilization with the mature portion of the zymogen. The highly conserved K37p interacts directly with the catalytic aspartates Asp-32 and Asp-217. Lowering the pH of the solution below 4.0 converts progastricsin into intermediate 1 (26) represented by II. Refolding of the prosegment in the vicinity of the active gastricsin brings the first scissile bond Phe-26p-Leu-27p to the exposed active site aspartates (III). Cleavage at the premature junction, Leu-43p-Ser-1, (IV) is likely an intermolecular cleavage (28) and results in intermediate 2 (V), a molecular species that consists of Ala-1p to Phe-26p noncovalently associated with mature gastricsin (17). The final step in the conversion results from the dissociation of the Nterminal peptide 1–26 of the prosegment and refolding the residues Ser-1 to Ala-13 to replace the region of the prosegment in the six-stranded β-sheet of gastricsin (VI). Progastricsin consists of a single polypeptide chain of 372 aa (21). The N-terminal extension or prosegment is 43 aa in length and comprises residues Ala-1p to Leu-43p. The prosegment is folded into a compact domain having an initial extended β-strand (Val-3p to Lys-8p) followed by three helical segments: Ile-13p to Lys-20p, Leu-22p to Arg-28p, Pro-34p to Arg-39p (16). The third helical segment (a 310 helix) packs against the active site residues and the εNH3+ group of a conserved lysine residue (Lys-37p in progastricsin) forms ion pair interactions with the carboxyl groups of the two catalytic aspartates, Asp-32 and Asp-217. Two tyrosine side chains Tyr-38p and Tyr-9 form symmetric H-bonded interactions with the carboxylates of Asp-217 and Asp-32, respectively, further restricting access to the active site. The phenolic side chain of Tyr-9 occupies the S1 binding pocket; Tyr-38p is in the S1 binding pocket. The tertiary structure of the prosegment (Leu-1p to Tyr-37p) in porcine pepsinogen (15) is virtually identical to that described above for progastricsin (16). The polypeptide chain from Tyr-38p to Tyr-9 in progastricsin adopts a conformation that is different from the equivalent segment of chain in the pepsinogens (15, 22). As well, a portion of the polypeptide chain in gastricsin Tyr-125 to Ala-136 (Fig. 1A) is displaced from the position that this chain segment occupies in all other aspartic protease zymogens and active enzymes (16). The trigger for initiating the conversion of the gastric aspartic protease zymogens is a drop in pH (5). At neutral pH, the structures of the zymogens are stabilized by the electrostatic interactions of the ion pairs and the inactive conformation is maintained (16). However, when the zymogens reach the acid pH (2.0) of the lumen of the stomach, the carboxylate groups become protonated and the repulsive interactions among the net positive charges of the prosegment destabilize its interactions in the active site of the protease. Kinetic studies in the late 1930s showed that the conversion of porcine pepsinogen into pepsin was an autocatalytic process (5, 23). In addition, the fact that the loss of pepsinogen was not accompanied by an equivalent increase in the appearance of pepsin implied the presence of intermediate species on the pathway (5). Spectroscopic studies of this conversion process established that there are conformational changes (24) in the 5-ms to 2-s time scale (25). Rapidly changing the pH back to neutrality can reverse these conformational changes. Biochemical studies of the conversion of human progastricsin to gastricsin showed the presence of at least two intermediates (26). Intermediate 1 is the species formed rapidly after the pH was dropped below 4.0. The prosegment is unfolded in intermediate 1 and the active site of gastricsin is exposed and accessible to substrates. The first hydrolytic event detected during the activation of progastricsin is the intramolecular cleavage of the Phe-26p to Leu-27p peptide bond (26). Subsequently, an intermolecular cleavage at the Leu-43pSer-1 peptide bond (the promature junction) results in the formation of transient intermediate 2 that can be stabilized by transferring the pH to neutrality (>6.5). The resulting molecular species has been characterized biochemically (26) and comprises residues Ala-1p to Phe-26p noncovalently associated with mature gastricsin (Ser-1 to Ala-329). Intermediate 2 recently has been characterized structurally (17), and its structure is depicted in Fig. 1B. The β-strand (Val-3p to Lys-8p) is in the same position as observed in the structure of progastricsin. In addition, the first helix (Ile-13p to Lys-20p) is intact and is very similarly oriented as it is in the zymogen structure. The two catalytic aspartates, Asp-32 and Asp-217, have a water molecule bound between them in the same position as the nucleophilic water observed in the native structures of all mature aspartic proteases (27). The S1 binding site is occluded, however, as the side chain of Tyr-9 still forms a hydrogen bond with the carboxylate of Asp-32. The segment Tyr-125 to Ala-136 has moved from its position in progastricsin
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10971
(Fig. 1A) to the position and conformation common among the mature enzymes whose structures have been solved (Fig. 1 B and C). The ion pair Arg-14p to Asp-11 in intermediate 2 at pH 6.5 stabilizes the N-terminal peptide, Ala-1p to Phe-26p, in its original location in the zymogen preventing the N-terminal residues of gastricsin (Ser-1 to Ala-12) from adopting their final position in the mature enzyme. On the other hand, intermediate 2 would be relatively short-lived at acid pH values <3.0. At these low pH values the carboxylate of Asp-11 would be protonated, and therefore the ion pair with Arg-14p would be severely weakened. Prolonged exposure of intermediate 2 to an acid environment favors dissociation of the β-strand of the zymogen and its replacement by the N terminus of mature gastricsin (Fig. 1C). Progastricsin (Fig. 2I) has stabilizing electrostatic interactions between the positively charged residues of the prosegment and the negatively charged groups of the gastricsin portion of the zymogen (16). These electrostatic interactions are weakened by the drop in pH that results in the protonation of the carboxylate groups of aspartic and glutamic residues (29–31). In particular, protonation of the catalytic aspartate groups, Asp-32 and Asp-217, weakens the interactions with Lys-37p, allowing the uncoiling of the 310 helix and permitting the diffusion of this segment away from the active site. The residues surrounding Lys-37p in progastricsin (Thr-29p to Asp-33p and Phe-40p to Leu-43p) all have substantially higher than average B factors, indicating that they are highly mobile and would easily undergo conformational changes that would expose the preformed active site (Fig. 2II). In contrast, the β-strand at the N terminus of the prosegment (Val-3p to Lys-8p) associates with the mature gastricsin through hydrogen bonding and hydrophobic interactions. These forces are not pH dependent. With the helical regions of the prosegment uncoiled (Fig. 2II) and the polypeptide from roughly Lys-11p to Ala-13 in a dynamic state of flux, eventually a sensitive peptide (e.g., Phe-26p-Leu-27p) would diffuse to the preformed active site and intramolecular cleavage would occur (Fig. 2III). The resulting cleaved form of the zymogen (Fig. 2IV) is enzymatically active and also would be free to catalyze intermolecular cleavages that have been detected kinetically with pepsinogen (32). This is the likely fate of the bond at the prosegment to mature junction (Leu-43pSer-1); it is cleaved intermolecularly and the peptide Leu-27p to Leu-43p dissociates from the complex. The noncovalent complex of Ala-1p to Phe-26p bound to gastricsin (intermediate 2 or Fig. 2V) can be stabilized by returning the pH to neutrality. The final step (Fig. 2 V to VI) in the conversion process involves a dissociation of the β-strand and helical regions (Ala-1p to Phe-26p) of the prosegment from gastricsin and its replacement by the N-terminal residues of gastricsin. The prosegments of the pepsinogens and the progastricsins have very similar sequences and three-dimensional structures. The sequences of prosegments of other aspartic proteases are also similar to those of the gastric enzymes, suggesting that the general features of the conversion process are shared among the chymosins and cathepsins D. Differences in the sites of internal cleavage and the kinetics of the activation process (33) are explained partly by the positions of the cleavage sites in the different prosegments (34).
Conversion of Proplasmepsin II The plasmepsin system presents a different view of aspartic protease activation than do the gastric proteases. Plasmepsin is the aspartic protease used by the malaria parasite Plasmodium to degrade hemoglobin in red blood cells. The plasmepsins are synthesized as inactive zymogens, the proplasmepsins, having N-terminal prosegments that differ both in sequence and in size from other known aspartic protease zymogens. Proplasmepsin prosegments contain approximately 125 aa and lack sequence similarity with the archetypal gastric zymogen prosegments, which are typically about 45 residues long (35–37). Proplasmepsin prosegments also contain a transmembrane helix that anchors these zymogens to the membrane during delivery from the endoplasmic reticulum to the digestive vacuole where activation and hemoglobin digestion occur (38). Activation of proplasmepsin in vivo is carried out by a maturase at acidic pH (38). Additionally, proplasmepsin II and P. vivax proplasmepsin can be activated autocatalytically at low pH, with the cleavage occurring upstream of the wild-type mature N terminus (39). The crystal structure of proplasmepsin II from P. falciparum revealed some surprising contrasts with the gastric aspartic protease zymogens (40). Instead of blocking a preformed active site, as in the gastric zymogens, the prosegment in proplasmepsin causes a major distortion of the molecule, preventing the formation of a functional active site. The recombinant proplasmepsin II used in the crystallographic studies had the prosegment truncated by the first 76 residues to facilitate expression (39). Almost the entire length of this shortened prosegment interacts with the mature portion of proplasmepsin II. The prosegment has a well-defined secondary structure, consisting of an initial β-strand, followed by two α-helices and a coil connection to the mature N terminus (Fig. 3). As in the gastric zymogens (15, 16, 22), the prosegment β-strand participates in the sixstranded β-sheet, the central motif of aspartic proteases, and becomes replaced by the mature N terminus upon activation (Fig. 3). Although the position of the prosegment β-strand is similar to that seen in gastric zymogens, the remainder of the prosegment adopts a very different disposition. Instead of running through the substrate-binding cleft, the two helices interact exclusively with the C domain of the molecule. The promature junction is located in a tight loop comprised of residues Tyr-122p to Asp-4, the Tyr-Asp loop, where Asp-4 plays a key role in maintaining the structure of the loop (with hydrogen bonds to Tyr-122p and Ser-1) and anchoring it to the C domain (with hydrogen bonds to Lys-238 and Phe-241) (Fig. 4a). The N terminus of the mature plasmepsin sequence differs in conformation between proplasmepsin II and plasmepsin II (40, 41). Upon activation, residues 1–14 undergo a large conformational change, placing Asp-4 to Phe-11 into the central β-sheet. Residues 15– 29 make a more subtle rearrangement that alters their interactions with the active site Psi loops (Fig. 4 b and c). When the central βsheet motif and C domain (residues 138–329) of plasmepsin II and proplasmepsin II are superimposed, their N domains (residues 30– 129) are related by a rotation of 14° about an axis running roughly in the plane of the central β-sheet and perpendicular to the strands. This domain movement observed in proplasmepsin II is novel in terms of its division into rigid bodies, magnitude, direction, and effect on activity (42). It renders the active site cleft more open in the zymogen than in the enzyme, severely distorting the geometry from that of the active site in plasmepsin II. In proplasmepsin II, the active site Psi loops are farther apart relative to plasmepsin II (Fig. 4b). Asp-34 and Asp-214 are too far apart in the zymogen to carry out the general base activation of a nucleophilic water molecule. The socalled immature active site is therefore catalytically inactive, and upon activation must collapse to the fireman’s grip configuration that defines the active site in all aspartic proteases of known structure (43) (Fig. 4c). The method of inactivation in proplasmepsin II is different from that observed in the gastric aspartic protease zymogens. In proplasmepsin there is no positively charged moiety (such as Lys-36p in pepsinogen) to neutralize the charge repulsion between the catalytic Asps at neutral pH (44). Instead, the two Asp residues are kept apart from each other and are engaged in a network of hydrogen bonds both within and between the
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10972
Psi loops (Fig. 4b). The function of the prosegment, together with the rearranged mature N terminus, is to maintain the molecule in the open conformation, leaving the active site accessible but greatly distorted.
FIG. 3. A structural view of the conversion of proplasmepsin II (Left) (40) to plasmepsin II (Right) (41). The N and C domains are colored yellow, the central motif is green, the prosegment (with its helices labeled) is magenta, and the Nterminal 30 aa of the mature sequence are cyan. The catalytic aspartic acid residues (34 and 214) are colored red. The tip of the flap in proplasmepsin II, which is disordered in the crystal structure, is shown as a dotted line. The peptide bonds cleaved in autoactivation (112p–113p) and in the maturase-assisted activation (124p–1) are marked by asterisks in proplasmepsin II. The structure of proplasmepsin II suggests that disruption of three salt bridges (Glu-87p with Arg-92p, Asp-91p with His-164, and Glu-108p with Lys-107p) at low pH plays a key role in autoactivation. Dissociation of these interactions at low pH should destabilize the prosegment structure and weaken the association between the prosegment and the C domain. The most dramatic effect of acidification, however, should occur at Asp-4. This residue keeps the promature junction locked in the compact Tyr-Asp loop and tethers this loop to the C domain (Fig. 4a). Protonation of the Asp-4 side chain should disrupt the interactions of its carboxylate oxygens (with Tyr-122p, Lys-238, and Phe-241), opening up the Tyr-Asp loop and introducing a slack of five residues into the prosegment harness. With this region of the prosegment loosened, the molecule may adopt the domain-closed form with a functional active site. It should be noted that the bond cleaved in autoactivation of proplasmepsin II, Phe-112p to Leu-113p, is located at the C terminus of the prosegment helix 2, which must be one of the early locations to lose its secondary structure upon acidification. Once the active site is formed, the scissile bond, now in an extended conformation, then can be presented for cleavage either in cis or in trans.
FIG. 4.(a) The promature junction in proplasmepsin II. The hydrogen bonding network of Asp-4, within the Tyr-Asp loop (Tyr-122p-Asp-4) and to the C-domain residues Lys-238 and Phe-241, is shown, (b) The immature active site in proplasmepsin II. The Psi loops (31–41 and 211–220) interact with each other through direct and water-mediated hydrogen bonds. In addition, both Psi loops form hydrogen bonds with the N-terminal residues 11–17. (c) The active site of plasmepsin II, showing the symmetrical arrangement of hydrogen bonds around the catalytic aspartates known as the fireman’s grip. The sphere between Asp-34 and Asp-214 is the oxygen atom from pepstatin that was present in the crystal structure (41). The Nterminal residues 15–18 and their interactions with the Psi loops also are shown.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10973
FIG. 5. A structural model for the N-terminal, autocatalytic excision of the enteroviral 3C proteases. The model is based on the crystal structure of the poliovirus 3C protease (HPV 3C) (63). The secondary structure of HPV 3C is shown in a ribbon representation. The N-terminal β-barrel domain is blue and the C-terminal β-barrel domain is mauve. (I) Model of the precursor of the 3C protease with the 3B|3C cleavage site sequence bound in the active site in the conformation of a cognate substrate of the 3C protease. The model was derived from the P5 to p2 residues of OMTKY3 bound in the active site of Streptomyces griseus protease B (SGPB) (65) after the optimal superposition of HPV 3C and SGPB (63). Included in this figure are the residues starting at the P5 (Thr) position of the 3B protein. The P5 to P1 residues and residues 1–5 of HPV 3C (P1' to P5') are colored gray; residues 6–13 are dark gray. The side chains of three active site residues, the nucleophile Cys-147 (yellow), the general acid-base catalyst His-40 (blue), and the S1 specificity determinant His 161 (light blue), are included. Residues 1–11 of HPV 3C reach into the active site of the protease and are in a mostly extended conformation. After the intramolecular cleavage the new N terminus Gly-1 dissociates from the active site while the P5 to P1 residues are still bound (II). Subsequently residues 6–13 of HPV 3C fold into a stable α-helix (colored black), which prevents the new N terminus from binding again to the active site and renders the conformational change irreversible. Arg-13 of the conserved sequence motif K/RR/KNL/I, which forms the last turn of the N-terminal helix in HPV 3C, anchors the N terminus to the structure. (III) The crystal structure of HPV 3C is shown with the N-terminal α-helix in black. The rearrangement of the N terminus in this model is accompanied by small conformational changes of β-strands aI and bI of the N-terminal domain and the loop (yellow) that connects β-strands aII and bII of the C-terminal domain. Autoactivation of proplasmepsin II takes place readily between pH 3.8 and 4.7 (45). The lower pH range covers the pKas of Asp and Glu carboxylates in proteins (46), even taking into account some pKa depression that may be expected because of these residues’ participation in salt bridges and hydrogen bonds. For instance, the involvement of Asp-4 in a number of hydrogen bonds and a salt bridge (Fig. 4a) is likely to lower its side-chain pKa relative to that of a solvent-exposed carboxylate. The requirement for low pH for activation by a maturase is less conclusive based on the proplasmepsin II structure. The promature junction is located at the surface of the molecule and therefore should be accessible to the external maturase. Acidification may be necessary to induce the Tyr-Asp loop opening for the Gly-124p to Ser-1 scissile bond to assume an extended conformation suitable for proteolytic cleavage. Alternatively, low pH may be required if the maturase itself has an acidic pH optimum. Further studies of the maturase will be needed to resolve this issue.
Autocatalytic Excision of Picornaviral 3C Proteases Picornaviruses constitute a large family of positive-sense, single-stranded RNA viruses (47). An early and important step in the picornaviral lifecycle is the translation of the single-stranded viral RNA genome into a single large polyprotein (48,
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10974
49). The viral polyprotein is processed into the individual viral gene products by the viral 3C protease, itself a part of the polyprotein (50). The picornaviral 3C protease is the prototype of the new class of chymotrypsin-like cysteine proteases (49, 51, 52). It can cleave itself out of the viral polyprotein in cis and in trans, when it is expressed as part of the polyprotein or separately (53, 54). The autocatalytic excision is not correlated with concomitant development of the proteolytic activity. The precursors of the 3C gene product already have proteolytic activity (55–58). In the viruses of the genus enterovirus the precursor 3CD (the 3D gene product constitutes the RNA-dependent RNA polymerase) shows a proteolytic activity that is distinct from that of 3C. In poliovirus, and presumably in most other enteroviruses, the proteolytic activity of the precursor 3CD is required for the efficient processing of the capsid precursor proteins (58). In hepatitis A virus the 3ABC gene product appears to be an important, proteolytically active intermediate of the polyprotein processing (57). Palmenberg and Rueckert (59) examined the kinetics of the polyprotein processing in the picornavirus, encephalomyocarditis virus. Their data suggest that the autocatalytic excision of the 3C gene product can be a truly intramolecular event. Further evidence for an intramolecular excision of the 3C protease from poliovirus was provided by Hanecak et al. (60). Taken together, these data suggest that the autocatalytic excision of 3C from the polyprotein at both the N and C termini can be either intramolecular or intermolecular. Once atomic resolution structures of 3C proteases became available (61–63), it was possible to develop structural models for the autocatalytic excision of the picornaviral 3C proteases. The crystal structures confirmed that the picornaviral 3C proteases are structurally related to the chymotrypsin family of serine proteases. Based on some of the unique structural details, the authors of the crystal structure papers (61–63) proposed similar models for an autocatalytic, intramolecular cleavage at the N terminus of 3C. They also agreed that it is much less obvious how an intramolecular cleavage could occur at the C terminus of 3C. The N-terminal residues of the picornaviral 3C proteases form a stable α-helix that precedes the first strand of the N-terminal βbarrel domain. This helix packs against the surface of the C-terminal domain of 3C. The last turn of this α-helix is formed by the residues of a highly conserved sequence motif K/RR/KNI/L (48). Another unusual feature of the picornaviral 3C proteases is an antiparallel β-ribbon that extends from the C-terminal β-barrel (49). It forms an extension of the second and third β-strands of the C-terminal domain and corresponds topologically to the methionine loop of the chymotrypsin-like serine proteases. This feature is also present in the bacterial serine proteases such as α-lytic protease and Streptomyces griseus protease B (64, 65). The recent crystal structure of α-lytic protease complexed with its prosegment (2) revealed that this feature plays an important role in the folding of the protease and in the autocatalytic, intramolecular processing of the precursor of α-lytic protease. The structural model of an intramolecular cleavage at the N terminus of the picornaviral 3C proteases (Fig. 5) predicts that the Nterminal α-helix folds to its final conformation only after the 3C protease has cleaved its own N terminus (61–63). Before the intramolecular cleavage at the 3B|3C site, the corresponding residues [Gly-1 to Lys-12 in human polio virus (HPV) 3C] must be in an extended conformation (Fig. 5I) to reach into the active site through the cleft between β-strand bI from the N-terminal domain and the loop connecting β-strands aII and bII from the C-terminal domain. The loop that connects β-strands aII and bII had to be moved in the model of the precursor molecule (Fig. 5I), with respect to its position in the native HPV 3C protease structure (Fig. 5III) to accommodate this. Several residues from β-strand aI also are slightly moved away from their positions in the structure of the native 3C protease to widen the cleft between the N- and C-terminal domains through which the N terminus passes. After the autocatalytic cleavage at Gly-1 of HPV 3C the new N terminus dissociates out of the active site (Fig. 5II). The folding of residues 5–13 into a stable helix, which packs tightly onto the surface of the molecule, subsequently would render this conformational change irreversible. It is necessary to remove the new N terminus from the protease active site to prevent intramolecular, competitive product inhibition of the protease. The conserved sequence motif K/RR/KNI/L that eventually forms the last turn of the N-terminal helix anchors the residues of the Nterminal helix to the core structure of the protease. The side chains of Arg-13 and Asn-14 interact with the highly conserved sequence motif KFRDI of the RNA-binding site of the 3C protease. The residues that will become the N-terminal helix are in an extended conformation in the precursor (Fig. 5I). The up-down side-chain pattern in this extended conformation places the small side chains of Ala-7, Ala-9, and Ala-11 (P7, P9, and P11) into the cleft between the two domains of the proteases and the larger side chains of residues Tyr-6, Val-8, and Met-10 point to the surface. Larger side chains than alanine in positions 7, 9, and 11 would not have fitted easily into the surface of the cleft. We suggest therefore that the three alanine residues are important for the conformation of the N terminus in the precursor as well as for the formation of the N-terminal helix. It is much more difficult to envision an intramolecular cleavage of the picornaviral 3C protease at its own C terminus. The crystal structure of the core proteins from Sindbis and Semlicki forest viruses (66) show how an additional β-strand can reach from the C terminus to the active site of a chymotrypsin-like protease; however, the unique antiparallel β-ribbon of the picornaviral 3C proteases that extends from β-strands bII and cII and interacts with the N-terminal domain would prevent this (Fig. 5III). We thank Perry d’Obrennan for help in making Fig. 2. Mae Wylie has been very helpful in getting the manuscript into its final polished form. A.R.K. was supported by a Medical Research Council of Canada Studentship; N.K.-B. was the holder of an Alberta Heritage Foundation for Medical Research Studentship. This work has been supported by the Medical Research Council of Canada and by Grant UO1AI38249 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. 1. Neurath, H. (1957) in Advances in Protein Chemistry XII, eds. Anfinsen, C.B., Jr., Anson, M.L., Bailey, K. & Edsall, J.T. (Academic, New York), pp. 319–386. 2. Sauter, N.K., Mau, T., Rader, S.D. & Agard, D.A. (1998) Nat. Struct. Biol 5, 945–950. 3. Khan, A.R. & James, M.N.G. (1998) Protein Sci. 7, 815–836. 4. Davie, E.W., Fujikawa, K. & Kisiel, W. (1991) Biochemistry 30, 10363–10370. 5. Herriott, R.M. (1939) J. Gen. Physiol. 22, 65–78. 6. Vernet, T., Khouri, H.E., Laflamme, P., Tessier, D.C., GourSalin, B., Storer, A.C. & Thomas, D.Y. (1991) J. Biol. Chem. 266, 21451–21457. 7. Aviles, F.X., Vendrell, J., Guasch, A., Coll, M. & Huber, R. (1993) Eur. J. Biochem. 211, 381–389. 8. Nagase, H., Enghild, J.J., Suzuki, K. & Salvesen, G. (1990) Biochemistry 29, 5783–5789. 9. Huber, R. & Bode, W. (1978) Acc. Chem. Res. 11, 114–122. 10. Schechter, I. & Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157–162. 11. Bode, W., Schwager, P. & Huber, R. (1978) J. Mol. Biol. 118, 99–112. 12. Becker, J.W., Marcy, A.I., Rokosz, L.L., Axel, M.G., Burbaum, J.J., Fitzgerald, P.M.D., Cameron, P.M., Esser, C.K., Hagmann, W.K., Hermies, J.D. & Springer, J.P. (1995) Protein Sci. 4, 1966–1976.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURAL ASPECTS OF ACTIVATION PATHWAYS OF ASPARTIC PROTEASE ZYMOGENS AND VIRAL 3C PROTEASE PRECURSORS
10975
13. Turk, D., Podobnik, M., Kuhelj, R., Dolinar, M. & Turk, V. (1996) FEBS Lett. 384, 211–214. 14. Coulombe, R., Grochulski, P., Sivaraman, J., Menard, R., Mort, J.S. & Cygler, M. (1996) EMBO J. 15, 5492–5503. 15. James, M.N.G. & Sielecki, A.R. (1986) Nature (London) 319, 33–38. 16. Moore, S.A., Sielecki, A.R., Chernaia, M.M., Tarasova, N.I.& James, M.N.G. (1995) J. Mol. Biol 247, 466–485. 17. Khan, A.R., Cherney, M.M., Tarasova, N.I. & James, M.N.G. (1997) Nat. Struct. Biol 4, 1010–1015. 18. Fujinaga, M., Chernaia, M.M., Tarasova, N.I., Mosimann, S.C. & James, M.N.G. (1995) Protein Sci. 4, 960–972. 19. Esnouf, R.M. (1997) J. Mol Graphics 15, 133–138. 20. Merritt, E.A. & Murphy, M.E.P. (1994) Acta Crystallogr. D 50, 869–873. 21. Taggart, R.T., Cass, L.G., Mohandas, T.K, Derby, P., Barr, P.J., Pals, G. & Bell, G.I. (1989) J. Biol Chem. 264, 375–379. 22. Bateman, K.S., Cherney, M.M., Tarasova, N.I. & James, M.N.G. (1998) in The Aspartic Proteases: Retroviral and Cellular Enzymes, ed. James, M.N.G. (Plenum, New York), pp. 259–263. 23. Herriott, R.M. (1938) J. Gen. Physiol. 21, 501–540. 24. McPhie, P. (1972) J. Biol Chem. 247, 4277–4281. 25. Auer, H.E. & Glick, D.M. (1984) Biochemistry 23, 2735–2739. 26. Foltmann, B. & Jensen, A.L. (1982) Eur. J. Biochem. 128, 63–70. 27. Davies, D.R. (1990) Anna. Rev. Biophys. Chem. 19, 189–215. 28. Al-Janabi, J., Hartsuck, J. & Tang, J. (1971) J. Biol Chem. 247, 4628–4632. 29. Foltmann, B. (1981) Essays Biochem. 17, 52–84. 30. Perlmann, G.E. (1963) J. Mol Biol 6, 452–464. 31. Glick, D.M., Shalitin, Y. & Hitt, C.R. (1989) Biochemistry 28, 2626–2630. 32. Marciniszyn, J., Huang, J.S., Hartsuck, J.A. & Tang, J. (1976) J. Biol Chem. 251, 7095–7102. 33. Kageyama, T., Ichinose, M., Miki, K, Athauda, S.B., Tanji, M. & Takahashi, K. (1989) J. Biochem. (Tokyo) 105, 15–22. 34. Dunn, B. (1997) Nat. Struct. Biol 4, 969–972. 35. Dame, J.B., Reddy, R.G., Yowell, C.A., Dunn, B.M., Kay, J. & Berry, C. (1994) Mol Biochem. Parasitol. 64, 177–190. 36. Berry, C., Dame, J.B., Dunn, B.M. & Kay, J. (1995) in Aspartic Proteases: Structure, Function, Biology, and Biomedical Implications, ed. Takahashi, K. (Plenum, New York), pp. 511–518. 37. Francis, S.E., Gluzman, I.Y., Oksman, A., Knickerbocker, A., Mueller, R., Bryant, M.L., Sherman, D.R., Russell, D.G. & Goldberg, D.E. (1994) EMBO J. 13, 306–317. 38. Francis, S.E., Banerjee, R. & Goldberg, D.E. (1997) J. Biol Chem. 272, 14961–14968. 39. Hill, J., Tyas, L., Phylip, L., Kay, J., Dunn, B.M. & Berry, C. (1994) FEBS Lett. 352, 155–158. 40. Khazanovich Bernstein, N., Cherney, M.M., Loetscher, H., Ridley, R.G. & James, M.N.G. (1999) Nat. Struct. Biol 6, 32–37. 41. Silva, A.M., Lee, A.Y., Gulnik, S.V., Maier, P., Collins, J., Bhat, T.N., Collins, P.J, Cachau, R.E., Luker, K.E., Gluzman, I.Y., et al. (1996) Proc. Natl. Acad. Sci. USA 93, 10034–10039. 42. Sali, A., Veerapandian, B., Cooper, J.B., Moss, D.D., Hofmann, T. & Blundell, T.L. (1992) Proteins 12, 158–170. 43. Fusek, M. & Vetvicka, V. (1995) Aspartic Proteases: Physiology and Pathology (CRC, New York), pp. 22–24. 44. Sielecki, A.R., Fujinaga, M., Read, R.J. & James, M.N.G. (1991) J. Mol Biol 219, 671–692. 45. Moon, R.P., Bur, D., Loetscher, H., D’Arcy, A., Tyas, L., Oefner, C., Grueninger-Leitch, F., Mona, D., Rupp, K, Dorn, A., et al. (1997) Eur. J. Biochem. 244, 552–560. 46. Tanford, C. (1962) Adv. Protein Chem. 17, 69–165. 47. Rueckert, R.R. (1996) in Fields Virology, eds. Fields, B.N., Knipe, D.M., Howley, P.M., Channock, R.M., Melnick, J.L., Monath, T.P., Roizmann, B. & Straus, S.E. (Lippincott-Raven, Philadelphia), pp. 609–654. 48. Bergmann, E.M. & James, M.N.G. (1999) in Proteases of Infectious Agents, ed. Dunn, B. (Academic, San Diego), pp. 139–163. 49. Bergmann, E.M. & James, M.N.G. (1999) in Handbook of Experimental Pharmacology, eds. von der Helm, K. & Korant, B. (Springer, Heidelberg), in press. 50. Palmenberg, A.C. (1990) Annu. Rev. Microbiol. 44, 602–623. 51. Gorbalenya, A.E. & Snijder, E.J. (1996) Perspect. Drug Discovery Des. 6, 64–86. 52. Ryan, M.D. & Flint, M. (1997) J. Gen. Virol. 78, 699–723. 53. Harmon, S.A., Updike, W., Jia, X.-Y., Summers, D.F. & Ehrenfeld, E. (1992) J. Virol. 66, 5242–5247. 54. Richards, O.C., Ivanoff, L.A., Bienkowska-Szewczyk, K., Butt, B., Petteway, S.R., Jr., Rothstein, M.A. & Ehrenfeld, E. (1987) Virology 161, 348– 356. 55. Davis, G.J., Wang, Q.M., Cox, G.A., Johnson, R.B., Wakulchik, M., Datson, C.A. & Villarreal, E.C. (1997) Arch. Biochem. Biophys. 346, 125–130. 56. Jürgensen, D., Kusov, Y.Y., Facke, M., Kräusslich, H.G. & Gauss-Müller, V. (1993) J. Gen. Virol. 74, 677–683. 57. Probst, C., Jecht, M. & Gauss-Müller, V. (1998) J. Virol. 72, 8013–8020. 58. Ypma-Wong, M.F., Dewalt, P.G., Johnson, V.H., Lamb, J.G. & Semler, B.L. (1988) Virology 166, 265–270. 59. Palmenberg, A.C. & Rueckert, R.R. (1982) J. Virol. 41, 244–249. 60. Hanecak, R., Semler, B.L., Ariga, H., Anderson, C.W. & Wimmer, E. (1984) Cell 37, 1063–1073. 61. Bergmann, E.M., Mosimann, S.C., Chernaia, M.M., Malcolm, B.A. & James, M.N.G. (1997) J. Virol. 71, 2436–2448. 62. Matthews, D.A., Smith, W.W., Ferre, R.A., Condon, B., Budahazi, G., Sisson, W., Villafranca, J.E., Janson, C.A., McElroy, H.E., Gribskov, C.L. & Worland, S. (1994) Cell 77, 761–771. 63. Mosimann, S.C., Chernaia, M.M., Sia, S., Plotch, S. & James, M.N.G. (1997) J. Mol Biol 273, 1032–1047. 64. Fujinaga, M., Delbaere, L.T.J., Brayer, G.D. & James, M.N.G. (1985) J. Mol Biol 184, 479–502. 65. Huang, K, Lu, W., Anderson, S., Laskowski, M., Jr. & James, M.N.G. (1995) Protein Sci. 4, 1985–1997. 66. Tong, L., Wengler, G. & Rossmann, M.G. (1993) J. Mol Biol 230, 228–247.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10976
The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation,” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. MICHAEL GROLL*, WOLFGANG HEINEMEYERI†, SIBYLLE JÄGER†, TOBIAS ULLRICH*, MATTHIAS BOCHTLER*, DIETER H. WOLF†, AND ROBERT HUBER*‡ *Max-Planck-Institut für Biochemie, D-82152 Martinsried, Germany; and †Institut für Biochemie, Universität Stuttgart, D-70569 Stuttgart, Germany ABSTRACT We present a biochemical and crystallographic characterization of active site mutants of the yeast 20S proteasome with the aim to characterize substrate cleavage specificity, subunit intermediate processing, and maturation. β1 (Pre3), β2(Pupl), and β5(Pre2) are responsible for the postacidic, tryptic, and chymotryptic activity, respectively. The maturation of active subunits is independent of the presence of other active subunits and occurs by intrasubunit autolysis. The propeptides of β6(Pre7) and β7(Pre4) are intermediately processed to their final forms by β2(Pup1) in the wild-type enzyme and by β5(Pre2) and β1(Pre3) in the β2(Pup1) inactive mutants. A role of the propeptide of β1(Pre3) is to prevent acetylation and thereby inactivation. A gallery of proteasome mutants that contain active site residues in the context of the inactive subunits β3 (Pup3), β6(Pre7), and β7(Pre4) show that the presence of Gly-1, Thr1, Asp17, Lys33, Ser129, Asp166, and Ser169 is not sufficient to generate activity. Proteasomes are essential, ubiquitous intracellular proteases that degrade a broad variety of cytoplasmic, nuclear, and membrane proteins that have been marked for degradation by the attachment of polyubiquitin chains (1–3). Eukaryotic proteasomes are large protein complexes with a molecular mass around 2,000 kDa, with a modular architecture (4, 5). The catalytic core of the molecule is the 20S proteasome, a cylindrical particle that consists of four heptameric rings made from seven different subunits each, which are present in two copies and in unique locations so that the particle has overall 2-fold symmetry (1, 4–7). The yeast 20S proteasome subunits fall into two different classes phylogenetically related to the two subunits α and β of the archaebacterial proteasome (8) and have been named accordingly (7). The α-subunits are not catalytically active and form antechambers to the central cavity of the 20S complex that is built from the β-subunits. In Thermoplasma acidophilum proteasomes,all β-subunits are transcribed and translated from one gene only and are expressed as precursors. In the process of particle maturation, aII copies of the β-subunit become active, so that two rings of seven catalytic sites each are formed on the inner walls of the central chamber. The N-terminal threonine residue is exposed by this processing activity as the nucleophile in peptide bond hydrolysis (9, 10). It will subsequently be referred to as Thr1, thus assigning negative integers to residues of the propeptide. Based on the crystal structure of the T.acidophilum 20S proteasome, the distance between active site threonines was suggested as the molecular ruler that determines the length distribution of proteasome generated peptides (9). A more complex picture for the mechanism of oligopeptide product generation was suggested by the crystal structure of the yeast 20S proteasome (7). It contains seven different α- and β-type subunits arranged in unique locations (Fig. 1). Four β-type subunits are inactive because they contain either unprocessed [β3(Pup3) and β4(Pre1)] or intermediately processed propeptides [β6(Pre7) and β7 (Pre4)]. The remaining three subunits β1(Pre3), β2(Pupl), and β5(Pre2) have N-terminal threonine residues, are active, and have specificities determined largely by the nature of their S1 pockets (7). Specific mutants of the active β-type subunits have been isolated (11). They allowed the identification of different substrate specificities (11, 12) of the proteasome and led to a hypothesis for an intermolecular processing mechanism of inactive β-subunits. Functional and structural analysis of the mutant proteasomes allows us to investigate substrate specificities, catalytic and autolytic mechanisms, and intermediate processing of propeptides. They also provide hints to the role of propeptides in proteasome maturation and enzymatic activity and help to clarify the mechanism by which peptide product length is controlled. They provide critical tests of possible allosteric interactions in the proteasome. A number of mutants of inactive subunits was generated to define the roles of individual residues for inactivity with the ultimate goal to activate those subunits.
MATERIALS AND METHODS Protein Preparation and Analysis. Yeast strains that express mutant proteasomes were generated as described (11). Cells were grown on a 51 scale, and the modified enzymes were purified as reported for the wild-type (7). 20S proteasomes were separated into subunits by reversed phase HPLC. One-hundred-microgram samples were loaded on a RP60 Supersphere column (Merck). The column was washed with a gradient from 0 to 30% acetonitrile in 0.1% trifluoroacetic acid. Single subunits were eluted in a gradient from 30 to 60% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 0.3 ml/min and at a back pressure of 140 bar (1 bar=100 kPa). Peaks were identified and propeptides characterized by N-terminal sequence analysis and mass spectrometry. Crystals of 20S proteasome mutants from Saccharomyces cerevisiae were grown in hanging drops at 24°C as described (7). The crystals were frozen in a stream of cold nitrogen gas (90 K). Data were collected by using synchrotron radiation with λ=1.1 Å on the BW6 beamline at the Deutschen Elektronen-synchrotron Centre (Hamburg, Germany) (Table 3). The anisotropy of diffraction was corrected by an overall temper-
‡To
whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID code 1RYP).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10977
ature factor by comparing observed and calculated structure amplitudes by using X-PLOR (13). Electron density was averaged 10 times over the 2-fold noncrystallographic symmetry axis by using MAIN (14). Model building was carried out with FRODO (15).
FIG. 1. (a) Topology of the yeast 20S proteasome. The active site threonine 1 residues are located at the inner wall of the cylindrical particle. (b) Scheme of the β-rings with given distances between the active site threonines.
RESULTS AND DISCUSSION Subunit Processing. The topology of the yeast 20S proteasome is shown in Fig. 1a with the relevant distances between the active sites given in Fig. 1b. We have purified mutant yeast 20S proteasomes with a reduced number of active subunits carrying exchanges of Thr1 for Ala in β1 and β2. In β5, Lys33 was exchanged for Ala or Arg because β5T1A is not viable. Double mutants of β1 and β2 can be made. Some of these mutants show reduced growth (11), but 20S proteasomes can be isolated. We have characterized the β-subunits chemically by Edman degradation and, in some cases, by mass spectrometry after separation of the individual subunits by HPLC (Tables 1 and 2). The active subunits β1, β2, and β5 are processed autocatalytically and independently of each other. Inactivating β1 does not affect processing of β2 and vice versa. Similarly, the mutation of β5K33A and β5K33R leads to inactivity of β5 but has no effect on maturation of β1 and β2. This is consistent with earlier findings (16, 17), including pulse-chase experiments, which demonstrate that subunit maturation occurs late in proteasome assembly (11, 16, 18–20) after the formation of 15S–16S proteasome precursor particles. These particles are believed to be half proteasomes. As the active sites in 20S proteasomes are nearly 30 Å apart from each other, it appeared not possible that the Gly-1Thr1 cleavage occurs by a neighboring subunit. The data on β5 maturation are less straightforward to interpret. β5K33R has very low enzymatic activity but is autoprocessed. β5K33A is also inactive, but partially processed. We find clear electron density for the propeptide to residue Cys-8 in this mutant, but we can isolate by HPLC and mass spectrometry also the autoprocessed species (Table 2). An explanation might be an exceptional lability of the Gly-1Thr1 bond under the strongly acidic conditions of sample preparation for mass spectrometry. The β1 and β2 T1A exchange in both the single and the double mutants leads to a failure in autoprocessing and to the presence of intact or intermediately processed propeptides of these subunits. In the β1T1A β2T1A double mutant, β1 has its full length propeptide attached, and β2 is -intermediately processed after Leu-15. β7 is cleaved after Ile-19. In β6, cleavage after Ala-17 and Thr-14 is found. Cleavage occurs after nonpolar residues, consistent with cleavage by β5. Cleavage sites are at a sufficient distance from residue 1 to reach the remaining active centers of β5 in the same ring for β6 and β7 and in the opposite ring for β2 (Fig. 1b). In the single β1TlA-mutant, processing of β6 and β7 is as in the wild type, but β1 is cleaved after Arg-10, obviously by β2, whereas in β2T1A the β6 and β7 propeptides are longer than in the wild type. Here, β2 itself could not be characterized. The inactive subunits β6 and β7 are intermediately processed by one of the active subunits. β6 is adjacent to β5 on the same ring and to β2 on the opposite ring but further away from β1 on both rings of the 20S proteasome (Fig. 1). The nine amino acid propeptide in the mature wild-type protein is too short to span the distance to either of the β1 subunits. Experimentally, we find that inactivating β1 in the β1T1A-mutant, β5 in the β5K33A-mutant, and β1 and β5 in the β1TIA β5K33R mutant has no effect on the propeptide processing of β6. In contrast, a significantly longer propeptide remains attached to β6 in the β2T1A-mutant. We conclude that β6 is processed by β2. Cleavage occurs after His-10 (Table 1), consistent with the trypsin-like activity of β2. Because β2 in the same ring is too far away to be reached by a nonapeptide Gln-9 to Gly-1, β2 of the opposite ring must be the subunit that processes β6. In the case of β7, the situation is similar, but the subunits β5 and β1 swap roles. β7 is close to β2 on the opposite ring and to the subunits β1 on both rings. β5 is too far away to be involved in the final maturation step. Experimentally, the wild-type propeptide of β7 is found in the β1T1A, in the β5K33A mutant, and in the β1T1Aβ5K33R double mutant. In the β2T1A mutant, the cleavage that occurs in the wild type is suppressed, identifying β2 as the responsible subunit in the wild type. The cut occurs after Asn-9, a residue for which β2 has some specificity (12). These data substantiate previous biochemical findings on β7 maturation in the β2T1A single and β1T1A β2T1A double mutant, which led to the hypothesis that inactive β-subunits are processed by the closest active neighbor subunit (11).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10978
The intermediately processed propeptides of β6 and β7 had been found in well defined locations in the molecular structure of the wild-type protein such that their N termini lie at the inner annulus of the β-subunit rings far removed from the sites of proteolytic cleavage defined here (7). The same holds for the intermediately processed β1 propeptide in β1TIA and in β1T1Aβ5K33R. It has defined electron density to Leu-9, which also lies at the inner annulus, not far (16 Å) from β6Gln-9 and β7Thr-8. These observations indicate a major rearrangement of the propeptides after intermediate processing and fixation at the final sites seen in the crystal structure. In β1T1A β2T1A, the full length propeptide of β1 and the intermediately processed propeptides of β2, β6, and β7 have well defined electron density up to residues Met-19 (β1), Ala-14(β2), Gln-9(β6), and Thr-8(β7), respectively. Table 1. Yeast 20S proteasome mutants prepared and analyzed by N-terminal sequencing β1(Pre3) β2(Pup1) β3(Pup3) β4(Pre1) β5(Pre2) Wild type Gly-1 Gly-1 Gly-1 Thr1 Thr1 Met-9 Met-1 Thr1 β1(Pre3) without propeptide
Acetyl (mass*)
Gly-1 Thr1
Met-9
Met-1
Gly-1 Thr1
β1(Pre3) T1A
Arg-10 Leu-9 β2(Pup1) Gly-1 Thr1
Gly-1 Thr1
Met-9
Met-1
Gly-1 Thr1
XXX
Met-9
Met-1
Gly-1 Thr1
Not viable
Not viable
Not viable
Not viable
Not viable
Gly-1 Thr1
Gly-1 Thr1
Met-9
Met-1
β2(Pup1) T1A β5(Pre2) T1A β5(Pre2) K33A β1(Pre3) T1A β2(Pup1) T1A β1(Pre3) T1A β5(Pre2) K33R β2(Pup1) T1A β5(Pre2) K33R β3(Pup3) G1T β6(Pre7) G1T/ A129S/ A130G/ H166D/ V169S β7(Pre4) R33K/ F129S
β6(Pre7) His-10 Gln-9 β2(Pup1) His-10 Gln-9 β2(Pup1) His-10 Gln-9 β2(Pup1) Ala-17 Ser-16 β5(Pre2) Not viable
β7(Pre4) Asn-9 Thr-8 β2(Pup1) Asn-9 Thr-8 β2(Pup1) Asn-9 Thr-8 β2(Pup1) Val-10 Asn-9 β1(Pre3) Not viable
His-10 Gln-9 β2(Pup1) Ala-17 Ser-16
Asn-9 Thr-8 β2(Pup1) Ile-19 Ala-18
His-10 Gln-9 β2(Pup1)
Asn-9 Thr-8 β2(Pup1)
Leu-15 Ala-14 β5(Pre2); β5(Pre2) Gly-1 Thr1
Met-9
Met-1 (mass*) β5(Pre2);
Met-9
Met-1
XXX (mass*) Gly-1 Thr1 β5(Pre2); β5(Pre2) Gly-1 Thr1
Not viable
Not viable
Not viable
Not viable
Not viable
Not viable
Not viable
Gly-1 Thr1
Gly-1 Thr1
Met-9
Met-1
Gly-1 Thr1
Gly-1 Thr1
Gly-1 Thr1 β2(Pup1) (mass*)
Met-9 β2(Pup1)
Met-1
Gly-1 Thr1
His-10 Gln-9 β2(Pup1) His-10 Gln-9
Asn-9 Thr-8 β2(Pup1) Asn-9 Thr-8
Gly-1 Thr1
Gly-1 Thr1
Met-9
Met-1
Gly-1 Thr1
His-10 Gln-9 β2(Pup1)
Asn-9 Thr-8 β2(Pup1)
Met-19 Arg-10 Leu-9 β2(Pup1)
P1 and P1' cleavage sites of the processed subunits are given, and responsible active subunits are indicated, (mass*), a hint for comparison with analysis by mass spectroscopy in Table 2.
Implications for Cleavage Specificity. Two β subunits, β3 and β4, have propeptides of eight and one amino acids, respectively, which are too short to reach any catalytic site in the mature particle and are, indeed, not cleaved. The propeptides ofallother subunits are longer, and processing intermediates are observed. The discussed mutants are defective in some of the final maturation steps and show changes in the processing pattern. As shown above, most of the subunits responsible for these cleavages are defined and can be related to cleavage specificities. In the β1T1A-mutant, a nine-residue propeptide cleaved after Arg-10 is found, consistent with cleavage by β2 in the same ring, according to its tryptic specificity and distance. Processing is completely suppressed in the β1T1Aβ2T1A double mutant, and the β1Met-19 N terminus is observed. In the β2TlA-mutant, autoactivation is suppressed, but the subunit could no longer be separated by HPLC. We were able to characterize the cleavage site of the propeptide of β2 in the double mutant β1T1A β2T1A between Leu-15 and Ala-14. As the only active subunit left, β5 must be responsible for this cut, assigning to it branched chain amino acid preferring (BrAAP) specificity, consistent with previous studies (12). In the case of β5, we have mutated Lys 33 to Ala and to Arg, abolishing activity. In the β5K33A mutant, the resulting propeptide of β5 is heterogeneous and could not be analyzed by Edman degradation. A fraction is found that is autolysed and has a Thr1 N terminus. In the x-ray structure, however, there is defined density to Cys-8, indicating, that the major proportion is not autolysed. However, β5K33R is fully autolysed.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
Table 2. Results of mass spectrometry of the subunits in the different yeast 20S proteasome mutants β1(Pre3) β2(Pup1) β3(Pup3)– MET+Ac β4(Pre1)+Ac β5(Pre2) Wild type t: 21,494 t: 25,085 t: 22,514 t: 22,558 t: 23.300 e: 21,492 e: XXX e: 22,504 e: 22,559 e: 23,297 β1(Pre3) t: 22,376 t: 25,085 t: 22,514 t: 22,558 t: 23.300 T1A e: 22,374 e: XXX e: 22.514 e: 22,559 e: 23,296 β1(Pre3) without propeptide β2(Pup1) T1A
t: 21,536 e: 21,539 t: 21,494 e: 21,495
t: 25,085 e: XXX t: XXX e: XXX
t: 22,514 e: XXX t: 22,514 e: 22.516
t: 22,516 e: 22,559 t: 22,558 e: 22,559
t: 23.300 e: 23,303 t: 23.300 e: 23,300
β3(Pup3) G1T β5(Pre2) K33A
t: 21,494 e: 21,497 t: 21,494 e: 21,496
t: 25,085 e: XXX t: 25,085 e: XXX
t: 22,559 e: 22,548 t: 22,514 e: XXX
t: 22,558 e: 22,560 t: 22,558 e: 22,560
t: 23.300 e: 23,302 e: 23.243 r: 23,246
β6(Pre7) G1T/A12 9S/A130G /H166D/V 169S β1(Pre3) T1A/ β2(Pup1) T1A
t: 21,494 e: 21,496
t: 25,085 e: XXX t1:23,870 e1:23.872
t: 22,514 e: 22,516
t: 22,558 e: 22,560
t: 23.300 e: 23,301
β6(Pre7) t: 24,851 e: 24,850 t: 24,851 e: 24,833 (–H2O) t: 24,851 e: 24,854 t: 25,631 e: 25,547 (+H2O) t: 24,851 e: 24,856 t: 24,851 e: 24,838 (–H2O) t: 24,851 e: 24,850
t: 23,547 e: 23,562
t: 26,436 e: XXX t2:25,631 e2:25,629
t: 22,514 e: 22,516
t: 22,558 e: 22,560
t: 23.300 e: 23,301
t: 25,327 e: 25,341
10979
β7(Pre4) t: 25.919 e: 25.919 t: 25.919 e: 25.920 t: 25.919 e: 25.921 t: 26.033 e: 26,045 t: 25.919 e: 25.921 t: 25.919 e: 25.920 t: 25.919 e: 25.921
t: 26,832 e: 25.833
t, theoretical; e, experimental;1, additionally observed peak of autolysed β6;2, additionally observed peak of partially processed β6, which was not found by N-terminal sequencing and was not found in the β2T1A mutation.
β6 and β7 are processed to their final forms by β2 of the opposite ring. Therefore, we have analyzed the β2T1A-mutant for changes in the cleavage pattern of β6 and β7 propeptide. In β6, the cut occurs between Ala-17 and Ser-16, as analyzed by Edman degradation of an HPLC fraction. In the β1T1A β2T1A double mutant, a component with cleavage between Thr-14 and Pro-13 is found by mass spectrometry. This bond must be hydrolyzed by β5, assigning small neutral amino acid preferring (SNAAP) specificity to β5. In the β2T1A-mutant, β7 has one extra amino acid at the N terminus compared with the wild type. Inactivating β1 in addition to β2 shifts the cleavage further upstream to Ile-19 Ala-18. We conclude that β1 and β5 cleave after Val-10 and Ile-19, respectively, demonstrating BrAAP activity for both subunits, consistent with the apolar character of the P1 pocket of β5. In the case of β1, we assume that the positive charge of Arg 45 at the base of its P1 pocket is compensated by a bound bicarbonate anion to allow binding of neutral ligands, as had been observed before in the Leu-Leu-Norleucinal complex of the wild-type protein (7, 21).
FIG. 2. Stereodiagram of the superposition of β1 (green) and N-acetyl-β1 (yellow) around the Thr1 site. The structures match closely. The Role of the β1 Propeptide. The propeptide of β5 has been shown to be essential for cell viability but is functional when expressed in trans, suggesting a chaperone-like role in proteasome biogenesis (20). To investigate the role of the propeptide of β1, we have replaced its propeptide with ubiquitin. As in other linear ubiquitin fusions (22, 23), ubiquitin is cleaved by ubiquitin C-terminal hydrolases (24) to liberate the N-terminal threonine. The mutant proteasomes were inactive when assayed for postacidic cleavage (PGPH) activity. Their β1 subunit could be isolated by HPLC but was blocked for N-terminal sequencing. Structural analysis of the mutant proteasomes showed no significant differences to the wild-type structure except for extra density at the amino group of Thr1 that was interpreted as an acetyl group (Fig. 2) and confirmed by mass spectroscopy (Table 2). We conclude that the propeptide of β1 has a role in preventing co- or posttranslational
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10980
acetylation and inactivation of this subunit. The lack of enzymatic activity of the N-acetyl-β1 mutant supports the proposed mechanism of catalysis (9) assigning to the amino group of site Thr1 the role of the proton acceptor, but steric hindrance of substrate docking by the acetyl group also may contribute to inactivity. It is noted that the acetyl group is not cleaved via of the conserved Lys33 is in maintaining the appropriate structure and electrostatic potential in the vicinity of the active autolysis, probably for steric and electronic reasons. The role (7, 21). Table 3. Crystallographic data of data collection and refinement β2(Pup1) β5(Pre2) β1(Pre3) β1(Pre3) Space group P21 P21 P21 P21 Cell a=136.7 α=135.6 α=135.4 α=135.5 constants (Å/°) b=300.6 β=300.3 β=302.5 β=300.7 c=145.2 γ=144.0 γ=145.5 γ=144.4 β=113.1 β=113.0 β=112.6 β=112.9 Resolution, Å 50–2.5 50–2.5 50–2.7 50–1.9 Observation, 2σ 606959 951542 702094 2181093 Uniques 289028 343517 270036 752101 Completeness 88.3 93.3 93.8 92.9 14.4 12.9 12.8 11.9 Rmerge, % 30.3/36.5 26.0/31.2 27.5/36.4 26.8/33.0 R/Rfree, % rms bonds, Å 0.012 0.012 0.012 0.011 2.0 1.9 1.84 1.8 rms angles, °
β3(Pup3) P21 α=135.5 β=301.2 γ=146.5 β=112.8 50–2.9 631736 225640 94.5 12.2 21.1/27.3 0.011 1.85
β6(Pre7) –5* P21 α=135.7 β=300.3 γ=144.6 β=113.2 50–1.95 1755406 731544 91.1 12.1 28.5/32.1 0.011 1.933
β1(Pre3) without propeptide P21 α=135.9 β=301.6 γ=144.5 β=112.7 50–2.9 600449 218.345 94.2 13.6 22.7/297 0.012 1.89
FIG. 3. (a) Stereodiagram of the β1T1A β5K33R double mutant in the vicinity of residue Thr1 in β5. The electron density is calculated with phases from the wild-type β5 model, (b) Stereodiagram of wild-type (green) and β5K33R (white) mutant around Thr1. They superimpose closely except for the site of mutation. β5K33R autolyses and has a free Thr1. (c) Comparison of the wild-type (green) and β5K33A (white) mutant. Loss of the Lys33 side chain leads to a large movement of the backbone of Thr1. The mutant is unable to autolyse and has the propeptide attached. The Role of Lys33 in the Enzymatic Mechanism. The conservative exchange of Lys33 to arginine abolishes both autolysis and proteolysis in T.acidophilum proteasomes (25). We were particularly interested in this mutation because
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10981
arginine in position 33 occurs naturally in the subunit β7 of the yeast proteasome, where it displaces the Thr1 side chain, leading to incompetence in autolysis and to enzymatic inactivity (7). We exchanged Lys33 in β5 of the yeast proteasome with arginine. Crystals that diffract to 1.9-Å resolution (Table 3) could be obtained with a double mutant, which additionally has Ala exchanged for Thr1 in subunit β1. In contrast to wild-type β7 and the quintuple mutant of β6 (see below), aII residues in the vicinity of the active site of β5, including Thr1, remain in their wild-type positions. The arginine residue has its side chain in the same orientation as the lysine residue, but its guanidino group is tilted with respect to the position of the amino group in the lysine residue to avoid a clash with Thr1 (Fig. 3 a and b). As in T.acidophilum proteasomes, the chymotryptic activity of this mutant against chromogenic substrates is abolished. However, in contrast to results obtained for the T.acidophilum proteasome, the propeptide in the yeast mutant is cleaved. We attribute this observation to a weak residual activity that suffices for autolysis during particle maturation. The mutant grows slowly at 30°C but not at 37°C (11), and it overexpresses 20S proteasomes. The phenotype could be attributable either to the lack of chymotryptic activity or to delayed or impaired proteasome maturation. Genetic studies favor the latter explanation (11, 20). Because autolysis still occurs in the β5K33R mutant, we analyzed the β5 mutant carrying the Lys33Ala mutation. The mutant strain was viable, although again it grew slowly and contained unusually high amounts of 20S proteasome. As expected, both autolysis and proteolysis did no longer occur. The 2.5-Å crystal structure of this mutant shows defined density for the propeptide and a major rearrangement of the position of Thr1 that fills the cavity created by the loss of the lysine residue and displaces Met45 (Fig. 3c). Mass spectrometry of a fraction separated by HPLC, however, showed also the presence of some correctly processed species (Table 2).
FIG. 4. A gallery of superposition of main chain traces around Thr 1. a and b show the three active subunits β1, β2 and β5. In c and d, β1 is compared with wild-type β3 and β3G1T, respectively, in e and f, β1 is superimposed with wild-type β6 and the 5-fold β6 mutant (β6*), and, in g and h, β1 is compared with β7 and β4. Some Structural and Functional Comparisons. A comparison of the refined molecular models of the mutants β1T1A, β2T1A, and β1TIA β2T1A showed no significant variation of subunit positions or backbone structures. The activity against chromogenic substrates of a particular subunit is insignificantly altered by the presence or absence of intact sites of other subunits. We had previously shown that the covalent binding of a specific bound irreversible inhibitor of β2 has no significant influence on the PGPH and chymotryptic activity associated with β1 and β5 and does not show noticeable structural changes (26). Similarly, there is no measurable change in the activity and structure of β1 and β5 by strong binding of bifunctional reversible inhibitors to β2 (27). Also, yeast 20S
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10982
proteasome with lactacystin bound to β5 shows no structural change compared with the unligated species (7). These results do not support the existence of allosteric interactions between the active sites in general and argue against interactions mediated by conformational equilibria in particular. We are aware, however, that crystal lattice forces may oppose ligand-induced conformational changes occurring in solution.
FIG. 5. Stereo diagram of the 5-fold β6 mutant in the vicinity of residue 1. The electron density is calculated with phases from the wild-type β6 model (black bonds). The mutations A129S, G1T, and the rearrangement of K33 are clearly visible (red bonds). Reactivation Studies. All proteasomal β-subunits are members of a family of proteins having diverged from a single ancestor possibly similar to the archaebacterial β subunit. Nevertheless, only three subunits, β1, β2, and β5, are proteolytically active in yeast and higher eukaryotes The other β-subunits, β3, β4, β6, and β7, are inactive and unable to autolyse. β3, β4, and β6 lack the nucleophilic threonine in position 1, and β7 has Arg33 and Phe 129 instead of Lys33 and Ser129, respectively, as the most conspicuous changes. The conservation of backbone geometry and of the majority of residues making up the active site also in inactive proteasome βsubunits has prompted us to investigate the possibility of reactivating inactive subunits. We first chose the inactive subunits β3 and β6 as promising targets for subunit activation experiments because of the close similarity of their backbone fold with the active subunits β1, β2, and β5 (Fig. 4 a-c and e). β3. Gly1 replaces the canonical threonine in β3 as the most conspicuous exchange. It was mutated to threonine. The resultant yeast strain is viable and does not show a growth phenotype. Purified proteasomes from this strain show a blocked N terminus as the wild type. An antibody was raised against β3, and the migration of the mutant and of the wild-type subunit on denaturing SDS gels was compared. No difference could be observed, implying that the propeptide was not cleaved and the subunit remains inactive. Mass spectrometry confirms these results (Table 2). Additionally, we determined the crystal structure of this mutant, which, when compared with the wild-type β3-subunit, does not show major rearrangements and confirms that the propeptide is attached (Fig. 4 c and d). β6. We repeated the experiment in an analogous manner with β6. Although this subunit has a severely impaired catalytic machinery with Gly1, Ala129, His166, and Val169 instead of the cannonical Thr1, Ser129, Asp166, and Ser169, its backbone superimposes well with those of the active subunits, and the position of Lys33 is identical (Fig. 4e). Gly1 is shifted slightly toward Lys33 compared with the active subunits. We have replaced Gly1, Ala129, His166, and Val169 by their equivalents in active subunits. In addition, we exchanged Ala130 with glycine because this residue is conserved inallthree active subunits, although its role in catalysis is not obvious. The 5-fold mutant is again viable, but it has a severe growth defect. In comparison with the wild type, cells are up to 10×larger and express severalfold more proteasome, which could be purified and crystallized. The crystal structure analysis at 1.95-Å resolution shows defined electron density at β6 for all nine residues of the partially processed propeptide, but it is substantially lower than in the wild type and particularly blurred at residues Asn-2 and Gly-1. Temperature factors of the propeptide are very high. Also, the mass spectrum of the corresponding HPLC fraction showed the molecular weight of the Gln-9 species, but a component with the molecular weight, corresponding to the autolysed species, also occurs. We conclude that the mutant protein is partially autolysed. Residues Asp17, Ser129, Asp166, and Ser169 of the mutant subunit β6 are positioned as the corresponding residues in active wildtype subunit, but Thr1 remains where Gly1 in the wild-type β6 subunit is. A close contact between the Thr1 and Lys33 side chains displaces the lysine side chain into an outwardly oriented position, where it is stabilized by hydrogen bonds to Glu31 and Asp53 (Figs. 4f and 5). The distortion of Thr1 with respect to its position in active subunits prevents the binding of a water molecule in the vicinity of Thr1, as seen in active subunits (7). As the phenotype of the mutant is unlikely be accounted for by an extra proteasomal activity, we have looked for other explanations. The major activities of wild-type proteasomes are present but somewhat reduced. Therefore, we suspect a decreased stability of the quintuple mutant. β6 is in contact with β5 and β7 in the same ring and β2 and β3 of the opposite ring. His166 and Val169 contact β5, β2, and β3 whereas Ala129 and Ala130 contact β7. As seen from the lack of a phenotype of the triple mutant, β6G1T A129S A130G, which presumably has a displaced lysine residue and impaired contacts with β7, and from the lack of a phenotype of the quadruple mutant β6A129S A130G H166D V169S, individual
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE CATALYTIC SITES OF 20S PROTEASOMES AND THEIR ROLE IN SUBUNIT MATURATION: A MUTATIONAL AND CRYSTALLOGRAPHIC STUDY
10983
residue effects count to be weak. Only in the quintuple mutant, where contacts of β6 with all neighboring β-subunits are disturbed, is a notable phenotype seen. β7. Based on our observation that the displacement of the mutationally introduced Thr1 with respect to its position in active subunits could explain the failure to activate β3 and β6, and based on the perfect match of the polypeptide backbone around Thr1 of β7 and of the active subunits (Fig. 4g), we then attempted to activate β7. Two residues have to be replaced, Arg33 and Phe129. The resulting yeast strain was viable and indistinguishable from the wild-type. N-terminal sequencing of β7 revealed the presence of the wild-type propeptide. In the absence of a crystal structure, we can only suspect that the distortion in the backbone of wild-type β7 in the region around Phe129, which we attribute mainly to unfavorable interactions with Asp 166 (Fig. 4g), is still present in the mutant and responsible for the inactivity and inability to autolyse. We did not try to activate β4 because major differences between the Cα-traces of this subunit and of the active subunits exist (Fig. 4h). Note Added in Proof. While this paper was in press, a publication by Arendt and Hochstrasser (28) appeared suggesting acetylation of β1, β2, and β5 subunits by genetic methods in mutants lacking the respective propeptides. These results are in agreement with our findings in β1 by analytical methods. We thank Silvia Körner and Frank Siedler (Max-Planck-Institut für Biochemie, Martinsried, Germany) for help with mass spectrometry, Karlheinz Mann (Max-Planck-Institut für Biochemie, Martinsried, Germany) for help with N-terminal sequence analysis, and G.B. Bourenkow and H.Bartunik (DESY, Hamburg, Germany) for assistance with the x-ray experiments. The Sonderforschungsbereich 469 provided financial support. The work was furthermore supported by a grant from the Deutsche Forschungsgemeinschaft (Bonn) and the Fonds der Chemischen Industrie (Frankfurt). 1. Hilt, W. & Wolf, D.H. (1996) Trends Biochem. Sci. 21, 96–102. 2. Hershko, A. & Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425–479. 3. Hochstrasser, M. (1996) Annu. Rev. Genet. 30, 405–409. 4. Baumeister, W., Walz, J., Zühl, F. & Seemüller, E. (1998) Cell. 92, 367–380. 5. Peters, J.M., Cejka, Z., Harris, R.J., Kleinschmidt, J.A. & Baumeister, W. (1993) J. Mol Biol. 234, 932–937. 6. Coux, O., Tanaka, K. & Goldberg, A.L. (1996) Annu. Rev. Biochem. 65, 801–847. 7. Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H.D. & Huber, R. (1997) Nature (London) 386, 463–471. 8. Dahlmann, B., Kopp, F., Kuehn, L., Niedel, B., Pfeifer, G., Hegerl, R. & Baumeister, W. (1989) FEBS Lett. 251, 125–131. 9. Löwe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W. & Huber, R. (1995) Science 268, 533–539. 10. Seemüller, E., Lupas, A, Stock, D., Löwe, J., Huber, R. & Baumeister, W. (1995) Science 268, 579–581. 11. Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U. & Wolf, D.H. (1997) J. Biol. Chem. 272, 25200–25209. 12. Nussbaum, A.K., Dick, T.P., Keilholz, W., Schirle, M., Stevanovic, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D.H., Huber, R., et al. (1998) Proc. Natl. Acad. Sci. USA 95, 12504– 12509. 13. Brunger, A. (1992) X-PLOR Version 3.1; A System for X-Ray Crystallography and NMR (Yale Univ. Press, New Haven, CT). 14. Turk, D. (1992) Ph.D. thesis (Technical Univ.; Munich). 15. Jones, T.A. (1978) J. Appl. Crystallogr. 15, 24–31. 16. Schmidtke, G., Kraft, R., Kostka, S., Henklein, P., Frömmel, C, Löwe, J., Huber, R., Kloetzel, P.M. & Schmidt, M. (1996) EMBO J. 15, 6887–6898. 17. Ditzel, L., Stock, D. & Löwe, J. (1997) Biol. Chem. 378, 239–247. 18. Frentzel, S., Pesold-Hurt, B., Seelig, A. & Kloetzel, P.M. (1994) J. Mol. Biol. 236, 975–981. 19. Nandi, D., Woodward, E., Ginsburg, D.B. & Monaco, J.J. (1997) EMBO J. 16, 5363–5375. 20. Chen, P. & Hochstrasser, M. (1996) Cell 86, 961–972. 21. Ditzel, L., Huber, R., Mann, K., Heinemeyer, W., Wolf, D.H. & Groll, M. (1998) J. Mol. Biol. 279, 1187–1191. 22. Bachmair, A, Finley, D. & Varshavsky, A. (1986) Science 234, 179–186. 23. Arfin, S.M. & Bradshaw, R.A. (1988) Biochemistry 27, 7979– 7984. 24. Wilkinson, K.D. (1997) FASEB J. 11, 1245–1256. 25. Seemüller, E., Lupas, A. & Baumeister, W. (1996) Nature (London) 382, 468–470. 26. Loidl, G., Groll, M., Musiol, H.-J., Ditzel, L., Huber, R. & Moroder, L. (1999) Chem. Biol. 6, 197–204. 27. Loidl, G., Groll, M., Musiol, H.-J., Huber, R. & Moroder, L. (1999) Proc. Natl. Acad. Sci. USA 96, 5418–5422. 28. Arendt, C.S. & Hochstrasser, M. (1999) EMBO J. 18, 3575–3585.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10984
The structure of the human β II-tryptase tetramer: Fo(u)r better or worse
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation,” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. CHRISTIAN P. SOMMERHOFF*†, WOLFRAM BODE‡, PEDRO J. B. PEREIRA‡, MILTON T. STUBBS§, JÖRG STURZEBECHER¶, GERD P. PIECHOTTKA*, GABRIELE MATSCHINER*, AND ANDREAS BERGNER‡ *Abteilung Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik und Poliklinik, Klinikum Innenstadt der Ludwig-Maximilians-Universität, Nuβbaumstrasse 20, D-80336 Munich, Germany; ‡Abteilung für Strukturforschung, Max-PlanckInstitut für Biochemie, Am Klopferspitz 18a, D-82152 Martinsried, Germany; §Institut für Pharmazeutische Chemie der PhilippsUniversität Marburg, Marbacher Weg 6, D-35032 Marburg, Germany; and ¶Klinikum der Universität Jena, Zentrum für Vaskuläre Biologie und Medizin, Nordhäuserstrasse 78, D-99089 Erfurt, Germany ABSTRACT Tryptases, the predominant serine proteinases of human mast cells, have recently been implicated as mediators in the pathogenesis of allergic and inflammatory conditions, most notably asthma. Their distinguishing features, their activity as a heparin-stabilized tetramer and resistance to most proteinaceous inhibitors, are perfectly explained by the 3Å crystal structure of human βII-tryptase in complex with 4-amidinophenylpyruvic acid. The tetramer consists of four quasiequivalent monomers arranged in a flat frame-like structure. The active centers are directed toward a central pore whose narrow openings of approximately 40 A× 15 Å govern the interaction with macromolecular substrates and inhibitors. The tryptase monomer exhibits the overall fold of trypsin-like serine proteinases but differs considerably in the conformation of six surface loops arranged around the active site. These loops border and shape the active site cleft to a large extent and formallcontacts with neighboring monomers via two distinct interfaces. The smaller of these interfaces, which is exclusively hydrophobic, can be stabilized by the binding of heparin chains to elongated patches of positively charged residues on adjacent monomers or, alternatively, by high salt concentrations in vitro. On tetramer dissociation, the monomers are likely to undergo transformation into a zymogen-like conformation that is favored and stabilized by intramonomer interactions. The structure thus provides an improved understanding of the unique properties of the biologically active tryptase tetramer in solution and will be an incentive for the rational design of mono- and multi-functional tryptase inhibitors. Human mast cell tryptases (EC 3.4.21.59) comprise a family of trypsin-like serine proteinases closely related in sequence that are derived from ≥3 nonallelic genes (1, 2). Tryptases (at least isoenzymes αI, βI, βII, and βIII) are highly and selectively expressed in mast cells and to a lesser extent in basophils (3, 4). Only β-tryptases, however, appear to be activated intracellularly and stored in secretory granules (5, 6), accumulating to much larger amounts than any other of the granule-associated serine proteinases of leukocytes and lymphocytes. On mast cell activation, β-tryptases are secreted bound to heparin in diverse allergic and inflammatory conditions ranging from asthma and rhinitis to psoriasis and multiple sclerosis. Various studies performed in animals and humans have provided considerable evidence that tryptases are directly involved in the pathogenesis of asthma (7–9), a hypothesis also supported by apparent genetic links of tryptases to airway reactivity (10, 11). Several unique properties distinguish tryptases from other trypsin-like proteinases (reviewed in refs. 12 and 13). Most notably, tryptases are enzymatically active in the form of a noncovalently linked tetramer. The tetramer is stabilized by association with negatively charged aminoglycans such as heparin or high ionic strength conditions in vitro. On dissociation, reversible only under certain conditions, the monomers lose activity, apparently because of transition into a zymogen-like state (14, 15). This mechanism is thought to govern tryptase activity in vivo. With the exception of the “atypical” Kazal-type inhibitor leech-derived tryptase inhibitor (LDTI) (16, 17), human tryptases are resistant to inhibition by proteinaceous inhibitors. In accordance with their trypsin-like activity, tryptases efficiently hydrolyze a number of peptide substrates including the neuropeptides “vasoactive intestinal peptide” and “peptide histidine methionine” (18). Few macromolecular substrates are cleaved, however, leading to the activation of prostromelysin, prourokinase, and the protein-ase-activated receptor-2 (19–21) and the inactivation of fibronectin and of the procoagulant functions of high molecularmass kininogen and fibrinogen (22–24). These distinguishing features are well explained by the crystal structure of the human lung βII-tryptase tetramer, whose overall architecture has been summarized recently (25). Here, we describe the identification of the tetramer within the crystal packing, the detailed structure of the monomers, and their interactions in the tetramer. In addition, structural features likely to favor a zymogen-like conformation of isolated monomers and models of the interaction with stabilizing heparin proteoglycans and inhibitors are presented. Identification of the Relevant Tryptase Tetramer. In the x-y plane of the tryptase crystals, the tryptase-monomers are arranged in flat rectangular tetrameric aggregates that form extended protein layers (Fig. 1a). Within these layers, each tetramer is rotated about the crystallographic a- and b-axes by 7°, in agreement with the self-rotation function. The tetramers appear well separated from their neighbors in one direction (x-direction in Fig. 1a) but are in somewhat closer contact in the perpendicular direction (y in Fig. 1a). In the z-direction, the tetramers are stacked along the crystallographic 41 screw axis. Because of the 7° tilt of each tetramer from the x–y plane, their projections (Fig. 1b) alternate between leaning to the left, being horizontal, and leaning to the right, respectively, giving rise to a 7° precession motion of the
†To
whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviations: APPA, 4-amidinophenylpyruvic acid; LDTI, leech-derived tryptase inhibitor. Data deposition: The atomic coordinates have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID code 1A0L).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10985
local (2-fold; see below) rotation axis along the crystallographic 41 screw axis. The largely complementary interaction surfaces between the monomers of the tetramer are typical for intersubunit contacts, whereas neighboring tetramers interact with one another via much more usual crystal contacts. Thus, within a tetramer, monomer A (Fig. 2) interacts with monomers B and D via interfaces of sizes 540 Å2 and 1,075 Å2, respectively (solvent inaccessible surface probed by using a sphere of 1.4-Å radius; Collaborative Computational Project No. 4 suite). In contrast, the four monomers of one given tetramer interact with monomers from neighboring tetramers via interfaces of less than 280 Å2 (in the x-y plane) and 265 Å2 (along the z-axis), respectively. The contacts between tetramers include a number of hydrogen bonds and six unique salt bridges and thus are qualitatively similar to those usually observed in typical crystal contacts.
FIG. 1. Packing of the human βII tryptase crystal, (a) View along thez-axis showing one layer of tryptase molecules in the x-y plane. The tryptase monomers are grouped into tetrameric aggregates that form extended sheets. Each of these tryptase tetramers is clearly delimited from its neighbors in both directions. A “reference” tetramer is shown in red for simplicity, (b) View across the z-axis. In the z direction, layers of tetramers are stacked on each other along the 41 screw axis. The local 2fold symmetry axis is tilted from the z direction by 7°, causing increased crystal-stabilizing contacts between layers stacked in the z-direction. One unit cell (82.9×82.9×172.9Å), occupied by four tryptase tetramers, is indicated by a white bordered box. These packing considerations suggest that the tetramer emphasized in Fig. 1 represents the enzymatically active tetramer of human β-tryptase. This tetramer selection is supported by the finding that the six loops that deviate most from the structures of other trypsinlike proteinases are aII involved in forming monomer-monomer contacts within a tetramer. More important, this unique tetramer perfectly explains the distinguishing properties of tryptase in solution, e.g., the resistance to proteinaceous inhibitors other than LDTI, the unusual substrate specificity, and the stabilization by the binding of heparin-like glycosaminoglycans (see below). Overall Tetramer Structure. In the tryptase tetramer, monomers (arbitrarily assigned A, B, C, and D in Fig. 2) are positioned at the corners of a flat rectangular frame leaving a continuous central pore. The tetramer displays almost perfect 222 symmetry that, however, is not exact because of the crystallographically asymmetric environment and an imperfect internal packing (see below). The horizontal and the vertical 2-fold axes, which cross each other in the center of the tetramer, relate monomers A to B and C to D, or A to D and B to C, respectively. The third 2-fold symmetry axis relating monomers A to C and B to D is arranged virtually perpendicular to the other 2-fold axes and runs almost through their point of intersection in the central pore. The active centers of the four monomers are directed toward the central pore (Fig. 2). This pore exhibits a rectangular cross section and is twisted by 30° about the tetramer axis. It possesses two narrow openings of dimension 40 Å×15 Å, and widens in its central part to a cross section of 50 Å×25 Å, just large enough for elongated peptides of the diameter of an α-helix to thread though the exits and to interact with the active sites. Both pore entrances are partially obscured by the 147-loops (see below), which project from each of the monomers but on alternative entrance sides, so that only two diagonally arranged active centers can be viewed directly (Fig. 2). With 33 basic (including 12 His residues) and 24 acidic residues per monomer, human tryptase exhibits an average percentage of charged residues comparable to related serine proteinases, but is only slightly positively charged at neutral pH. These charges are not evenly distributed along the molecular surface, however. Rather, negatively charged residues cluster preferentially on the inner porefacing surface, conferring the pore with a quite negative electrostatic potential, and along the peripheral A–D (and B–C) edges. In contrast, the A–B (and C–D) peripheries and one front side of the monomer surface are positively charged and probably are involved in heparin binding (see below and Fig. 6). Monomer Structure. The tryptase monomer exhibits the typical β-strand-dominated fold seen in other trypsin-like serine proteinases. The core is made by two six-stranded
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10986
β-barrels that are packed together and further clamped by three transdomain segments (Fig. 3). This core structure is covered by a number of polypeptide loops, a short α-helical turn (Ala-55-Gly-66, not shown in Fig. 3a), and two regular α-helices, the so-called “intermediate helix” (Glu-164-Leu-173A) and the C-terminal helix (Arg-230-Val-242). The catalytic residues Ser-195, His-57, and Asp-102 (chymotrypsinogen numbering) are located in the junction between both barrels. The active-site cleft runs perpendicular to this barrel junction. In the “standard orientation” shown in Fig. 3, this cleft runs approximately horizontally across the molecular surface facing the viewer and is ready to accommodate and bind extended peptide substrates extending from left to right. One hundred sixty-two and 168 residues of the tryptase monomer are topologically equivalent to the archetypal proteinases chymotrypsin (26) and trypsin (27), respectively, with an rms deviation of their α-carbon atoms of 0.65 Å for both comparisons. The numbering of the tryptase residues given in this article is predominantly based on the equivalence with chymotrypsinogen (28) and at only a few trypsincharacteristic sites on that with trypsin (27).
FIG. 2. Overall structure of the tryptase tetramer. The four monomers A, B, C, and D (clockwise) are shown as blue, red, green, and yellow ribbons, each surrounded by a semitransparent surface. The inhibitor molecules APPA are given as orange CPK models, each binding into one of the four S1 specificity pockets.
FIG. 3. The tryptase monomer in standard orientation, i.e., as seen approximately from the middle of the central pore of the tetramer toward the active site of monomer A (represented by Ser-195, His-57, and Asp-102), (a) Ribbon representation of a tryptase monomer. The amidino group of the APPA molecule interacts with Asp-189 in the S1 pocket. Ser-195 O-γ is bound covalently to the APPA carbonyl group forming a hemiketal. The six unique surface loops of tryptase that surround the active site and are engaged in intermonomer contacts are shown in special colors, namely (anticlockwise) the 147-loop (light blue), the 70- to 80-loop (yellow), the 37-loop (orange), the 60-loop (magenta), the 97-loop (green), and the 173-flap (red). All other tryptase segments are given in dark blue. The side chains of the catalytic triad residues as well as Asp-143, Asp-145, and Asp-147 in the acidic 147-loop are shown as a ball-and-stick model. (b) Overlay of the structures of the tryptase monomer and bovine trypsin, both given as ropes. The color-coding of tryptase is as in a, whereas trypsin is shown in gray. The most relevant deviations from the trypsin backbone appear in the colored loop regions of tryptase. In detail, however, the topology of the tryptase monomers deviates significantly from these reference proteinases (Fig. 3b), probably more than any other trypsin-like serine proteinase. In particular, six surface loops that border and shape the active-site cleft are unique (Fig. 3a). These loops comprise the 147-loop (including the 152-“spur”), the 70- to 80-loop, the 37-loop, the 60-loop, the 97loop, and the 173-loop (Fig. 3a). The 147-loop, which together with Gln-192 forms the rather acidic southern wall of the active-site cleft, is shortened by one residue in its initial part, but contains a two-residue insertion (Pro-152-Pro-152A-cisPro-152B-Phe-153Pro-154) in its proline-rich and hydrophobic 152-spur. The neighboring 70- to 80-loop to the east, which in the calcium-binding serine proteinases winds around a stabilizing calcium ion (27), is three residues shorter and more compact in tryptase. It is probably not designed for calcium binding, in spite of topologically similar liganding groups; Glu-70 and Asp-80, involved in a partially buried salt bridge cluster with Arg-34, are oppositely arranged to the two calcium-binding Glu residues in trypsin. The 37-loop, above the 70- to 80-loop, possesses two additional residues (Pro-37A and Tyr-37B), which bulge away from the loop axis. The adjacent 60-loop, with five inserted residues, turns away from the cleft abruptly to the north, where it kinks at cisPro-60A to approach the general main chain course of other serine proteinases. At position 69, a buried Arg replaces the Gly residue that is strictly conserved in most other homologous proteinases, allowing for a special conformation. Although the 97-loop, at the northern rim of the cleft, contains the same number of residues as other serine proteinases, it differs considerably in conformation. The N-terminal part is shortened by two residues between positions 96 and 97, thus placing Ala-97 in the position normally occupied by residue 99,
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10987
whereas its C-terminal part makes an unusual extra helical turn before arriving at Asp-102. By far the largest insertion, with nine residues, occurs in the 173-loop. After the unusually long three-turn intermediate helix, the 10 residues from His-173 to Val-173I form an exposed flap centered around the imidazole side chain of His-173. With 245 amino acid residues, the tryptase monomer possesses 15 and 22 residues more than the B-chains of chymotrypsin and trypsin, respectively. Compared with chymotrypsinogen, most of these extra residues present in all tryptases known so far are inserted in the 37-loop (two residues), the 60-loop (+5), the 147-loop (+1), the 173-loop (+9), at position 221A (+1) and at the C terminus (+1), whereas the 70- to 80-loop (–3) and the 214- to 220-loop (–1, as inalltrypsin-like serine proteinases) are shorter. On the reverse side, the largely hydrophobic cluster of four Trp residues (Trp-27, -29, -207, and -137) is noteworthy. Only the indole moieties of the latter two Trp are significantly exposed to the surface. At the C terminus, only the main chain atoms of the two penultimate residues Lys-244 and Lys-245 are well defined by electron density, while the C-terminal Pro-246 could not be located. The side chain of the single Nlinked sugar attachment site in human βII-tryptase, Asn-204, extends away from the molecular surface opposite to the active site. Some residual electron density exists distal to its carboxamide group, which is not large enough to account for a covalently linked sugar residue. As found in almost all trypsin-like serine proteinases [except, e.g., single-chain tissue type plasminogen activator (29)], the Nterminal Ile-16-Val-17 segment is inserted in the Ile-16 pocket, forming a solvent inaccessible salt bridge between its free Ile-16 αamino group and the carboxylate group of Asp-194. The formation of this salt bridge after activation cleavage creates a functional substrate recognition site by reorienting the Asp-194 side chain from an external position in the zymogen, where it might hydrogen bond to a surface located His-40··· Ser-32 pair forming the so-called “zymogen triad,” to an internal position in the active molecule (30, 31). This reorientation restructures the surrounding “activation domain,” which in trypsin(ogen) mainly includes the linings of the Ile-16 pocket and the S1 specificity pocket (i.e., segments Ile-16-Gly-19, Tyr-184-Asp-194, Gly-216-Asn-223, and Gly-142-Tyr-151), and the “oxyanion hole” formed by the amide groups of Gly-193 and Ser-195 (28, 32, 33). The single-chain zymogen and the activated monomer are adequately described by a two-state model, in which an inactive conformation is in equilibrium with an active form possessing a structured activation domain (31). The partition between both forms depends on environmental conditions such as the endogenous free Ile-16-Val-17 N-terminal segment (34), free Ile-Val dipeptide (31), ligands in the substrate binding site (30, 36), or other effectors such as fibrin with respect to tissue plasminogen activator or tissue factor in the case of Factor VIIa (29, 37). This conformational partition can be influenced by internal molecular groups that stabilize or destabilize one or the other state. Tryptase possesses the zymogen triad residues His-40 and Ser-32, which would stabilize the zymogen state. In addition, the acidic residues Asp-143, Asp-145, and Asp-147 arranged around the Ile-16 cleft could form a negatively charged anchoring site that could compete with the Ile-16 pocket for the Ile-16 α-amino group, thus destabilizing the structured active state of the tryptase monomer. Furthermore, some of the loops in contact with the activation domain of tryptase, such as the long 173-loop or the 70- to 80-loop, which has been shown to be strongly correlated with the equilibrium state in bovine elastase “subunit III” (38), could influence the structured state. The conformation of the tryptase 173-loop, probably held in place in the tetramer by contacts with monomer D, certainly has an effect on the stability of the integrated monomer. Interestingly, tissue factor, thought to support insertion of the N-terminal Ile-16 α-amino terminus of activated Factor VIIa B-chain on complex formation (37), likewise binds to the 173-loop at the intermediate helix flank (39). Interfaces. All monomer-monomer contacts within the tetramer are realized via six loops arranged around the active center. These loops, emphasized by special colors in Figs. 3–5, differ fundamentally in their conformation and partly in size from those of other trypsin-like serine proteinases. Monomers A and B interact with one another through the 147-loop, the 70- to 80-loop, and the 37-loop (Fig. 4d). Each 152-spur slots into a cleft formed by the 37- and the 70- to 80-loop of its own monomer and the 152-spur of the opposing neighbor. At the center of the interface, the side chains of Phe-153 and Tyr-75 from each subunit form an approximate tetrahedron (Fig. 5a). The side chain of Tyr-75 from monomer B (D) would clash with the equivalent A (C) side chain if they were arranged in a symmetrical manner. Instead, the phenolic group of Tyr-75 of monomer A turns in the opposite direction, breaking the 2fold symmetry (see the partial electron density in Fig. 5a). This A–B (C–D) interface is exclusively hydrophobic, with a remarkable number of Tyr and Pro side chains involved, and lacks any intermonomer hydrogen bonds. Toward the pore, the side chains of the two Arg-150 residues oppose one another. The charges of their guanidyl groups presumably make unfavorable energy contributions to the A–B interaction.
FIG. 4. Loop arrangements in the tetramer. The six special loops engaged in monomer-monomer interactions are shown in the color coding introduced in Fig. 3. (a) The D–A dimer as seen from outside of the tetramer along the local 2-fold axis, (b) The monomer viewed in standard orientation, (c) Front view of the tetramer. (d) The A–B dimer seen from outside of the tetramer along the local 2-fold axis. Monomer A interacts with monomer D through the entire northern rim consisting of the 173-flap, the 97-loop, and the 60-loop (Figs. 4a and 5b), again via equivalent loops. Both 97-loops rest with their 95–99 segments on one another (Fig. 4a), with both Ile-99 side chains in direct contact. Further toward both peripheries, segment Pro-60A-Asp-60B and the opposing segment Gly-173BTyr-173D run antiparallel to one another, forming two-rung antiparallel ladders between Gly-173B-Tyr-173D and Pro-60A-Val-60C (Fig. 5b). Each Tyr-95 aromatic side chain nestles into the bend of the opposing 173-flap, and each Tyr-173D phenolic side chain slots into a hydrophobic cleft made by the 60-loop and the 97-loop of the opposing monomer. In addition, both monomers are crossconnected by salt bridges between Asp-60B and Arg-224 and
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10988
by four hydrogen bonds involving both main and side chains (Fig. 5b). Thus, the A–D (and the corresponding B–C) interface comprises a number of polar/charged interactions in addition to several hydrophobic contacts.
FIG. 5. Stick representation of the contact interfaces between monomers, (a) The AB-interface seen from inside the tetramer along the local 2-fold axis, shown together with the final 2F0-Fc electron density map for both Tyr-75 side chains contoured at 1 σ level. The monomers and loops are given in the color coding introduced in Figs. 3 and 4. (b) The AD-interface (half side) observed approximately perpendicular to the local 2-fold axis, shown together withallintermonomer hydrogen bonds and salt bridges (green dots). Segments of monomers A and D are given in blue and yellow, respectively. The A–B homodimer carries a number of positively charged residues at the periphery, which cluster and form an obliquely oriented two-lobed patch of positive charges that extends toward one of the front sides of each monomer, giving rise to the blue-colored electrostatic potential surfaces in Fig. 6. With an overall length of almost 100 Å, this patch would allow tight electrostatic binding of an extended heparin chain of 20 sugars running obliquely along the A–B edge as shown in Fig. 6. The length of such heparin chains is in good agreement with the experimentally observed stabilization of the tetramer by heparin fractions of molecular mass 5,500 Da and above (40). On the peripheral surface of the A–D (and the corresponding B–C) homodimer, in contrast, positive charges are counterbalanced by adjacent negative ones. Interaction with Substrates and Inhibitors. The immediate vicinity of the tryptase active site is quite similar in structure to that of trypsin. The specificity S1 pocket, which opens to the west of the reactive Ser-195 (Fig. 3a), is virtually identical to that of trypsin and well suited to accommodate P1-Lys and Arg side chains. The 4-amidinophenylpyruvic acid (APPA) molecule inserts into this pocket in the same manner as in the complex with trypsin (41). Thus, its amidino group hydrogen is bonded to both Asp-189 carboxylate oxygens, Gly-219 O and Ser-190 Oγ, and its phenyl ring is sandwiched between peptide planes 215–216 and 190–192. Ser-195 Oγ bonds to the carbonyl group of the tetrahedral pyruvate part of APPA (Fig. 3a), and hydrogen bonds to His-57 Nε. As indicated by the relatively low equilibrium dissociation constant of the APPA-tryptase complex [Ki 0.71 µM; (42)], APPA fits well to the tryptase active site. Toward the south of the active site of tryptase, the side chains of Asp-143, Asp-145, and Asp-147 protrude from the relatively flat and hydrophobic southern embankment (Fig. 3a). The resulting negative charge cluster provides a second anchoring point for dibasic synthetic tryptase inhibitors such as bis-benzamidines (17, 42, 43), allowing favorable interactions with a distal basic group such as in pentamidine. The structural basis of the unexpected high affinity of bifunctional inhibitors containing suitably arranged adjacent imidazole moieties such as present in the inhibitor BABIM and closely related analogues (43, 44) has recently been revealed: two nitrogen atoms
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10989
of the two methylene-connected benzimidazoles coordinate a zinc zinc that also binds to the active-site located Ser-195 Oγ and His-57 Nε (44). The zinc-mediated binding enhancement of BABIM-like inhibitors is particularly large but not restricted to tryptase.
FIG. 6. Model of the binding of a 20-mer heparin-like glycosaminoglycan chain along the A–B edge of the tryptase-tetramer. The solid-surface representation of tryptase indicates positive (blue) and negative (red) electrostatic potential contoured from –4 kT/e to 4 kT/e. The heparin chain (green/yellow/red stick model) is long enough to bind to clusters of positively charged residues on both sides of the monomer-monomer interface, thereby bridging and stabilizing the interface which is exclusively hydrophobic in nature (see Fig. 5a). Toward the east, the substrate-binding site of tryptase is not only bounded by the side chains of Tyr-37B and Tyr-74 of monomer A, but also by the Phe-153 benzyl group and the 152-spur of the neighboring monomer B. Thus, binding of extended substrate chains is limited to about P5 (Fig. 7). Toward the north, the 97-loop of monomer A borders the substrate binding region in a manner different from most other serine proteinases, and together with the side chains of Phe-94, Ala-97, and Gln-98 of monomer D forms a projecting “canopy.” The S2 subsite underneath is open and larger than that of trypsin. The S3/S4 subsite above the Trp-215 indole moiety is fully blocked by the side chain of Gln-98 and the phenolic group of Tyr-95 provided by monomer D. Toward the west, however, the substrate-binding site is bordered exclusively by segments of the D-monomer, in particular the His-57 imidazole ring and segment 57– 60. Thus, the active centers of monomers A and D (B and C) are spatially close (distance 23 Å for the A–D pair) to each other in the tryptase tetramer, rendering the tryptase tetramer suitable for the specific binding of bifunctional inhibitors with relatively short spacers.
FIG. 7. View from the LDTI inhibitor (represented only by its reactive site loop P7 to P3) toward the active-site cleft. The P1 Lys residue is buried. The central pore of tryptase restricts the size of accessible substrates and inhibitors considerably. For larger proteins such as fibronectin and the zymogens of stromelysin-1 and urokinase-type plasminogen activator, the cleavage sites must be extended into the active sites. Docking experiments with C-terminally truncated prostromelysin-1 (45) and with single-chain tissue plasminogen activator (29) as a model for prourokinase show that the activation cleavage loops of these proproteinases must be extracted from their crystal structures to allow binding in the tryptase active center. More flexible peptides, in contrast, could easily thread through the pore of the tetramer to be processed or destroyed. Flexible polypeptide chains with two distant basic residues, as in “vasoactive intestinal peptide” (18), might even dock to adjacent active sites simultaneously to produce fragments of distinct length. The active centers of the tryptase monomers are also largely inaccessible for macromolecular inhibitors. The only exception known is LDTI, an “atypical” Kazal-type inhibitor that is smaller than the classical members of this family (16). LDTI has been shown to bind to trypsin through its reactive-site loop (residues P4 to P4) in a canonical manner (17, 46). In the model of the complex with tryptase monomer A, the four N-terminal residues preceding this binding segment could bend toward the south (with respect to Figs. 3 and 7), leading to the juxtaposition of the basic Lys-I1-Lys-I2 amino terminus (with the suffix I identifying inhibitor residues) with the carboxylate groups of Asp-143 and Asp-147 of monomer A. Alternatively, the two Lys residues could interact with Asp-60B of molecule D. The involvement of such electrostatic interactions is supported by the deleterious effect of deletions and substitutions of these basic residues on the affinity of LDTI toward tryptase but not trypsin (17). The LDTI reactivesite loop, running from Cys-I14 (P5) to Pro-I22 (P4; ovomucoid numbering), is relatively small compared with classical Kazal-type inhibitors, allowing good overall fit to the restricted substrate binding groove (Figs. 7 and 8a). Furthermore, its central helix is one turn shorter, so that it just fits into the central pore of the tetramer on canonical binding to the active site of monomer A with only a few narrow contacts of its molecular antipole, opposite to its reactive-site loop, with the 147-loop of monomer D. Docking of a second LDTI molecule is possible at the opposite active centers of either monomer B or monomer C (Fig. 8a). A slight collision between Cys-I56 and Gly-I28 of two bound LDTI molecules could be relieved by minor torsion in the proteinase-inhibitor interfaces, as observed for other canonically binding inhibitors such as eglin c (46). Any such torsion in the LDTI molecule bound to monomer A would impose an opposing torsion in the LDTI molecule bound to monomer B, facilitating such a relaxation. The simultaneous binding of two LDTI molecules to the tetramer is in good agreement with experimental results showing 50% inhibition of the cleavage activity toward small chromogenic substrates by nanomolar LDTI concentrations (16). Modeling experiments with more elongated classical Kazal-type inhibitors or with the prototypical bovine pancre-
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10990
atic trypsin inhibitor indicate strong collisions of their distal pole segments with the neighboring monomers D and B, in particular with the 147-loops, explaining the observed inactivity of these inhibitors toward tryptase (Fig. 8b). The central portion of the two-domain mucous proteinase inhibitor (MPI=SLPI=HUSI-I) would clash with the A–D interface region of the tryptase tetramer if bound to the active site of monomer A (Fig. 8c) via its inhibitorily active second domain (47). Similarly, elafin (=SKALP), an inhibitor corresponding to the MPI second domain (48), should not be able to inhibit tryptase. The much larger plasma proteinase inhibitors are clearly far too bulky to fit into the narrow pore of the tryptase tetramer and gain access to one of the active centers.
FIG. 8. Models of the interaction of the human tryptase tetramer with proteinaceous inhibitors. The tryptase tetramers are shown as green ribbons. An inhibitor molecule (blue) is modeled into the active site of monomer A by superposition of the proteinase moiety of known proteinase-inhibitor complexes to a tryptase monomer. For LDTI and BPTI the target proteinase was trypsin (17, 49), for MPI chymotrypsin (47). The active sites of the other tryptase monomers are occupied by APPA molecules (orange). Parts of the inhibitors clashing with the structure of tryptase (i.e., a distance smaller than 1.5 Å between the Cα-atoms of the respective molecules) are highlighted in red. (a) In addition to one molecule of the “atypical” Kazal-type inhibitor LDTI bound to the tryptase monomer A a second molecule (shown in pink and yellow) can bind to the active site of either monomer B or C. (b) Bovine pancreatic trypsin inhibitor (aprotinin). (c) Human mucous proteinase inhibitor bound to tryptase with its inhibitorily active second domain.
CONCLUSION In summary, the structure of the βII-tryptase tetramer has been identified based on the four crystallographically independent quasiidentical monomers and the analysis of their arrangement within the crystal packing. With its frame-like architecture and its active centers facing a narrow central pore, the resulting tryptase tetramer structure explains most of the distinct properties of the biologically active tryptase tetramer in solution. The unusual substrate specificity, with a preference for peptidergic substrates, and the resistance to proteinaceous inhibitors other than LDTI are both caused by the limited accessibility of the active sites within the narrow central pore. The tetramer can be stabilized by heparin glycosaminoglycan chains larger than 20 sugar residues, a length required to bridge the weaker of the two distinct monomer-monomer interfaces. The loss of enzymatic activity on dissociation of the tetramer is caused by stabilization by internal molecular groups of a zymogen-like rather than the active state. Finally, the knowledge of the structure of the active center of the monomer as well as of the distances between neighboring active sites allows the rational design of multifunctional inhibitors. Such inhibitors that bind to more than one active center will ideally have potentiated affinity, conferring selectivity for the tryptase tetramer. Such inhibitors will be valuable as pharmacological tools to probe the pathophysiological function(s) of tryptases in vivo and may have therapeutic potential against asthma and other mast-cell related disorders. We are grateful to R.Huber and H.Fritz for their generous support. We thank D.Grosse and R.Mentele for their excellent help in crystallization and amino acid sequence analysis. This work was supported by Sonderforschungsbereich 469 of the University of Munich, the Deutsche Forschungsgemeinschaft (STU 161, BO 1279), the Fonds der Chemischen Industrie, and programs BIO4-CT98– 0418 and TMR ERBFXCT 98–0193 of the European Union. 1. Miller, J.S., Westin, E.H. & Schwartz, L.B. (1989) J. Clin. Invest. 84, 1188–1195. 2. Pallaoro, M., Fejzo, M.S., Shayesteh, L., Blount, J.L. & Caughey, G.H. (1999) J. Biol Chem. 274, 3355–3362. 3. Schwartz, L.B., Irani, A.M., Roller, K., Castells, M.C. & Schechter, N.M. (1987) J. Immunol. 138, 2611–2615. 4. Xia, H.Z., Kepley, C.L., Sakai, K., Chelliah, J., Irani, A.M. & Schwartz, L.B. (1995) J. Immunol 154, 5472–5480. 5. Schwartz, L.B., Sakai, K., Bradford, T.R., Ren, S., Zweiman, B., Worobec, A.S. & Metcalfe, D.D. (1995) J. Clin. Invest. 96, 2702–2710. 6. Sakai, K., Ren, S. & Schwartz, L.B. (1996) J. Clin. Invest. 97, 988–995. 7. Caughey, G.H. (1997) Am.J.Respir. Cell Mol. Biol. 16, 621–628. 8. Johnson, P.R. A., Ammit, A.J., Carlin, S.M., Armour, C.L., Caughey, G.H. & Black, J.L. (1997) Eur. Respir. J. 10, 38–43. 9. Rice, K.D., Tanaka, R.D., Katz, B.A., Numerof, R.P. & Moore, W.R. (1998) Curr. Pharm. Des. 4, 381–396. 10. De Sanctis, G.T., Merchant, M., Beier, D.R., Dredge, R.D., Grobholz, J.K., Martin, T.R., Lander, E.S. & Drazen, J.M. (1995) Nat. Genet. 11, 150– 154. 11. Hunt, J.E., Stevens, R.L., Austen, K.F., Zhang, J., Xia, Z. & Ghildyal, N. (1996) J. Biol. Chem. 271, 2851–2855. 12. Schwartz, L.B. (1994) Methods Enzymol. 244, 88–100. 13. Caughey, G.H. (1995) Mast Cell Proteases in Immunology and Biology (Dekker, New York). 14. Ren, S., Sakai, K. & Schwartz, L.B. (1998) J. Immunol. 160, 4561–4569. 15. Selwood, T., McCaslin, D.R. & Schechter, N.M. (1998) Biochemistry 37, 13174–13183. 16. Sommerhoff, C.P., Söllner, C., Mentele, R., Piechottka, G.P., Auerswald, E.A. & Fritz, H. (1994) Biol. Chem. Hoppe-Seyler 375, 685–694. 17. Stubbs, M.T., Morenweiser, R., Stürzebecher, J., Bauer, M., Bode, W., Huber, R., Piechottka, G.P., Matschiner, G., Sommerhoff, C.P., Fritz, H., et al. (1997) J. Biol. Chem. 272, 19931–19937.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
THE STRUCTURE OF THE HUMAN ΒII-TRYPTASE TETRAMER: FO(U)R BETTER OR WORSE
10991
18. Tam, E.K. & Caughey, G.H. (1990) Am.J.Respir. Cell Mol Biol 3, 27–32. 19. Gruber, B.L., Marchese, M.J., Suzuki, K., Schwartz, L.B., Okada, Y., Nagase, H. & Ramamurthy, N.S. (1989) J. Clin. Invest. 84, 1657–1662. 20. Stack, M.S. & Johnson, D.A. (1994) J. Biol. Chem. 269, 9416–9419. 21. Molino, M., Barnathan, E.S., Numerof, R., Clark, J., Dreyer, M., Cumashi, A., Hoxie, J.A., Schechter, N., Woolkalis, M. & Brass, L.F. (1997) J. Biol. Chem. 272, 4043–4049. 22. Lohi, J., Harvima, I. & Keski-Oja, J. (1992) J. Cell. Biochem. 50, 337–349. 23. Little, S.S. & Johnson, D.A. (1995) Biochem. J. 307, 341–346. 24. Schwartz, L.B., Bradford, T.R., Littman, B.H. & Wintroub, B.U. (1985) J. Immunol. 135, 2762–2767. 25. Pereira, P.J., Bergner, A., Macedo-Ribeiro, S., Huber, R., Matschiner, G., Fritz, H., Sommerhoff, C.P. & Bode, W. (1998) Nature (London) 392, 306–311. 26. Blevins, R.A. & Tulinsky, A. (1985) J. Biol. Chem. 260, 4264– 4275. 27. Bode, W. & Schwager, P. (1975) J. Mol. Biol. 98, 693–717. 28. Wang, D., Bode, W. & Huber, R. (1985) J. Mol. Biol. 185, 595–624. 29. Renatus, M., Engh, R.A., Stubbs, M.T., Huber, R., Fischer, S., Kohnert, U. & Bode, W. (1997) EMBO J. 16, 4797–4805. 30. Huber, R. & Bode, W. (1978) Acc. Chem. Res. 11, 114–122. 31. Bode, W. (1979) J. Mol. Biol. 127, 357–374. 32. Freer, S.T., Kraut, J., Robertus, J.D., Wright, H.A.T. & Xuong, N.H. (1970) Biochemistry 9, 1997–2009. 33. Bode, W., Fehlhammer, H. & Huber, R. (1976) J. Mol. Biol. 106, 325–335. 34. Hedstrom, L., Lin, T.Y. & Fast, W. (1996) Biochemistry 35, 4515–4523. 35. Bode, W., Schwager, P. & Huber, R. (1978) J. Mol. Biol. 118, 99–112. 36. Bolognesi, M., Gatti, G., Menagatti, E., Guarneri, M., Marquart, M., Papamokos, E. & Huber, R. (1982) J. Mol. Biol. 162, 839–868. 37. Higashi, S. & Iwanaga, S. (1998) Int.J.Hematol. 67, 229–241. 38. Pignol, D., Gaboriaud, C., Michon, T., Kerfelec, B., Chapus, C. & Fontecilla Camps, J.C. (1994) EMBO J. 13, 1763–1771. 39. Banner, D.W., D’Arcy, A., Chene, C., Winkler, F.W., Guha, A., Konigsberg, W.H., Nemerson, Y. & Kirchhofer, D. (1996) Nature (London) 380, 41–46. 40. Alter, S.C., Metcalfe, D.D., Bradford, T.R. & Schwartz, L.B. (1987) Biochem. J. 248, 821–827. 41. Walter, J. & Bode, W. (1983) Hoppe-Seylers Z. Physiol. Chem. 364, 949–959. 42. Stürzebecher, J., Prasa, D. & Sommerhoff, C.P. (1992) Biol Chem. Hoppe-Seyler 373, 1025–1030. 43. Caughey, G.H., Raymond, W.W., Bacci, E., Lombardy, R.J. & Tidwell, R.R. (1993) J. Pharmacol. Exp. Ther. 264, 676–682. 44. Katz, B.A., Clark, J.M., Finer Moore, J.S., Jenkins, T.E., Johnson, C.R., Ross, M.J., Luong, C., Moore, W.R. & Stroud, R.M. (1998) Nature (London) 391, 608–612. 45. Becker, J.W., Marcy, A. L, Rokosz, L.L., Axel, M.G., Burbaum, J.J., Fitzgerald, P.M., Cameron, P.M., Esser, C.K., Hagmann, W.K., Hermes, J.D., et al. (1995) Protein Sci. 4, 1966–1976. 46. Bode, W. & Huber, R. (1992) Eur. J. Biochem. 204, 433–451. 47. Grütter, M.G., Fendrich, G., Huber, R. & Bode, W. (1988) EMBO J. 7, 345–351. 48. Tsunemi, M., Matsuura, Y., Sakakibara, S. & Katsube, Y. (1996) Biochemistry 35, 11570–11576. 49. Huber, R., Kukla, D., Bode, W., Schwager, P., Bartels, K., Deisenhofer, J. & Steigemann, W. (1974) J. Mol. Biol. 89, 73–101.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10992
Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for Patched
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation,” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. NAOYUKI FUSE*†, TAPAN MAITI*†, BAOLIN WANG*, JEFFERY A. PORTER*‡, TRACI M. TANAKA HALL§¶, DANIEL J. LEAHY§, AND PHILIP A. BEACHY*|| * Department of Molecular Biology and Genetics and §Department of Biophysics and Biophysical Chemistry, Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205 ABSTRACT The amino-terminal signaling domain of the Sonic hedgehog secreted protein (Shh-N), which derives from the Shh precursor through an autoprocessing reaction mediated by the carboxyl-terminal domain, executes multiple functions in embryonic tissue patterning, including induction of ventral and suppression of dorsal cell types in the developing neural tube. An apparent catalytic site within Shh-N is suggested by structural homology to a bacterial carboxypeptidase. We demonstrate here that alteration of residues presumed to be critical for a hydrolytic activity does not cause a loss of inductive activity, thus ruling out catalysis by Shh-N as a requirement for signaling. We favor the alternative, that Shh-N functions primarily as a ligand for the putative receptor Patched (Ptc). This possibility is supported by new evidence for direct binding of Shh-N to Ptc and by a strong correlation between the affinity of Ptc-binding and the signaling potency of Shh-N protein variants carrying alterations of conserved residues in a particular region of the protein surface. These results together suggest that direct Shh-N binding to Ptc is a critical event in transduction of the Shh-N signal. Hedgehog (Hh) proteins constitute a family of secreted signaling molecules that govern patterns of cellular differentiation during embryogenesis (reviewed in refs. 1–3). The hedgehog (hh) gene was first identified and isolated in Drosophila, where its multiple roles include patterning of larval segments and adult appendages. Vertebrate hh homologues also are involved in many aspects of developmental patterning. The Sonic hedgehog (Shh) member of this family, for example, is required for patterning of the neural tube and other tissues (4). Hedgehog protein biogenesis (reviewed in ref. 5) has been best studied for the Drosophila protein but very likely is similar for Hedgehog proteins fromallspecies. After cleavage of an amino-terminal signal sequence on entry into the secretory pathway, the Hh protein undergoes an intramolecular autoprocessing reaction that involves internal cleavage between the Gly-Gly residues of an absolutely conserved GCF tripeptide (6, 7). The amino-terminal product of this cleavage, which is the species active in signaling (7), also receives a covalent cholesteryl adduct (8). Autoprocessing at this site and covalent linkage to cholesterol have been experimentally confirmed for the Shh protein (7–9). In Drosophila, a Hedgehog protein from a construct truncated at the internal site of cleavage is active in signaling, but this protein is not spatially restricted in its signaling activity and therefore causes gross mispatterning and lethality in embryos (10). The autoprocessing reaction thus is required not only to release the active signal from the precursor but also to specify the appropriate spatial distribution of this signal within developing tissues, presumably through insertion of the cholesteryl moiety into the lipid bilayer of the plasma membrane. Recent studies also have revealed palmi-toylation of the amino-terminal cysteine of the amino-terminal signaling domain of the Shh secreted protein (Shh-N); the occurrence of this second lipid modification is regulated by autoprocessing and may also influence the activity and distribution of Shh-N (9). The patterning of the ventral neural tube is thought to require an inductive signal from the underlying mesodermal cells of the notochord (11). Shh protein is synthesized in the notochord and can induce differentiation of ventral cell types such as floor plate cells and motor neurons from neural plate explants in vitro (12); a similar role for Shh in vivo is confirmed by a loss of these cell types in mice lacking Shh gene function (4). Shh protein thus appears to constitute the inductive patterning signal from the notochord, and in vitro explant experiments have demonstrated a concentration-dependent response, with low concentrations of Shh-N protein inducing motor neuron differentiation and higher concentrations inducing increasing numbers of floor plate cells, ultimately to the exclusion of motor neurons (12, 13). Shh-N protein at concentrations below those required to induce differentiation of motor neurons or floor plate cells can repress expression of cell markers of dorsal neural tube, such as Pax-7 and Pax-3, in neural plate explants (14, 15). This repression of dorsal cell markers is presumed to mediate the transition of naive neural plate cells into ventral progenitor cells, which then differentiate into motor neurons or ventral interneurons at later stages of embryogenesis. Thus, the concentration-dependent activity of Shh-N has been proposed to regulate the dorso-ventral patterning of the developing neural tube. Several components have been identified as candidates for receptor function in transduction of the Hh protein signal (reviewed in ref. 3). The patched (ptc) gene, originally identified in Drosophila, encodes a multipass transmembrane protein (Ptc). ptc mutations in Drosophila embryos cause inappropriate activation of wingless gene expression, a phenotype opposite that of hh mutations, thus suggesting that ptc functions as a negative effector in hh signaling (16, 17). The observations that hh ptc double mutant embryos resemble ptc mutants and
†N.F.
and T.M. contributed equally in this work. address: Ontogeny, Inc., Cambridge, MA 02138. ¶Present address: National Institute on Environmental and Health Sciences, Research Triangle Park, NC 27709. ||To whom reprint requests should be addressed at: Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, 725 North Wolfe Street PCTB-714, Baltimore, MD 21205. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviations: Shh-N, the amino-terminal signaling domain of the Sonic hedgehog secreted protein; HNF-3β, hepatocyte nuclear factor 3β; Ptc-CTD, Ptc with a truncation resulting in a 140-residue carboxyl-terminal deletion. ‡Present
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10993
that, in a ptc mutant background, ectopic Hh expression produces no further phenotypic effects, together suggest that the Ptc gene product acts downstream of Hh to regulate its signaling activity (16, 18, 19). Genetic epistasis studies further suggest that the smoothened gene (smo), which encodes another transmembrane protein (Smo), functions downstream of ptc in the hh signaling cascade (reviewed in ref. 3). Because smo is required for hh signaling, it has been proposed that Smo activates the Hh pathway and that Ptc inhibits Smo activity. Genetic mosaic analysis in the Drosophila wing imaginal disc showed that Ptc has, in addition to a cellautonomous negative effect on Hh signaling, an ability to sequester the Hh protein and prevent its movement to adjacent cells (20). Vertebrate homologues of both ptc and smo genes have been identified (reviewed in ref. 3). Shh-N was found to bind to cells expressing Ptc or both Ptc and Smo, but not to cells expressing Smo alone (21, 22). Moreover, Ptc interacted with Smo independently of the presence of Shh-N, suggesting that the two transmembrane proteins form a complex. An integrated view of Drosophila genetic analyses and biochemical studies of vertebrate homologues suggests a model in which the Ptc-Smo complex might function as Hh receptor, with direct binding of Hh to Ptc releasing Smo activity from inhibition by Ptc. It must be noted, however, that these biochemical studies did not examine the role of a physical interaction between Shh-N and Ptc in activation of the Shh pathway. In addition, these biochemical studies did not exclude the possibility that Shh-N interacts not directly with Ptc but with another component of a complex that includes Ptc, because the crosslinked binding complexes were extremely large and were not analyzed with regard to their composition. The model just described assumes a role for Shh-N as a ligand for a receptor. The crystal structure of the Shh-N protein, however, suggested an alternative possibility. This structure revealed a zinc ion coordinated in an arrangement remarkably similar to that of thermolysin, carboxypeptidase A, and other zinc hydrolases (23). Even more striking is the remarkable similarity in folded structure of a portion of Shh-N to the catalytic domain of D,D-carboxypeptidase from Streptomyces albus, a cell wall enzyme closely related in structure and activity to other bacterial enzymes involved in conferring vancomycin resistance (Fig. 1 B and D) (24, 25). Although the functional role of this putative hydrolase in Shh-N is not known, one possibility is that signaling requires Shh-N hydrolytic activity on as yet unknown substrates. Thus, several fundamental questions about the mechanisms of Shh-N signaling remain unanswered. Does Shh-N function as a ligand or as an enzyme? Is Ptc interaction with Shh-N direct and is this a critical event in transduction of the Shh-N signal? To illuminate these issues, we used the structure as the basis for design of mutations expected to abolish zinc hydrolase activity within Shh-N. We also used structure-based systematic mutagenesis to produce Shh-N proteins with alterations in evolutionarily conserved surface residues and then compared the signaling activity of these altered proteins in neural plate explants to their capacity for binding to Ptc-expressing cultured cells. We found that Shh-N signaling does not require catalytic activity and instead correlates critically with the ability of Shh-N to bind directly to Ptc.
MATERIALS AND METHODS Preparation of Recombinant Shh-N Mutant Proteins. Constructs for altered Shh-N were made by standard methods (26). Recombinant proteins were expressed in Escherichia coli and purified as described previously (12). To prepare the 32P-labeled Shh-N protein, a protein kinase A site tag (RRASV) was introduced at the carboxy terminus of Shh-N, and the tagged Shh-N was phosphorylated in a reaction containing [γ-32P]ATP. Cy2-labeled recombinant Shh-N was prepared by using CyDye FluoroLink Reactive Dye (Amersham).
FIG. 1. A possible catalytic site in Shh-N. (A) Model for an apparent zinc hydrolase catalytic site derived from the crystal structure of Shh-N (23). Glu-177 and His-135 residues are presumed to be essential for catalysis (see text), and His-141, Asp-148, and His-183 coordinate the Zn2+ ion. (B) Superimposed alpha-carbon traces of Shh-N (yellow) and D,Dcarboxypeptidase from Streptomyces albus (green). The portion of these proteins displaying structural homology is drawn, with the Zn2+ ions shown as blue spheres. Residues within the structurally homologous portion of Shh-N that are altered in SC (four of six) and SD (two of three) (see text) are located in structurally diverged loops and are highlighted in red. (C) Coomassie blue staining of purified recombinant wild type (WT) and E177A (EA), H135A (HA) and double mutant (EH) Shh-N proteins resolved in SDS/PAGE (15%); molecular mass markers are indicated at left (kDa). (D) Structure-based alignment of amino acid sequence from the portions of mouse Shh (mSHH) and Streptomyces albus D,D-carboxypeptidase (DD-C) shown in B. The residues involved in zinc coordination or hydrogen bonding of the water molecule are shown in dark blue, and other conserved residues are in light blue. Target sites for mutagenesis are indicated in green (for zinc hydrolase mutants) or red (for SC and SD mutants, see below). Chicken Neural Plate Explant Culture. Chicken intermediate neural plate explant culture methods have been described previously (12, 27). Neural plate explants were stained with either mouse anti-Pax-7 [PAX7, Developmental Studies Hybridoma Bank (DSHB)], rabbit anti-hepatocyte nuclear factor (HNF)-3β (K2, a gift from T.M.Jessell, Columbia University), or mouse anti-Islet-1 (40.2D6, DSHB) antibodies. Cell Culture for Ptc Expression. Fragments encoding full-length mouse Ptc and carboxyl-terminal Myc-tagged Ptc-CTD (Ptc with a truncation resulting in a 140-residue carboxyl-terminal deletion; amino acids nos. 1–1,291, a gift from M.P. Scott, Stanford University) were inserted into pIND(Sp) vector (Invitrogen). To make stable cell lines, EcR-293 cells
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10994
(Invitrogen) were transfected with recombinant constructs or empty vector, and several independent clones for each construct were isolated. Shh-N-Ptc-Binding Assay. Ptc expression was induced in cloned stable derivatives of the cell line EcR-293 by addition of ponasterone A (Invitrogen). After induction, 2.5×105 cells were mixed with increasing concentrations (0.1 nM-50 nM) of 32P-Shh-N (for Scatchard analyses) or with a fixed concentration (0.9 nM) of 32P-Shh-N and various concentrations of competitors (for competitive binding assays). After incubation at 4°C, cells were collected, and the bound 32P-Shh-N was determined. For the qualitative Ptc-binding assay, QT6 cells transiently transfected with pRK5-Ptc-CTD were incubated with 2 nM Cy2-labeled Shh-N protein and 160 nM unlabeled competitor. The ability of the unlabeled protein to compete for binding of Cy2-Shh-N protein to cells was directly observed by fluorescence microscopy. Crosslinking of 32P-Shh-N to Ptc. Induced EcR-293 cells were incubated with the 32P-labeled Shh-N at a final concentration of 2 nM at 4°C. Unlabeled Shh-N was added as competitor to 200 nM. After the cells were washed once with PBS, labeled Shh-N was crosslinked to cells by adding freshly prepared disuccinimidyl suberate (Pierce) to 5 mM in PBS and incubating for 50 min. at 4°C. Crosslinked cells were washed with cold PBS and lysed in 0.15 mM NaCl/0.05 mM Tris-HCl, pH 7.2/1% Triton X-100/1% sodium deoxycholate/0.1% SDS (RIPA) buffer containing proteinase inhibitors. Lysate proteins were fractionated by SDS/PAGE (6%) and visualized by staining with Coomassie blue. After the gel was dried, crosslinked products were visualized by autoradiography.
RESULTS Zinc Hydrolase Activity Is Not Required for Shh-N Signaling. To determine whether Shh-N acts as an enzyme, glutamate-177 (E177) and histidine-135 (H135) were substituted by alanine. E177 forms a hydrogen bond to a zinc-bound water molecule, and H135 is positioned to stabilize a potential tetrahedral intermediate (Fig. 1A; ref. 23). By analogy with other zinc hydrolases, both residues are likely to be essential for catalytic activity (28). Furthermore, the VanX protein, a structural homologue of Shh-N, displays a reduction in activity
FIG. 2. Signaling activities of Shh-N zinc hydrolase mutants. (A–C) Chicken intermediate neural plate explants double stained for expression of the motor neuron marker Islet-1 (blue) and the floor plate marker HNF-3β (red). No Islet-1- or HNF-3β-positive cells were observed in control explants (A), whereas 5 nM (B) and 25 nM (C) concentrations of wild-type Shh-N induced expression of Islet-1 and HNF-3β, respectively. (D–L) Neural plate explants double stained with antibodies against a dorsal marker Pax-7 (green) and the floor plate marker HNF-3β (red). Explants cultured with medium only (D) express Pax-7 but not HNF-3β. Wild-type Shh-N protein fully repressed expression of Pax-7 at 4 nM (E) and uniformly induced HNF-3β inallcells at 20 nM (F). The EH and EA mutant proteins repressed Pax-7 at 4 nM (G, I, respectively), albeit somewhat less efficiently, and were able to uniformly induce HNF-3β expression at 20 nM (H and J, respectively). The H135A (HA) mutant protein was indistinguishable from wild type (K, at 4 nM and L, at 20 nM). Images were captured using a×40 objective. Table 1. Properties of altered Shh-N proteins Mutation sites Pax-7 repression, nM Protein WT HA EA EH SA
SB SC SD SE SF SG
Wild type (a a 25– 198) H135A E177A E177A, H135A K75A, E76A, Y81A, D105A, N116A, E189A, K195A N51A, V52A, T56A, E168A P42A, K46A, R154A, S157A, S178A, K179A E90A, D132A, E138A P42A, K46A R154A, S157A S178A, K179A
Ptc-CTD affinity, nM 0.48
5E1 IP
Heparin binding
~4
HNF-3β induction, nM ≤20
++
+
~4 ~10 ~10 ~4
≥20 ≥20 ≥20 ≤20
0.63 1.7 1.7 0.66
ND ND ND ++
+ + + +
~4
≥20
0.48
++
+
1,000
1,000
36
–
–
~10
≥20
0.84
++
+
~20 ~70 ~30
~100 ≥100 ~100
2.4 9.1 4.3
– + +
+ + +
Protein signaling was tested at initial concentrations of 4, 20,100, 500, and 1,000 nM and subsequently at 10 nM concentration intervals for EA, HA, EH, SD, SE, SF, and SG. The minimum concentration required for complete repression of Pax-7 and for uniform induction of HNF-3β is shown for each protein. As an indication of affinity for Ptc-CTD, binding coefficients (KI) for binding of mutant Shh-N proteins to Ptc-CTD were derived from competitive binding experiments in Fig. 6 A and B by using the equation KI=[IC50]/(l+[L]/KL), where [IC50] is the concentration of unlabelled mutant proteins required for 50% competition. [L] is the concentration of unbound wild-type protein (32P-Shh-N) and KL is the dissociation constant for wildtype Shh-N. Immunoprecipitation by 5E1 monoclonal antibody (Fig. 7) and binding to heparin-agarose are indicated. ND, not determined.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10995
of more than six orders of magnitude on alteration of the R71 residue (29), which corresponds to H135 in Shh-N (25). These substitutions (E177A, H135A) were introduced individually and in combination into an E.coli expression vector, and purified altered proteins were prepared (Fig. 1C). We used a chicken intermediate neural plate explant culture system to test the signaling activity of recombinant proteins (12). Wild-type Shh-N protein applied to these explants induced motor neurons at 5 nM and predominantly floor plate cells at 25 nM, as monitored by expression of Islet-1 and HNF-3β, respectively (Fig. 2 A–C). Shh-N protein at 4 nM sufficed for suppression of the dorsal marker Pax-7 (Fig. 2 D and E). The concentrations of Shh-N required for these inductive events, although slightly higher than previously reported (12, 15, 27), were reproducible in the assay protocol used in this study. All three of the zinc hydrolase mutant Shh-N proteins tested, E177A (EA), H135A (HA), and the double mutant (EH), retained the capacity to repress Pax-7 expression and to induce floor plate cells in the explants (Fig. 2 G–L). Whereas the EA and EH mutant proteins displayed slightly reduced signaling activity, the HA protein was indistinguishable from wild type (Fig. 2 G–L; Table 1). Because the altered residues are absolutely critical for catalytic activity in other zinc hydrolases (28, 29), retention of signaling activity by Shh-N hydrolase mutant proteins indicates that catalytic activity is not required for signaling. The reduced potency for EH and EA in signaling may reflect a destabilization of folded protein structure, as might be expected from substitution of Ala for the largely buried side chains of the Glu-177 and His-135 residues. Indeed, the EA and EH altered proteins displayed a somewhat reduced affinity for Ptc-CTD protein, which may account for their reduced potency, whereas HA was essentially indistinguishable from wild type (Table 1; see below).
FIG. 3. Direct binding of Shh-N to Ptc. (A) Ptc and Ptc-CTD expression in stably transfected cloned cell lines. Cell lysates were prepared from stable EcR-293 cell lines carrying pIND(Sp) (empty vector control), pIND(Sp)-Ptc, or pIND(Sp)-PtcCTD, and proteins were fractionated by SDS/PAGE (6%) followed by blotting and detection with anti-Ptc antibody (Santa Cruz Biotechnology). Two bands (dots) were detected in lysates from Ptc or from Ptc-CTD cells, but not from control cells. (B) Crosslinking of 32P-labeled Shh-N protein to Ptc and Ptc-CTD. EcR-293 cells expressing Ptc and Ptc-CTD were incubated with 32P-Shh-N protein in absence (–) or presence (+) of a 100-fold excess of unlabeled Shh-N protein and then crosslinked. Cell lysates were subjected to SDS/PAGE (6%) and crosslinked products detected by autoradiography. Autoradiographic images for control and Ptc and for Ptc-CTD are presented at distinct contrast settings to highlight the crosslinked species. Migration of marker proteins (in kDa) is shown at left. (C, D) Scatchard analysis of the high-affinity component of 32P-Shh-N binding to EcR-293 cells expressing Ptc (C) or Ptc-CTD (D). (E) Summary of predicted molecular masses of Ptc and Ptc-CTD, experimental values estimated from Western blotting (A), and apparent masses of crosslinked products (B). Experimental values are the average of several independent determinations. Also shown are estimates of the binding coefficients of Shh-N for Ptc and for Ptc-CTD, and estimates of the number of binding sites per cell. Direct Binding of Shh-N Protein to Ptc. Because the analyses above suggested a noncatalytic function of Shh-N protein, we next focused on Shh-N interaction with Ptc (21, 22). To determine whether Shh-N protein directly interacts with Ptc, we generated stable cloned EcR-293 cell lines for ecdysone-inducible expression of full length Ptc and Ptc-CTD (see Materials and Methods). Such stable cell lines, but not a control line carrying the empty vector, expressed Ptc and Ptc-CTD proteins when induced with the ecdysone analog, ponasterone A (Fig. 3A). On protein blots probed with anti-Ptc antibody, two broad bands were detected for Ptc (dots, 168 kDa and 157 kDa) or for Ptc-CTD (dots, 163 kDa and 141 kDa). The estimated masses of the faster-migrating species were close to the molecular masses predicted from primary sequence (159 kDa for Ptc and 144 kDa for Ptc-CTD) (Fig. 3E). For sensitive detection of Shh-N binding to Ptc, a 32P-labeled Shh-N protein was prepared by introducing a protein kinase A (PKA) site at the carboxy terminus of Shh-N followed by labeling of the purified recombinant protein with PKA and [γ-32P]ATP (see Materials and Methods). Addition of this kinase site at the carboxy terminus did not affect signaling activity of Shh-N (data not shown). We performed crosslinking of 32P-labeled Shh-N protein to EcR-293 cells expressing Ptc or Ptc-CTD in the presence of a bivalent crosslinker, disuccinimidyl suberate. As shown in Fig. 3B, crosslinked products were detected in lysates of Ptc and Ptc-CTD cells, but not in those of control cells. These crosslinked species were abolished by competition with unlabeled Shh-N protein (+ lanes), demonstrating a specific interaction. The crosslinked species form a single band, not two as detected in Western blotting, suggesting that a particular form of Ptc or Ptc-CTD might bind to Shh-N. The estimated molecular masses of the crosslinked products (172 kDa for Ptc and 158 kDa for Ptc-CTD) differ by 14 kDa, which corresponds closely to the differences in mass between Ptc and Ptc-CTD and definitively indicates the participation of Ptc and Ptc-CTD in these complexes. The apparent masses of these complexes furthermore are close to the sums of the masses of Shh-N plus Ptc or of Shh-N plus Ptc-CTD (178 kDa and 163 kDa, respectively) ( Fig. 3E), suggesting a 1:1 stoichiometry of Ptc and Shh-N in these complexes. These results strongly suggest that Shh-N interacts directly with Ptc protein. Quantitative analysis of 32P-Shh-N binding to these cells revealed a high-affinity Ptc-dependent component of binding that could be competed by nanomolar concentrations of unlabeled Shh-N and a low-affinity component that was not dependent on Ptc expression and that could not be competed by Shh-N. Scatchard analysis of the Ptc- and Shh-N-specific high affinity component (Fig. 3 C and D) indicated that the binding coefficients of Ptc and Ptc-CTD for 32P-Shh-N protein are similar (0.58 nM and 0.48 nM respectively; Fig. 3E) (21). Assuming, as argued above, that one Shh-N ligand binds to one Ptc molecule, the number of binding sites per cell for PtcCTD (210,000) is about 5.5 times higher than that for Ptc (38,000) (Fig. 3E). The temperature utilized in these binding studies (4°C) is not permissive of endocytosis, indicating that Shh-N binding initially occurs on the cell surface, even though immunofluorescence studies clearly demonstrate that Ptc and
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10996
Ptc-CTD proteins are predominantly localized inside cells (data not shown). The difference in number of binding sites for these two proteins thus could be caused either by a higher degree of surface localization for Ptc-CTD or, alternatively, by a higher level of PtcCTD expression as compared with Ptc (Fig. 3A), a phenomenon also consistently observed in transiently transfected cells (data not shown). Thus we cannot at present distinguish whether the 140 residues absent from Ptc-CTD influence the subcellular localization of the Ptc protein or its steady-state levels within the cell.
FIG. 4. Alteration of Shh-N surface residues. (A) Ribbon diagram and (B, C) surface representations of Shh-N. B is shown in the same orientation asy A, but C is rotated 180° about a vertical axis relative to A and B. Surface-exposed evolutionarily conserved residues that were selected for alteration cluster into four major regions: SA (blue), SB (green), SC (red), and SD (yellow). Residues mutagenized are indicated in Table 1. (D) Coomassie blue stain of an SDS/PAGE separation of purified mutant Shh-N proteins. SE, SF, and SG denote proteins with distinct subsets of the altered residues in SC (see Table 1). Migration of molecular mass markers indicated at left (in kDa). Figs. 1B and 4A made with MOLSCRIPT (36); Fig. 4 B and C were made with GRASP (37). The Role of Shh-N Surface Residues in Signaling and in Ptc Binding. Having demonstrated a direct and high-affinity interaction between Ptc and Shh-N, we set out to determine the significance of this interaction by examining the correlation between Ptc binding and signaling potency of altered Shh-N proteins. The Shh-N protein was subjected to systematic mutagenesis to identify surface residues involved in signaling and potential ligand/receptor interactions. Because Hh proteins can act similarly across species and in distinct biological settings [Shh, for example, is active in Drosophila (30, 31) and distinct vertebrate proteins can act in common pathways (32)], it seems likely that surface residues potentially important in inductive activities and ligand/receptor interactions would be conserved. The Shh-N structure was used to identify surface residues based on degree of side chain exposure to solvent (23). Among these surface residues, those that are evolutionarily conserved were geographically divided into four major regions named SA, SB, SC, and SD (Fig. 4 A–C) and subjected to mutagenesis. We initially generated four mutant proteins, each containing multiple alanine substitutions at the conserved surface residues within each region (see Table 1). Because the side chains of the residues selected are solvent exposed, we expected that the folded structures of these proteins would not be affected.
FIG. 5. Signaling activities of Shh-N proteins with altered surface residues. Neural plate explants stained for expression of Pax-7 (green) and HNF-3β (red). Explants were cultured in the presence of the indicated proteins at the indicated concentrations (nM). SA and SB proteins are as active as wild-type Shh-N, because they repress expression of Pax-7 at 4 nM and induce expression of HNF-3β at 20 nM. The SD protein is slightly less active than wild-type protein, and the SC mutant protein is completely inactive. The SE and SG proteins display reduced activity, and the SF protein is even less active. Results are summarized in Table 1. Images were captured using a×40 objective. The altered proteins were purified (Fig. 4D) and applied to chicken neural plate explant cultures. The SA and SB altered proteins repressed Pax-7 expression and induced floor plate cells in the explants as well as the wild-type protein (Fig. 5 A–D), and the SD altered protein displayed an approximate 2.5-fold reduction in activity (Fig. 5 F–H). In striking contrast, no signaling activity of the SC mutant could be detected even at 1 µM, a concentration 250-fold higher than that required for Pax-7 repression by wild-type protein (Fig. 5E; results summarized in Table 1). We next examined Ptc binding for these altered proteins using a competition binding assay. The SA, SB, and SD mutant proteins competed with the 32P-labeled wild-type Shh-N protein for binding to Ptc-CTD expressing cells as well or nearly as well as the wild-type protein (Fig. 6A), yielding similar binding coefficients (Table 1). Ptc-binding activity of the SC mutant, however, was not detectable (Fig. 6A; Table 1), suggesting a possible correlation between Ptc binding and signaling activity for the Shh-N protein. To explore this correlation further, we tested three additional proteins (SE, SF, and SG), each with alterations in two amino acid residues that comprise distinct subsets of the six residues altered in SC (see Table 1). All three of these mutant proteins displayed signaling activity in the explant culture assay, but only at significantly reduced levels. At 4 nM none of these three proteins repressed Pax-7 (Fig. 5I; data not shown); at 20 nM the SE and SG proteins repressed Pax-7 almost completely or partially, respectively, but SF did not (Fig. 5 J, L, and O). At 100 nM, the SE and SG proteins induced HNF-3β expression in most cells of the explant, but SF did so only in a small number of cells (Fig. 5 K, M, and P). Further assays at concentration intervals of 10 nM pinpointed the minimal concentrations required for Pax-7 repression, with values of 20, 30, and 70 nM for SE, SG, and SF, respectively (results in Table 1). Competition binding assays
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10997
also revealed a significantly reduced affinity of the SE and SG proteins for Ptc-CTD, and an even lower affinity for the SF protein (Fig. 6B; Table 1). These results indicate that normal Ptc binding and neural plate signaling activities require distinct contributions from multiple individual residues in the SC surface region. Furthermore, among proteins with alterations in distinct subsets of the SC mutant residues, Ptc-binding affinity correlated extremely well with neural plate signaling activity (Fig. 6C).
FIG. 6. Binding of altered Shh-N proteins to Ptc. (A and B) Competition by altered proteins for binding of 32P-Shh-N to EcR-293 cells expressing Ptc-CTD. Binding of 32P-Shh-N in the presence of each altered protein at various concentrations is normalized to the total value of 32P-Shh-N bound (approximately 35% of input) in the absence of competitor. The SC mutant, inactive in signaling, also fails to compete for binding to Ptc-CTD. The SE, SF, and SG proteins with intermediate levels of signaling activity, displayed intermediate levels of competition for binding to Ptc-CTD. Data are summarized in Table 1. (C) Signaling activity as a function of Ptc affinity. On the basis of neural plate signaling assays (Figs. 2, 5; Table 1), protein concentrations required for Pax-7 repression are plotted as a function of Ptc-binding affinity. The protein concentrations are plotted as ranges centered about the concentrations presented in Table 1. Note that there is an excellent correlation between Ptc binding and activity in Pax-7 repression. The zinc hydrolase mutants EA, HA, and EH (Table 1) also corroborate this correlation but are omitted for clarity. We also purified Shh-N proteins with deletions of amino- or carboxyl-terminal residues and examined their activities qualitatively in signaling and in Ptc binding (Table 2). An altered protein lacking nine amino-terminal residues (∆N34) displayed signaling and Ptcbinding activities indistinguishable from wild type. In contrast, ∆N50, which lacks 25 amino-terminal residues, completely lost both activities. We note that the residues deleted in ∆N50 include P42 and K46, which were altered in the SC and SE mutant proteins, and that the mutant ∆N45 (lacking 20 amino-terminal residues), which does not contain P42, also lost signaling activity. The activity defects in these proteins are more severe than those of the SE protein, suggesting that loss of these amino-terminal residues may have some effect on the overall structure or stability of the Shh-N protein. A deletion mutant lacking residues from 166 to the carboxy terminus, ∆C165, had neither signaling nor Ptc-binding activities, and ∆C101 also lost signaling activity (Table 2). These deletions also remove residues that are altered in the SC protein (R154, S157, S178, and K179 in ∆C101; S178 and K179 in ∆C165), but again, the deleted regions are sufficiently extensive that they would be expected to affect protein structure. Table 2. Properties of Shh-N deletion derivatives Residues present HNF-3β induction Protein WT wild type (a a 25–198) + ∆N34 a a 34–198 + ∆N45 a a 45–198 – ∆N50 a a 50–198 – ∆C165 a a 25–165 – a a 25–101 – ∆C101
Ptc-CTD binding + + ND – – ND
5E1 IP + + ND – – ND
Heparin binding + + – – + +
The properties of these mutant proteins were either indistinguishable or completely different from wild type in a qualitative neural plate assay for induction of HNF-3β or in a qualitative Ptc-binding competition assay using QT6 cells transiently transfected with Ptc-CTD and Cy2-labeled Shh-N (see Material and Methods). Immunoprecipitation by 5E1 monoclonal antibody and binding to heparin agarose are indicated. ND, not determined.
We note that inallof the altered proteins tested we failed to find a single example of a protein that retained signaling activity while losing the ability to bind Ptc. As seen in Fig. 6C, there is an excellent correlation between Ptc binding and signaling activity inallaltered proteins for which these properties can be measured, and these results strongly suggest that Ptc binding may be a critical requirement for signaling. Antibody Recognition and Heparin Binding of Altered Proteins. The monoclonal antibody 5E1, directed against Shh-N, blocks signaling in neural plate explants (14) (data not shown) and also blocks binding of the Shh-N protein to Ptc-expressing cells (data not shown). The reactivity of the 5E1 antibody with altered Shh-N proteins was examined by immunoprecipitation. We found thatallproteins that retain signaling and Ptc-binding activities, including wild type, SA, SB, SD, and ∆N34, also retain full reactivity with 5E1 (Fig. 7A; Tables 1, 2; data not shown). In contrast, the altered proteins SC, ∆N50, and ∆C165, which lost both signaling and Ptc-binding activities, were not immunoprecipitated by 5E1 (Fig. 7A; Tables 1, 2; data not shown). Altered proteins with intermediate signaling and Ptc-binding properties, such as SE, SF, and SG, displayed intermediate reactivities with 5E1 (Fig. 7B; Table 1). Reactivity of 5E1 with Shh-N proteins thus correlates well with Ptc binding and neural plate signaling activities. Because 5E1 works well for immunoprecipitation and for immunocytochemistry but very poorly in Western analysis (data not shown), it appears to recognize an epitope present on the native Shh-N protein but not in denatured protein. The strong correlation between 5E1 binding, Ptc binding, and neural plate signaling furthermore suggests that the 5E1 epitope coincides with determinants required for these activities. One possible explanation for the coordinate loss of signaling, 5E1 binding, and Ptc binding in the SC protein is that the folded structure of this protein might be disrupted. Circular dichroism analysis, however, indicates that the secondary structure profile of SC is similar to that of wild-type Shh-N (data not shown), suggesting that any disruption in folded structure must be highly local in nature. In addition, mutations in distinct subsets of the residues altered in SC display intermediate phenotypes, suggesting multiple independent contributions of individual residues in formation of the Ptc-interacting region of the protein surface.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10998
FIG. 7. Reactivity of 5E1 antibody with altered Shh-N proteins. After immunoprecipitation (IP) with the 5E1 monoclonal antibody, altered proteins were detected by Western blotting using a polyclonal antibody. The starting (input) and precipitated (IP) material are shown for each protein. (A) The wild-type, SA, SB, and SD altered proteins were precipitated well by the 5E1 antibody, but the SC protein was not. (B) SE, SF, and SG displayed intermediate reactivity with the 5E1 antibody. The Shh-N protein also binds to heparin [(12); data not shown], and the crystal structure contains a sulfate anion at a location near the SC region (23). In addition, recent evidence suggests that tout velu, a Drosophila gene whose mammalian homologues function in the polymerization of glycosamines for synthesis of heparan sulfate proteoglycans (33, 34), plays a role in the reception and transport of the Hh signal (35). We therefore tested whether the alterations in our proteins affect their ability to bind to heparin agarose. As seen in Tables 1 and 2, only three of the proteins tested, SC, ∆N45, and ∆N50, lost the ability to bind heparin agarose, and these three proteins are completely inactive in Ptc binding and signaling. Some of the proteins that lose signaling and Ptc-binding activity retained the ability to bind heparin, indicating that heparin binding is not sufficient for Ptc binding and for signaling. Our data, however, would be consistent with the idea that heparin binding may be necessary for Ptc binding and for signaling.
DISCUSSION The Putative Zinc Hydrolase in Shh-N. Alterations in residues that should be critical for the putative zinc hydrolase activity of Shh-N did not disrupt its ability to induce ventral neural cell types or to suppress dorsal markers, suggesting that catalytic activity is not required for Shh signaling in the neural plate. Although residues constituting the putative zinc hydrolase active site are widely conserved among Hh family members, they are not fully conserved in Drosophila (23), suggesting that hydrolase function is not required for signaling in this organism. We also introduced and ectopically expressed the E177A and EH mutant Shh constructs into Drosophila and compared their ability to mispattern the embryonic cuticle with that of wild-type Shh (30) and could detect no significant difference between them (H.E.F.Takahashi and P.A.B., unpublished data), further substantiating dispensability of catalytic activity for Shh-N signaling function in the context of developing Drosophila embryos. Furthermore, experiments with mutant proteins expressed in cultured cells suggest that the putative hydrolase activity is not required for the normal biogenesis and processing of Shh, nor for its normal state of modification (data not shown). We also note that we failed to detect any hydrolase activity of Shh-N in biochemical assays with a variety of substrates, including some like those for D,D-carboxypeptidase, which contained D-amino acid residues. The putative zinc hydrolase of Shh-N has thus resisted our attempts to reveal an activity, either in biochemical or in in vitro or in vivo signaling assays, raising the possibility that the putative catalytic site represents an evolutionary vestige of its common ancestry with the D,D-carboxypeptidase family of proteins. In this view, the zinc atom may have lost its ancestral role in catalysis but could have retained a role in stabilizing protein structure through interactions with the side chains of coordinating residues. The lack of conservation of coordinating residues in the Drosophila protein may indicate a replacement of these interactions by other stabilizing interactions. General dispensability of hydrolase activity in Hh signaling is consistent with the importance of surface residues conserved among Hh proteins for binding to Ptc and for signaling (see below). Alternatively, it is possible that Shh-N hydrolase retains a role not detected by our biochemical or in vitro and in vivo signaling assays. Such a role likely would be modulatory in nature, given the essentially normal signaling activity of hydrolase mutant proteins, and its discovery may require targeted recombination to mutagenize the endogenous mouse Shh gene. Direct Binding of Shh-N to Ptc and Activation of the Shh Pathway. Previous genetic and biochemical studies are consistent with the idea that Ptc may function as a Hh receptor. The biochemical analyses demonstrated that Shh-N protein binds to Ptcexpressing cells, that Ptc is coimmunoprecipitated with Shh-N and vice versa, and that Ptc can be crosslinked in a complex containing Shh-N (21, 22). Because the composition of the crosslinked complexes was not characterized, however, these studies could not exclude the possibility that instead of binding directly to Ptc, Shh-N may bind to another component of a complex that includes Ptc. These biochemical studies also did not examine the role of such an interaction in the activation of the Shh pathway. The latter is a particularly significant issue given the genetically demonstrated role of Ptc in sequestration of Hh protein to restrict its movement within Drosophila tissues (20). In addressing these questions, we have identified a crosslinked product containing radiolabeled Shh-N that is specifically competed by unlabeled Shh-N but not by the unlabeled mutant SC protein. This crosslinked complex also contains Ptc because its formation depends on Ptc expression and because it displays an apparent molecular mass difference that corresponds closely to the differences between full-length Ptc or Ptc-CTD. Finally, for both Ptc molecules, the apparent mass of the complex is close to the sum of Shh-N plus Ptc. Thus, although direct binding ideally would be demonstrated by studies with purified components, the properties of our crosslinked complexes strongly suggest a direct association between Shh-N and Ptc with a probable stoichiometry of 1:1. Given the possible anomalies in migration of such crosslinked species, we cannot rule out the possibility that more than one Shh-N molecule is present in these complexes, nor can we distinguish between the participation of the slower- or faster-migrating Ptc forms, which probably differ in their glycosylation (22). Although it has been reported that Ptc interacts with Smo independently of Shh-N (21), the apparent masses of our crosslinked products would appear to exclude Smo, which has a predicted mass of 87 kDa (21). It is possible that the cells we utilized do not express Smo endogenously or that high-level expression of Smo is required for formation of a complex with Ptc/Shh. Alternatively, our experimental conditions for crosslinking might disrupt Ptc-Smo interaction or fail to capture Smo protein. We also have identified, using altered Shh-N proteins, the region of the Shh-N protein surface that is involved in Ptc binding and have used these altered proteins to show that neural plate signaling activity is retained in proportion to the binding affinity for Ptc. Thus, the extensive alterations in surface residues of the SA, SB, and SD proteins do not affect
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
SONIC HEDGEHOG PROTEIN SIGNALS NOT AS A HYDROLYTIC ENZYME BUT AS AN APPARENT LIGAND FOR PATCHED
10999
or only mildly affect Ptc binding, and these proteins retain normal or nearly normal signaling activity. At the other extreme, the SC altered protein displays a complete loss of Ptc binding, and this is reflected in a complete loss of neural plate signaling activity. Even more telling, proteins carrying distinct subsets of the residues altered in SC result in intermediate levels of Ptc-binding activity and corresponding intermediate levels of neural plate signaling activity (Fig. 6C). Multiple individual residues within the SC surface region that contribute independently to Ptc binding thus also similarly contribute to signaling potency. Although our results cannot exclude a role for interactions with other proteins in reception of the Shh signal, they do strongly suggest that direct binding to Ptc is a critical step, and this information will serve as the basis for further elucidation of downstream events. We thank Drs. M.Scott and T.Jessell for various cDNAs and antibodies. We also thank J.Wrable for help with circular dichroism analysis, Dr. J.Taipale for suggestions on the crosslinking experiment, Dr. M.Cooper and K.Young for preparation of some recombinant proteins, Dr. O.Sundin for help with chicken embryo experiments, Dr. R.Mann for comments on the manuscript, and members of the Beachy laboratory for discussions and suggestions. N.F. was a postdoctoral fellow of the Human Frontier Science Program. D.J.L. and P.A.B. are investigators of Howard Hughes Medical Institute. This work was supported in part by grants from the American Paralysis Association and the Ara Parseghian Medical Research Foundation. Under a licensing agreement between Ontogeny, Inc. and the Johns Hopkins University, Dr. Beachy and the University hold equity in Ontogeny and are entitled to a share of royalties from sales of products related to the research described in this article. Dr. Beachy serves on Ontogeny’s Scientific Advisory Board and as a consultant to the company. All financial aspects of these arrangements are managed by the University in accordance with its policies. 1. Perrimon, N. (1995) Cell 80, 517–520. 2. Hammerschmidt, M., Brook, A. & McMahon, A.P. (1997) Trends Genet. 13, 14–21. 3. Goodrich, L.V. & Scott, M.P. (1998) Neuron 21, 1243–1257. 4. Chiang, C., Litingtung, Y., Lee, E., Young, K., Corden, J.L., Westphal, H. & Beachy, P. (1996) Nature (London) 383, 407–413. 5. Beachy, P.A., Cooper, M.K., Young, K.E., von Kessler, D.P., Park, W.J., Hall, T.M., Leahy, D.J. & Porter, J.A. (1997) Cold Spring Harbor Symp. Quant. Biol. 62, 191–204. 6. Lee, J.J., Ekker, S.C., von Kessler, D.P., Porter, J. A, Sun, B.I. & Beachy, P.A. (1994) Science 266, 1528–1537. 7. Porter, J. A, von Kessler, D.P., Ekker, S.C., Young, K.E., Lee, J.J., Moses, K. & Beachy, P.A. (1995) Nature (London) 374, 363–366. 8. Porter, J.A., Young, K.E. & Beachy, P.A. (1996) Science 274, 255–259. 9. Pepinsky, R.B., Zeng, C., Wen, D., Rayhorn, P., Baker, D.P., Williams, K.P., Bixler, S.A., Ambrose, C.M., Garber, E.A., Miatkowski, K., et al (1998) J. Biol. Chem. 237, 14037–14045. 10. Porter, J.A., Ekker, S.C., Park, W.-J., von Kessler, D.P., Young, K.E., Chen, C.-H., Ma, Y., Woods, A.S., Cotter, R.J., Koonin, E.V., et al (1996) Cell 86, 21–34. 11. Tanabe, Y. & Jessell, T.M. (1996) Science 274, 1115–1123. 12. Roelink, H., Porter, J.A., Chiang, C., Tanabe, Y., Chang, D.T., Beachy, P.A. & Jessell, T.M. (1995) Cell 81, 445–455. 13. Tanabe, Y., Roelink, H. & Jessell, T. (1995) Curr. Biol. 5, 651–658. 14. Ericson, J., Morton, S., Kawakami, A, Roelink, H. & Jessell, T.M. (1996) Cell 87, 661–673. 15. Ericson, J., Rashbass, P., Schedl, A., Brenner-Morton, S., Kawakami, A., van Heyningen, V., Jessell, T.M. & Briscoe, J. (1997) Cell 90, 169–180. 16. Ingham, P.W., Taylor, A.M. & Nakano, Y. (1991) Nature (London) 353, 184–187. 17. Ingham, P.W. & Hidalgo, A. (1993) Development (Cambridge, U.K.) 117, 283–291. 18. Tabata, T. & Kornberg, T.B. (1994) Cell 76, 89–102. 19. Ingham, P.W. (1993) Nature (London) 366, 560–562. 20. Chen, Y. & Struhl, G. (1996) Cell 87, 553–563. 21. Stone, D.M., Hynes, M., Armanini, M., Swanson, T.A., Gu, Q., L, J.R., Scott, M.P., Pennica, D., Goddard, A., Phillips, H., Noll, M.,, et al (1996) Nature (London) 384, 129–134. 22. Marigo, V., Davey, R. A, Zuo, Y., Cunningham, J.M. & Tabin, C.J. (1996) Nature (London) 384, 176–179. 23. Hall, T.M.T., Porter, J.A., Beachy, P.B. & Leahy, D.J. (1995) Nature (London) 378, 212–216. 24. Dideberg, O., Charlier, P., Dive, G., Joris, B., Frere, J.M. & Ghuysen, J.M. (1982) Nature (London) 299, 469–470. 25. Bussiere, D.E., Pratt, S.D., Katz, L., Severin, J.M., Holzman, T. & Park, C.H. (1998) Mol. Cell 2, 75–84. 26. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. & Struhl, K. (1994) Current Protocols in Molecular Biology (Wiley, New York). 27. Cooper, M.K., Porter, J.A., Young, K.E. & Beachy, P.A. (1998) Science 280, 1603–1607. 28. Christianson, D.W. (1991) Adv. Protein Chem. 42, 281–355. 29. Lessard, I.A. & Walsh, C.T. (1999) Chem. Biol. 6, 177–187. 30. Chang, D.T., Lopez, A, von Kessler, D.P., Chiang, C., Simandl, B.K., Zhao, R., Seldin, M.F., Fallen, J.F. & Beachy, P.A. (1994) Development (Cambridge, U.K.) 120, 3339–3353. 31. Krauss, S., Concordet, J.-P. & Ingham, P.W. (1993) Cell 75, 1431–1444. 32. Ekker, S.C., McGrew, L.L., Lai, C.-J., Lee, J.J., von Kessler, D.P., Moon, R.T. & Beachy, P.A. (1995) Development (Cambridge, U.K.) 121, 2337– 2347. 33. McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L.E., Dyer, A.P. & Tufaro, F. (1998) Nat. Genet. 19, 158–161. 34. Lind, T., Tufaro, F., McCormick, C., Lindahl, U. & Lidholt, K. (1998) J. Biol. Chem. 273, 26265–8. 35. Bellaiche, Y., The, I. & Perrimon, N. (1998) Nature (London) 394, 85–88. 36. Kraulis, P.J. (1991) J. Appl. Crystallogr. 24, 946–950. 37. Nicholls, A., Sharp, K.A. & Honing, B. (1991) Proteins 11, 281–296.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11000
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation,” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. D. A. MATTHEWS*, P. S. DRAGOVICH, S. E. WEBBER, S. A. FUHRMAN, A. K. PATICK, L. S. ZALMAN, T. F. HENDRICKSON, R. A. LOVE, T. J. PRINS, J. T. MARAKOVITS, R. ZHOU, J. TIKHE, C. E. FORD, J. W. MEADOR, R. A. FERRE, E. L. BROWN, S. L. BINFORD, M. A. BROTHERS, D. M. DELISLE, AND S. T. WORLAND Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, CA 92121 ABSTRACT Human rhinoviruses, the most important etiologic agents of the common cold, are messenger-active singlestranded monocistronic RNA viruses that have evolved a highly complex cascade of proteolytic processing events to control viral gene expression and replication. Most maturation cleavages within the precursor polyprotein are mediated by rhinovirus 3C protease (or its immediate precursor, 3CD), a cysteine protease with a trypsin-like polypeptide fold. High-resolution crystal structures of the enzyme from three viral serotypes have been used for the design and elaboration of 3C protease inhibitors representing different structural and chemical classes. Inhibitors having α,β-unsaturated carbonyl groups combined with peptidyl-binding elements specific for 3C protease undergo a Michael reaction mediated by nucleophilic addition of the enzyme’s catalytic Cys-147, resulting in covalent-bond formation and irreversible inactivation of the viral protease. Direct inhibition of 3C proteolytic activity in virally infected cells treated with these compounds can be inferred from dose-dependent accumulations of viral precursor polyproteins as determined by SDS/PAGE analysis of radiolabeled proteins. Cocrystalstructure-assisted optimization of 3C-protease-directed Michael acceptors has yielded molecules having extremely rapid in vitro inactivation of the viral protease, potent antiviral activity against multiple rhinovirus serotypes and low cellular toxicity. Recently, one compound in this series, AG7088, has entered clinical trials. Picornaviruses are small nonenveloped RNA viruses with a single strand of messenger-active genomic RNA 7,500–8,000 nucleotides in length, which is replicated in the cytoplasm of infected cells. The family currently is divided into six genera with similar genetic organization and translational strategies. Among its members are several important human and veter-inary pathogens, including poliovirus and coxsackievirus (Enterovirus), foot-and-mouth disease virus (Aphthovirus), encephalomyocarditis virus (Cardiovirus), hepatitis A virus (Hepatovirus), and human rhinoviruses (Rhinovirus). As a consequence of limitations imposed by a small monocistronic RNA viral genome, picornaviruses depend on a strategy for temporal gene expression that includes highly controlled cotranslational and posttranslational processing of a precursor polyprotein by virally encoded proteases to generate the individual structural and nonstructural proteins needed for viral replication. While still in the process of synthesis, the polyprotein is cleaved proteolytically by the virally encoded 2A protease to release P1, the precursor to capsid proteins, from P2–P3. Subsequent processing of P1 to 1AB, 1C, and 1D and all P2 and P3 processing to release proteins needed for RNA replication depend on viral 3C protease activity (1–3). In addition to its role in polyprotein processing, picornavirus 3C sequences are involved in proteolytic degradation of specific cellular proteins associated with host-cell transcription and in direct binding to viral RNA as part of a replication complex required for synthesis of plus-strand viral RNA (4–7). Rhinoviruses are primary causative agents of the common cold. Whereas these infections are usually mild and self-limiting, consequences can be more severe for the elderly, for immune-compromised individuals, and for those predisposed to respiratory illness such as asthma (8). In the case of picornaviruses with limited serotypic diversity, such as poliovirus, foot-and-mouth disease virus, and hepatitis A virus, highly protective vaccines have been developed that are in use worldwide. On the other hand, developing effective immunizations against rhinovirus infections or against the pathogenic nonpolio enteroviruses is anticipated to be more challenging, owing to the large number of existing serotypes: at least 100 rhinoviruses and 65 enteroviruses. In an attempt to address this need, we have undertaken a program directed at discovering rhinovirus 3C protease inhibitors with antiviral activity against the spectrum of known rhinovirus serotypes. The results of these efforts and the identification of an antirhinoviral compound now entering clinical trials are described below.
Picornaviral 3C Proteases Picornaviral 3C proteases are small monomeric proteins with molecular masses around 20 kDa. Crystal structures exist for 3C proteases from type 14 human rhinovirus (9), hepatitis A (10), and poliovirus (11). Viral 3C proteases fold into two topologically equivalent six-stranded β-barrels with an extended shallow groove for substrate binding located between the two domains. In rhinovirus 3C protease, the catalytically important residues Cys-147, His-40, and Glu-71 form a linked cluster of amino acids with an overall geometry similar to the Ser-His-Asp catalytic triad found in the trypsin-like family of serine proteases. The highly conserved sequence Gly-X-Cys-Gly-Gly in viral 3C proteases serves to position Cys-147 for nucleophilic attack on the substrate’s carbonyl carbon and to orient backbone NH groups of Gly-145 and Cys-147 to form an “oxyanion hole” for stabilization of a tetrahedral transition state (9). Thus, the catalytic machinery for activation of the
*To whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviation: CBZ, benzyloxycarbonyl. Data deposition: The atomic coordinates have been deposited in the Protein Data Bank, www.rcsb.org (PDB code 1CQQ).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11001
attacking nucleophile and stabilization of a tetrahedral intermediate-transition state in 3C proteases closely resembles that of trypsinlike serine proteases, suggesting that the viral 3C proteases are related mechanistically to serine proteases rather than to the papain-like cysteine proteases. Picornaviral 3C proteases process a limited number of cleavage sites in the virally encoded polyprotein. Most cleavages occur between Gln-Gly peptide bonds with distinct differences in the efficiency of cleavage at various junction sites. Recombinant rhinovirus 3C protease has an absolute requirement for Gln-Gly cleavage junctions in peptide substrates ranging from 7 to 11 aa in length (12).
Inhibitors of 3C Protease and the Issue of Serotypic Diversity Among Rhinoviruses Picornaviral 3C proteases represent a unique class of enzymes that integrate characteristics of both serine and cysteine proteases with an unusual specificity for Gln-Gly cleavage junctions. The absence of known cellular homologues contributes to interest in 3C protease as a potentially important target for antiviral drug design. However, the vast serotypic diversity among rhinoviruses raises the question of whether or not a single agent can effectively target 3C proteases from the 100 or so rhinovirus serotypes capable of infecting humans. Primary sequence data are available for 3C proteases from 10 different rhinovirus serotypes, including the type 2 and type 14 enzymes that have less than 50% amino acid identity. To address these diversity concerns before initiating a concerted drug-discovery effort, we undertook a program to obtain structural information on peptide-based inhibitors bound to 3C proteases from multiple rhinovirus serotypes. We wanted to identify the geometric and electronic factors that modulate protein/substrate (inhibitor) recognition, the extent to which specific residues that form the substrate (inhibitor) binding site of 3C protease are conserved across rhinovirus serotypes, and whether or not these binding-site residues are arranged similarly in 3C proteases from different virus serotypes. Peptide Aldehydes Bound to Serotype 2 Rhinovirus 3C Protease. Peptide aldehydes have been used extensively as inhibitors of serine and cysteine proteases, although they typically have not proven effective as drug candidates because of their poor pharmacological properties. They bind as reversible adducts in which the nucleophilic cysteine or serine makes a covalent bond with the carbonyl carbon of the aldehyde, forming a stable tetrahedral species. Short peptidic aldehydes having sequences similar to canonical 3C protease cleavage sites have been reported as inhibitors of both rhinovirus and hepatitis A viral proteases (13–15). The combination of glutamine at P1 with aldehyde functionality causes cyclization on the aldehyde. (16). To circumvent this problem, replacements for the γ-carboxamide were sought that prevent internal cyclization but retain high affinity for the 3C protease S1 specificity pocket (15). Compound I (Fig. 1) is an N-terminal protected tripeptide aldehyde in which the -CH2C(O)NH2 of Gln is replaced with an N-acetyl isostere. Compound I is a 6-nM inhibitor of type 14 human rhinovirus 3C protease. Whereas the original xray structural studies of rhinovirus 3C protease were performed by using the serotype 14 enzyme (9), subsequent analysis of inhibitor binding was carried out mainly with type 2 3C protease, both because of the relative ease in obtaining cocrystals and their generally superior diffraction properties. Fig. 2 shows the 2.2-Å x-ray structure of compound I complexed with serotype 2 rhinovirus 3C protease (15). The peptide aldehyde I binds to rhinovirus 3C protease in a partially extended conformation with inhibitor backbone atoms aligned for antiparallel β-sheet-type hydrogen bonding with an exposed β-strand (βE2) of the protein comprising residues 162–165. The inhibitor’s P1 side chain lies in a shallow pocket bounded by βE2, by residues 142–144, and by His-161, the last of which donates a hydrogen bond to the N-acetyl oxygen. This oxygen accepts a second hydrogen bond from the side-chain hydroxyl of Thr-142. The inhibitor’s acetyl methyl group is close to the backbone carbonyl of Thr-142 (3.3 Å), suggesting that substrates or inhibitors having a similarly positioned P1 glutamine-like side chain could form a third hydrogen bond to enhance specific recognition of a γ-carboxamide group.
FIG. 1. Rhinovirus 3C protease inhibitors. Ki, inhibition constant; kobs, observed rate of inactivation; I, inhibitor concentration. The P1 backbone amide makes a weak (3.2-Å) hydrogen bond with the carbonyl oxygen of Val-162. The deep S2 pocket easily accommodates the inhibitor’s bulky P2 Phe side chain, which is bounded on one side by the side chain of His-40 and on the other side by residues 127–130. Two ordered water molecules reside at the back of the S2 pocket. The side-chain hydroxyl and backbone NH of Ser-128 form hydrogen bonds with the inhibitor’s P2 NH and the carbonyl oxygen of the terminal benzyloxycarbonyl (CBZ) group, respectively. Two main-chain hydrogen bonds tether the inhibitor’s P3 Leu to backbone atoms of Gly-164, whereas the isobutyl side chain is mostly solvent-exposed. The benzyl portion of the CBZ group packs into a shallow hydrophobic pocket that probably accommodates a substrate’s P4 side chain. The side chain of Asn-165 is positioned directly above the benzene of CBZ, with its carboxamide NH pointing into the face of the aromatic ring, suggesting that some additional binding energy probably derives from this favorable amino-aromatic interaction (17). The affinity of peptide aldehyde inhibitors for trypsin-like serine proteases has been attributed to their ability to form, with the active-site serine, hemiacetals that resemble the transition state in amide hydrolysis, with the oxyanion stabilized in a structurally conserved oxyanion hole. Considering the structural homology between 3C protease and trypsin-like serine proteases, we anticipated that the tetrahedral hemithioacetal oxygen of compound I when bound to 3C would be positioned similarly within the oxyanion hole. Indeed, we showed previously that 2,3-dioxindole inhibitors (see Fig. 1, compound II) form stable tetrahedral adducts with 3C pro-
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11002
tease in which the O3 oxygen is stabilized in just this manner (18). However, compound I binds in a non-transition-state conformation with the oxygen of the hemithioacetal stabilized by hydrogen bonding to Nε2 of His-40.
FIG. 2. Compound I bound to serotype 2 human rhinovirus 3C protease. The protein is rendered as a semitransparent solventaccessible surface with associated protein backbone and side-chain atoms colored pink. Catalytic triad residues are blue. Red spheres represent ordered solvent molecules. Inhibitor atoms are colored green for carbon, blue for nitrogen, and red for oxygen. The inhibitor carbon covalently bonded to Cys-147 is highlighted in light green. Compared with 3C protease complexes with 2,3-dioxindole inhibitors, the complex with compound I also differs in the main-chain conformation for protein residues 144–145. The peptide linkage joining Ser-144 and Gly-145 flips around so that NH (residue 145), instead of pointing into the oxyanion hole, is directed out toward solvent where it hydrogen bonds with an ordered water molecule. This structure suggests that, for 3C, optimum alignment of NH dipoles to form a classically configured oxyanion hole analogous to that seen in trypsin-like serine proteases may not occur in the native protein but rather requires a conformational change induced by substrate (or inhibitor) binding. The Extended Substrate (Inhibitor) Binding Site for Rhinovirus 3C Protease Is Highly Conserved Among Different Viral Serotypes. High-resolution x-ray crystal structures for serotype 2 and serotype 16 3C proteases (overall amino acid sequence identity of 80%) bound to various peptide-based aldehyde inhibitors reveal that the two respective active sites are nearly identical (D.A.M., unpublished results). Not only do protein backbone atoms superpose within experimental error (<0.3 Å), but amino acid side chains interacting with peptide aldehyde inhibitors are identically conserved and oriented similarly in the complexes, except at position 130. Even for the more distantly related rhinovirus serotypes, there is a high level of amino acid identity for 3C protease residues that modulate binding of peptide aldehyde inhibitors such as compound I. There are 21 residues in serotype 2 3C protease that interact directly with the bound inhibitor. Of these, 17 are identically conserved in the 10 3C proteases of known sequence from different rhinovirus serotypes. For three of the nonconserved residues (residues 126, 144, and 146), interactions with the bound inhibitor are modulated by peptide backbone atoms only, suggesting that side-chain variation at these positions may not affect inhibitor binding significantly. Only in the case of residue 130 is there a nonconserved amino acid with a side chain directly contacting compound I. Residue 130 is either Asn or Thr in the 10 known rhinovirus 3C protease sequences. In the type 2 enzyme, Asn-130 is positioned at the back of the S2 specificity pocket where its side chain is in van der Waals contact with the inhibitor’s P2 benzyl group (Fig. 2). Nearby, but not directly contacting the P2 Phe, is a second nonconserved residue at position 69 (Lys or Asn, depending on serotype) that hydrogen bonds to ordered water molecules at the back of the S2 pocket. In summary, the available crystallographic and amino acid sequence data suggest that inhibitors of rhinovirus 3C protease could be expected to show efficacy against the enzyme from multiple viral serotypes provided they do not depend on binding determinants at the back of the S2 specificity pocket where structural variability between serotypes may be most pronounced. Strategies for Rhinovirus 3C Protease Inhibitor Design. Several considerations come into play when developing strategies for design of therapeutically efficacious serine and cysteine protease inhibitors. For many of. these proteins, specificity pockets for substrate (or inhibitor) recognition are shallow, and binding determinants are widely dispersed over
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11003
large surface areas. Difficulties inherent in discovering small molecules with high affinity for such binding sites are in many respects analogous to those encountered in attempting to disrupt protein-protein interactions with small effector molecules. Serine proteases such as factor Xa and thrombin, proteins involved in the blood-coagulation pathway with deep well defined S1 specificity pockets, have been targeted effectively with structurally diverse, small, noncovalent inhibitors and thus are exceptions to this generalization (19). However, for virally encoded serine and cysteine proteases of known structure, such as the herpes family of serine proteases, hepatitis C NS3 protease, and picornavirus 3C proteases, the fact that substrate recognition is modulated by extensive protein-protein interactions represents a significant impediment for design of specific inhibitors. We know that inhibitor potency can be enhanced by taking advantage of the possibility for covalent adduct formation afforded by the presence of a reactive serine or cysteine at the active sites of these proteases. In the case of 3C, these effects are dramatic. Whereas compound I has a Ki of 6 nM against the serotype 14 enzyme, reduction of the aldehyde functionality to the corresponding alcohol yields a molecule with no measurable inhibition at concentrations as high as 100 µM (15). An optimized 9-aa substrate for 3C has a Km of only 400 µM, showing weak binding to this protease even for relatively large peptide substrates (12). Not surprisingly, in light of these results, we have had little success identifying small noncovalent inhibitors of 3C protease. The alternative approach of incorporating specific noncovalent recognition plus an electrophile that can react covalently with the active site nucleophile is conceptually attractive. However, potency and the inherent chemical reactivity of the electrophilic center are usually correlated. Highly reactive electrophiles are likely to target nonselectively other cellular proteins and nonenzymatic biological nucleophiles, such as glutathione, rendering such agents unacceptable as drug candidates. In earlier work, we reported on the design of potent reversible 3C protease inhibitors based on a 2,3-dioxindole (isatin) core (18). When elaborated with substituents providing recognition in the S1 and S2 specificity pockets of 3C protease, inhibitors with low nanomolar Ki were obtained. An x-ray cocrystal structure of compound II revealed covalent attachment of Cys-147 to the electrophilic center (C2) with the carboxamide and benzothiophene groups positioned as expected in the S1 and S2 pockets (18). Unfortunately, all isatin inhibitors tested were devoid of antiviral activity and/or were toxic, properties most probably attributable to their high electrophilic reactivity. These findings led us to consider other types of covalent inhibitors where the chemical reactivity of the electrophilic center can be more effectively modulated in the context of molecules having high specificity for 3C protease.
Irreversible Michael Acceptors as Inhibitors of 3C Protease Peptidic substrates in which the scissile amide carbonyl is replaced by a Michael acceptor were first introduced as specific irreversible inhibitors of the cysteine protease papain by Hanzlik and coworkers (20, 21). We reasoned that, although this reaction is probably facilitated by the especially nucleophilic thiolateimidazolium ion pair in papain-like cysteine proteases, suitably activated Michael acceptors might also undergo addition by the presumably less nucleophilic catalytic cysteine of 3C. A trans-α, β-unsaturated ethyl ester incorporated into a CBZ protected tripeptide corresponding to the N-terminal portion of a canonical 3C protease cleavage sequence (Fig. 1, compound III) afforded a compound with relatively potent irreversible inhibition of 3C (22). The compound had moderate antiviral activity in HeLa cells infected with rhinovirus serotype 14, was nontoxic to the limit of its solubility, and was not inactivated by short exposure to DTT. These results encouraged us to initiate additional studies of Michael acceptors to enhance their activity against 3C protease further. Fig. 3 shows the 2.3-Å x-ray structure of compound III bound to serotype 2 3C protease. The peptidic portion of the molecule closely resembles that of the aldehyde I and binds similarly to the enzyme active site (24). Unlike compound I, the P1 side chain of compound III is identical to that for Gln, the P1 residue in the vast majority of 3C cleavage sequences. The carboxamide oxygen accepts hydrogen bonds from the side chains of His-161 and Thr-142, and the amide nitrogen donates hydrogen bonds to the backbone carbonyl oxygen of Thr-142 and to an ordered water molecule. Thus, all possible hydrogen bonding interactions for a Gln side chain are fully satisfied within the complimentary S1 binding site. The geometrical specificity conferred by these highly directional hydrogen bonds is important in orienting the inhibitor’s vinyl group (or in the case of a substrate, the susceptible carbonyl carbon) for nucleophilic attack by Cys-147. Cys-147 is covalently linked to the inhibitor’s electrophilic β-carbon with the carbonyl oxygen of the ethyl ester positioned above the oxyanion hole, where it makes a hydrogen bond to the backbone amide of Cys-147. As observed for aldehyde inhibitors bound to 3C protease, the 144–145 peptide linkage has the backbone amide pointing away from the oxyanion hole, although low occupancy (20%) of the other conformer having NH (residue 145) directed toward the oxyanion hole is seen in this and several other P1 Gln-containing Michael acceptors for which we have obtained high-resolution x-ray cocrystal structures. The ethyl ester portion of the Michael acceptor extends into the leaving group side of the protease active site formed by residues 22–25 and by the tight loop connecting β-strands βA2 and βB2. The leaving group pocket is of sufficient size to accommodate the ethyl ester group easily in an extended low-energy Z conformation. As noted previously, the stretch of amino acids 142–146 immediately N-terminal to the catalytic cysteine is important in 3C proteases for both substrate recognition and stabilization of the tetrahedral intermediate-transition state. In the absence of bound ligands, the corresponding residues in rhinovirus, poliovirus, and hepatitis A 3C proteases exist in multiple conformations and/or are highly mobile, as evidenced by average temperature factors of 50–60 Å2. In rhinovirus 3C protease cocrystal structures with inhibitors having Gln-like side chains, the segment 142–146 adopts a well defined conformation (except for the 144–145 peptide linkage, which has either of two conformations) with temperature factors below the average for the remainder of the protein. Thus, Gln side-chain recognition in the S1 pocket is tightly coupled with a disorder-to-order transition in a crucial region of the protein involved in transitionstate stabilization. The available crystallographic evidence suggests that peptides lacking Gln-like functionality at P1 are unable to select the catalytically relevant conformation for the protein segment 142–146 from an ensemble of accessible states, providing a structural explanation for the observation that proteolysis of short 7- to 11-aa peptides by 3C protease has an absolute requirement for Gln at the P1 position (12). This observation also underscores the probable importance of P1 Gln functionality in mechanism-based activation of Michael acceptors as inhibitors of 3C protease. Covalent irreversible inactivation of 3C by Michael acceptors proceeds according to a kinetic mechanism that can be broken down into two parts (Scheme 1).
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11004
FIG. 3. Compound III bound to serotype 2 human rhinovirus 3C protease. Color coding is the same as in Fig. 2. The inhibitor initially forms a reversible encounter complex with 3C, which can then undergo a chemical step (nucleophilic attack by Cys-147) leading to stable covalent-bond formation. The observed second-order rate constant for inactivation (kobs/I) depends on both the equilibrium binding constant k2/k1 and the chemical rate for covalent bond formation k3 (23). We anticipated that Michaelacceptor inhibitors with specificity for 3C protease would likely achieve high rates of enzyme inactivation by combining good equilibrium binding with a modest rate of covalent-bond formation. The rate of chemical inactivation presumably depends on not only the intrinsic electrophilic character of the inhibitor, but on how the reactive vinyl group is oriented in the active site relative to Cys-147 before nucleophilic attack and on the extent to which the transition state for the reaction can be stabilized by the enzyme. Mechanismbased activation of an inherently weak Michael acceptor as a means of increasing the rate of the chemical step, and thus kobs/I, is conceptually more attractive than attempting to achieve a similar effect by simply increasing intrinsic electrophilic reactivity, which would likely impart undesirable properties to such compounds. Within this conceptual framework, we experimented first with the effect of varying the Michael-acceptor electron-withdrawing group and then, for a subset of electrophiles with suitable antiviral and toxicity profiles, proceeded to a second level of optimization involving the 3C protease recognition portion of compound III.
Michael-Acceptor Inhibitors of 3C Protease: Structure-Activity Studies Variation of the Michael Acceptor. Recently, an extensive structure-activity study exploring modification of the Michaelacceptor portion of compound III has been published (24). The results can be summarized as follows. (i) A series of ester-derived Michael acceptors with substituted alcohol groupsallshowed good inhibitory activity with kobs/I values of 3,000 to 40,000 M–1.s–1. The benzyl ester had higher anti-3C protease activity than the parent compound (kobs/I=39,400 compared with 25,000 M–1.s–1 for compound III) but performed worse in the antiviral assay (EC50=3.2 vs. 0.54 µM for compound III). cis-α,β-Unsaturated esters or trans-α,βunsaturated esters substituted at the α-position had reduced activity compared with the benchmark compound III. (ii) Amide-containing Michael acceptors in general had reduced activity against 3C protease, poorer antiviral activity, and/or increased toxicity compared with the corresponding esters. (iii) Aliphatic and aryl α,β-unsaturated ketones were extremely potent anti-3C protease agents with kobs/I values between 120,000 and 500,000 M–1.s–1. However, these molecules had reduced antiviral activity (EC50 > 2 µM) and were toxic to cells. The ketones were also inactivated by short exposure to DTT, consistent with their expected high electrophilicity. (iv) Vinyl sulfones, nitriles, phosphonates, oximes, and several vinyl heterocycles had weak (kobs/I < 600 M–1.s–1) or no detectable inhibitory activity, (v) Michael acceptors with acyl lactam, acyl oxazolidinone, and acyl urea functionalities were potent 3C protease inhibitors but, like the corresponding ketones, were inactivated by exposure to nonenzymatic thiols. As a consequence of their good inhibitory activity against 3C protease, their encouraging antiviral activity, stability in the presence of nonenzymatic thiols, low cellular toxicity, and ease of synthesis, trans-α,β-unsaturated esters emerged as the Michael acceptors of choice with which to initiate the process of optimizing the peptidic portion of compound III.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11005
Variation of 3C Protease Recognition Elements. Analogs of compound III truncated after the P1 Gin or after the P2 Phe were poor 3C protease inhibitors with kobs/I values of 4.5 and 400 M–1.s–1, respectively. Therefore, structure-activity studies were conducted with tripeptide-derived molecules (24). Substitutions at P1. Michael acceptors incorporating any variation in the γ-carboxamide portion of the P1 side chain had weak or no 3C protease inhibitory activity. Inclusion of various heteroatoms in the aliphatic portion of the glutamine side chain also reduced activity compared with the benchmark molecule III (24). As described above, the serotype 2 3C protease cocrystal structure with compound III indicates that the P1 side-chain cis-NH is exposed to solvent. Selective alkylation of the amide was viewed as a means of reducing inhibitor peptide character without compromising binding. We enforced cis-amide geometry by incorporating a P1 lactam moiety into the inhibitor design. Based on modeling, we predicted that (S) stereochemistry would be required at the lactam α-carbon to position correctly lactam side-chain hydrogen bonding functionality, which is essential for recognition and binding in the S1 pocket. The resulting molecule was 10-fold more potent than compound III against type 14 3C protease and more than 5-fold better as an antiviral agent in cell culture (25). Substitutions at P2. Replacement of the P2 benzyl side chain generally leads to reduced inhibitory properties. Smaller aliphatic side chains having fewer van der Waals contacts with the large S2 specificity pocket are particularly poor inhibitors. In the case of type 14 3C protease, additional functionality at the 4-position can lead to modestly higher kobs/I values; however, the same compounds when tested against 3C from other rhinovirus serotypes were often less inhibitory than compound III. The 4-fluoroPhe analog was moderately more potent than the parent compound in assays against 3C protease from serotypes 2, 14, and 16 (24). The P2 backbone amide of compound III donates a hydrogen bond to the side-chain oxygen of invariant Ser-128. Ser-128 is located in a turn on an exposed, somewhat flexible loop forming one side of the S2 specificity pocket (Fig. 3). Various 3C protease cocrystal structures indicate that this loop can undergo small (1.5-Å) inhibitor-specific conformational changes. We reasoned that replacement of the P2–P3 peptide bond with ketomethylene functionality would reduce the peptidic character of the resulting molecule, whereas loss of the exposed surface hydrogen bond might not impact inhibitory activity severely. The ketomethylene inhibitor showed slightly reduced 3C protease inhibition (17,400 M–1.s–1), compared with that of compound III, but had improved antiviral properties (26). Substitutions at P3. The leucine side chain of compound III is solvent exposed. As expected, a wide variety of functionality is tolerated at this position with minor effects on enzyme inhibitory activity (24). Substitutions at P4. Attempts to optimize the N-terminal (P4) functionality focused initially on modifications to the benzyl portion of the CBZ group to enhance binding in the hydrophobic S4 specificity pocket. We were also interested in exploring replacements for the carbamate oxygen atom adjacent to the benzyl group. The cocrystal structure of compound III with serotype 2 3C protease (Fig. 3) reveals that this inhibitor oxygen atom is positioned partially inside the S4 pocket with a gap between it and the side chain of Phe-170 (24). The thiocarbamate analog of CBZ had significantly increased inhibitory activity (kobs/I=280,000 M–1.s–1) and improved antiviral properties (EC50=0.27 µM). A 1.9-Å crystal structure of the thiocarbamate analog of compound III bound to serotype 2 3C protease indicated that the thiocarbamate sulfur atom lies 1.5 Å deeper in the S4 pocket than the corresponding oxygen of compound III and is in van der Waals contact with Phe-170 (24). Replacement of oxygen with the larger, more easily polarized, and more easily dehydrated S atom probably accounts for much of the increase in kobs/I by enhancing equilibrium binding of the inhibitor to 3C protease before covalent-bond formation. Concerns about possible metabolic instability of P4 thiocarbamate containing 3C protease inhibitors prompted a more systematic search for other N-terminal amides with improved activity compared with compound III. Tripeptidyl ethyl propenoate Michael acceptors of sequence Leu-Phe-Gln were assembled on solid supports. The N-terminal amine was coupled to a variety of carboxylic acids and acid chlorides to yield approximately 500 N-terminal protected tripeptide Michael acceptors. These compounds were screened subsequently against type 14 3C protease by using high-throughput assay techniques (27). Accordingly, the N-terminal 5methylisoxazole-3-carboxamide analog was identified as a potent 3C protease inhibitor (kobs/I=260,000 M–1.s–1) with improved antiviral activity (EC50=0.25 µM) compared with that of compound III.
AG7088, a 3C Protease Inhibitor with Potent Antiviral Activity Against Multiple Human Rhinovirus Serotypes For each position in the N-terminal protected tripeptide portion of compound III, modifications were identified that imparted increased activity against 3C protease and better antiviral properties compared with those of the parent molecule. We anticipated that by combining several of these individually beneficial modifications into a single molecule, further improvements in enzyme inhibition and antiviral activity could be achieved. Below, the inhibitory, antiviral, and enzyme-specificity properties of one such compound, AG7088, are described further. Activity Against Rhinovirus 3C Protease. The covalent structure of AG7088 is shown in Fig. 1. The compound has excellent activity against serotype 14 3C protease (kobs/I=1, 470,000 M–1.s–1) and is a potent antiviral agent with low toxicity in the HeLa cell assay (EC50=0.013 µM; toxic concentration, 50% > 100 µM; ref. 28). AG7088 is highly specific for picornavirus 3C proteases, having negligible inhibitory activity against a panel of mammalian cysteine and serine proteases, including cathepsin B, elastase, chymotrypsin, trypsin, thrombin, and calpain (25). Direct inhibition of rhinovirus 3C proteolytic activity in virally infected H1-HeLa cells treated with AG7088 can be inferred from dose-dependent accumulations of viral precursor proteins shown by SDS/PAGE analysis of radiolabeled polyproteins (28). A crystal structure of AG7088 bound to serotype 2 3C protease was determined at 1.85-Å resolution (Fig. 4). The overall binding mode of AG7088 to 3C protease is generally similar to that described for compound III; however, the structurally distinct N-terminal protecting groups are oriented differently in the protein’s S4 binding subsite. As anticipated, the fivemember lactam ring at P1 makes three hydrogen bonds with the protease similar to those for com-pound III. However, as a result of constraints imposed on the internal geometry of the lactam ring, the hydrogen bond between the lactam amide NH and the backbone carbonyl of Thr-142 is longer (3.2 Å) and the geometry less favorable than in the case of compound III, in which optimal positioning of the P1 carboxamide by rotation about the Cδ–Cγ bond is less hindered. Why then does replacement of the P1 Gin in compound III with a five-member lactam ring increase kobs/I against type 14 3C protease by almost a factor of 10? The relatively rigid lactam side chain at P1 stands to lose less conformational entropy on binding in the S1 pocket than the more flexible Gin and therefore probably binds tighter to 3C protease than its acyclic counterpart. Another favorable effect of binding on entropy may result from the manner in which the lactam affects the conformation of unbound AG7088 in solution. We have determined the small-molecule crystal structure
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11006
of AG7088 (T.L.Hendrixson, unpublished results) and find that its conformation is very similar to that observed for AG7088 in complex with 3C protease. In both cases, the two lactam (CH2) groups pack against the side chain of the P3 valine, which may help stabilize the active conformer in solution thus reducing entropy loss on inhibitor binding. The two lactam (CH2) groups also create additional van der Waals contacts with backbone atoms of residues 143 and 144, which, compared with a P1 Gln, may further reduce the flexibility and conformational heterogeneity that is observed for this region in the absence of bound inhibitors. Particularly noteworthy is that, for AG7088 bound to 3C protease, the peptide bond 144–145 has its NH pointing in toward the oxyanion hole where it may play a role in hydrogen bonding to the carbonyl oxygen of the Michael acceptor in the transition state for Michael addition. We have determined cocrystal structures for five P1 cyclic lactam-containing 3C protease inhibitors, and in each case, the 144–145 peptide is in what we believe to be the active conformation. In contrast, more that 20 cocrystal structures of P1 Gln-containing irreversible 3C protease inhibitors aII show this peptide bond turned around with the backbone NH group pointing out into solvent (see Fig. 3). These results suggest that the greater ability of a P1 lactam to stabilize the catalytically active conformation of residues Nterminal to the nucleophilic Cys-147 may accelerate the chemical step and thus contribute to the increase in kobs/I compared with P1 Gln-containing analogs.
FIG. 4. AG7088 bound to serotype 2 rhinovirus 3C protease. The protein is rendered as a semitransparent solvent-accessible surface color coded at each residue according to amino acid conservation among the 10 serotypically distinct rhinovirus β C proteases of known primary structure. Residues indicated in dark blue are identically conserved among the 10 known sequences. Increasing amino acid variation at a particular residue is indicated by progressively warmer coloring, with purple signifying two differences and red signifying seven differences among the 10 known 3C protease sequences. Other color coding is the same as in Fig. 2, except that the fluorine atom of AG7088 is purple. In compound III, the P2 backbone amide donates a hydrogen bond to the side-chain hydroxyl of Ser-128. As a consequence of replacing this group with a methylene moiety in AG7088, surface-exposed Ser-128 moves 0.7 Å where it can interact preferentially with bulk solvent. The isoxazole group of AG7088 is more buried in the S4 pocket than the CBZ of compound III and is oriented orthogonal to the CBZ benzene ring. The isoxazole oxygen is positioned close to the side chain of Phe-170, which moves on average about 0.6 Å compared with its position in the complex with compound III. Deeper penetration of this group into S4 also causes positional changes (0.8 Å) centered around the backbone and side-chain atoms of Asn-165 with somewhat smaller displacements for Gly-166 as well. One consequence of these induced protein movements is that the shape of the S1 pocket changes slightly, particularly in the region proximate to the P1 side-chain amide and its attached methylene, suggesting that alterations in the N-terminal blocking group can affect binding of the P1 substituent. Antiviral Activity of AG7088 Against Rhinovirus Serotypes. In H1-HeLa or MRC-5 cell protection assays, AG7088 inhibited replication of all 48 rhinovirus serotypes tested to date (28), including representative virus strains derived from minor and major receptor groups (29). The mean EC50 and EC90 values are 0.023 µM (range: 0.003–0.081 µM) and 0.082 µM (range: 0.018–0.261 µM), respectively (28). Pirodavir and pleconaril are antipicornaviral agents that bind to viral capsids, preventing receptor attachment and/or viral uncoating. Pirodavir inhibited the replication of 42 of 47 rhinovirus serotypes tested with a mean EC50 value of 0.32/µM (range: 0.003–4.770 µM), whereas pleconaril inhibited replication of 42 of 45
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
STRUCTURE-ASSISTED DESIGN OF MECHANISM-BASED IRREVERSIBLE INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE WITH POTENT ANTIVIRAL ACTIVITY AGAINST MULTIPLE RHINOVIRUS SEROTYPES
11007
serotypes tested with a mean EC50 value of 0.822 µM (range: 0.003–8.112 µM) (28). The 50% cytotoxic concentration of AG7088 is > 1,000 µM compared with 150 µM and 77 µM for pirodavir and pleconaril, respectively (28). These studies establish AG7088 as a highly potent, nontoxic antirhinoviral agent with broad efficacy against multiple virus serotypes. The compound has been formulated for intranasal delivery and has recently entered clinical trials. Experimental Crystal Structure of AG7088 Bound to Serotype 2 Rhinovirus 3C Protease. Serotype 2 human rhinovirus 3C protease was incubated with a 3-fold molar excess of AG7088 in the presence of 2% (vol/vol) DMSO for 24 h at 4°C. The complex was concentrated to 6.8 mg/ml and then passed through a 0.22-µm cellulose-acetate filter. Crystals were grown at 13°C by using a hanging-drop vapor-diffusion method in which equal volumes (3 µl) of the protein-ligand complex and reservoir solution were mixed on plastic coverslips and sealed over individual wells filled with 1 ml of reservoir solution containing 20% (vol/vol) polyethylene glycol (molecular weight 10,000) and 0.1 M Hepes (pH 7.5). A single crystal measuring 0.3×0.1×0.1 mm (space group P212121; a=34.32, b=65.68, c=77.89 Å) was prepared for lowtemperature data collection by transfer to an artificial mother liquor solution consisting of 400 µl of the reservoir solution mixed with 125 µl of glycerol and then flash frozen in a stream of N2 gas at –170°C. X-ray diffraction data were collected with a MAR Research 345-mm imaging plate and processed with DENZO. Diffraction data were 89.2% complete to a resolution of 1.85 Å with R(sym)=1.9%. Protein atomic coordinates from the cocrystal structure of type 2 3C protease with compound I (15) were used to initiate rigid-body refinement in X-PLOR followed by simulated annealing and conjugate gradient minimization protocols. Placement of the inhibitor, addition of ordered solvent, and further refinement proceeded as described in ref. 15. The final R factor was 21.8% [12,184 reflections with F > 2σ(F)]. The root-mean-square deviations from ideal bond lengths and angles were 0.016 Å and 2.9°, respectively. The final model consisted of all atoms for residues 1–180 (excluding the side chain of residues 12, 21, 45, and 65) plus 221 water molecules. 1. Kräusslich, H.G. & Wimmer, E. (1988) Annu. Rev. Biochem. 57, 701–754. 2. Kay, J. & Dunn, B.M. (1990) Biochem. Biophys. Acta 1048, 1–8. 3. Lawson, M.A. & Semler, B.L. (1990) Curr. Top. Microbiol. Immunol. 161, 49–87. 4. Roehl, H.H., Parsley, T.B., Ho, T.V. & Semler, B.L. (1997) J.Virol. 71, 578–585. 5. Leong, L.E.C., Walker, P.A. & Porter, A.G. (1993) J. Biol Chem. 268, 25735–25739. 6. Andino, R., Rieckhof, G.E., Achacoso, P.L. & Baltimore, D. (1993) EMBO J. 12, 3587–3598. 7. Xiang, W., Harris, K.S., Alexander, L. & Wimmer, E. (1995) J. Virol. 69, 3658–3667. 8. Sperber, S.J. & Hayden, F.G. (1988) Antimicrob. Agents Chemother. 32, 409–419. 9. Matthews, D.A., Smith, W.W., Ferre, R.A., Condon, B., Budahazi, G., Sisson, W., Villafranca, J.E., Janson, C.A., McElroy, H.E., Gribskov, C.L., et al. (1994) Cell 77, 761–771. 10. Allaire, M., Chernaia, M.M., Malcolm, B.A. & James, M.N.G. (1994) Nature (London) 369, 72–76. 11. Mosimann, S.C., Cherney, M.M., Sia, S., Plotch, S. & James, M.N.G. (1997) J. Mol. Biol. 273, 1032–1047. 12. Long, L.A, Orr, D.C., Cameron, J.M., Dunn, B.M. & Kay, J. (1989) FEBS Lett. 258, 75–78. 13. Malcolm, B.A, Lowe, C., Shechosky, S., Mckay, R.T., Yang, C.C., Shah, V.J., Simon, R.J., Vederas, J.C. & Santi, D.V. (1995) Biochemistry 34, 8172–8179. 14. Shepherd, T.A., Cox, G.A., McKinney, E., Tang, J., Wakulchik, M., Zimmerman, R.E. & Villarreal, E.C. (1996) Bioorg. Med. Chem. Lett. 6, 2893– 2896. 15. Webber, S.E., Okano, K., Little, T.L., Reich, S.H., Xin, Y., Fuhrman, S.A., Matthews, D.A., Love, R.A., Hendrickson, T.F., Patick, A.K., III, et al. (1998) J. Med. Chem. 41, 2786–2805. 16. Kaldor, S.W., Hammond, M., Dressman, B.A, Labus, J.M., Chadwell, F.W., Kline, A.D. & Heinz, B.A. (1995) Bioorg. Med. Chem. Lett. 5, 2021– 2026. 17. Burley, S.K. & Petsko, G.A. (1988) Adv. Protein Chem. 39, 125–153. 18. Webber, S.E., Tikhe, J., Worland, S.T., Fuhrman, S.A, Hendrickson, T.F., Matthews, D.A., Love, R.A., Patick, A.K., Meador, J.W., Ferre, R.A., et al. (1996) J. Med. Chem. 39, 5072–5082. 19. Sanderson, P.E.J. & Naylor-Olsen, A.M. (1998) Curr. Med. Chem. 5, 289–304. 20. Hanzlik, R.P. & Thompson, S.A. (1984) J. Med. Chem. 27, 711–712. 21. Liu, S. & Hanzlik, R.P. (1992) J. Med. Chem. 35, 1067–1075. 22. Dragovich, P.S., Webber, S.E., Babine, R.E., Fuhrman, S. A, Patick, A.K., Matthews, D.A., Lee, C.A., Reich, S.H., Prins, T.J. & Marakovits, J.T. (1998) J. Med. Chem. 41, 2806–2818. 23. Meara, J.P. & Rich, D.H. (1995) Bioorg. Med. Chem. Lett. 5, 2277–2282. 24. Dragovich, P.S., Webber, S.E., Babine, R.E., Fuhrman, S.A., Patick, A.K., Matthews, D.A., Reich, S.H., Marakovits, J.T., Prins, T.J. & Zhou, R. (1998) J. Med. Chem. 41, 2819–2834. 25. Dragovich, P.S., Webber, S.E., Babine, R.E., Fuhrman, S.A., Patick, A.K., Matthews, D.A, Reich, S.H., Marakovits, J.T., Prins, T.J. & Zhou, R. (1999) J. Med. Chem. 42, 1213–1224. 26. Dragovich, P.S., Prins, T.J., Zhou, R., Fuhrman, S.A., Patick, A.K., Matthews, D.A., Ford, C.E., Meador, J.W., Ferre, R.A. & Worland, S.T. (1999) J. Med. Chem. 42, 1203–1212. 27. Dragovich, P.S., Zhou, R., Skalitzky, D.J., Fuhrman, S.A., Patick, A.K., Ford, C.E., Meador, J.W. & Worland, S.T. (1999) Bioorg. Med. Chem. Lett. 7, 589–598. 28. Patick, A.K., Binford, S.L., Brothers, M.A., Jackson, R.L., Ford, C.E., Diem, M.D., Maldonado, F., Dragovich, P.S., Zhou, R., Prins, T.J., et al. (1999) Antimicrob. Agents Chemother, in press. 29. Uncapher, C.R., DeWitt, C.M. & Colonno, R.J. (1991) Virology 180, 814–817.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
KINETIC STABILITY AS A MECHANISM FOR PROTEASE LONGEVITY
11008
Kinetic stability as a mechanism for protease longevity
This paper was presented at the National Academy of Sciences colloquium “Proteolytic Processing and Physiological Regulation” held February 20–21, 1999, at the Arnold and Mabel Beckman Center in Irvine, CA. ERIN L. CUNNINGHAM, SHEILA S. JASWAL, JULIE L. SOHL*, AND DAVID A. AGARD† Graduate Group in Biophysics, Howard Hughes Medical Institute, and Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143–0448 ABSTRACT The folding of the extracellular serine protease, α-lytic protease (αLP; EC 3.4.21.12) reveals a novel mechanism for stability that appears to lead to a longer functional lifetime for the protease. For αLP, stability is based not on thermodynamics, but on kinetics. Whereas this has required the coevolution of a pro region to facilitate folding, the result has been the optimization of native-state properties independent of their consequences on thermodynamic stability. Structural and mutational data lead to a model for catalysis of folding in which the pro region binds to a conserved β-hairpin in the αLP Cterminal domain, stabilizing the folding transition state and the native state. The pro region is then proteolytically degraded, leaving the active αLP trapped in a metastable conformation. This metastability appears to be a consequence of pressure to evolve properties of the native state, including a large, highly cooperative barrier to unfolding, and extreme rigidity, that reduce susceptibility to proteolytic degradation. In a test of survival under highly proteolytic conditions, homologous mammalian proteases that have not evolved kinetic stability are much more rapidly degraded than αLP. Kinetic stability as a means to longevity is likely to be a mechanism conserved among the majority of extracellular bacterial pro-proteases and may emerge as a general strategy for intracellular eukaryotic proteases subject to harsh conditions as well. Virtually all extracellular bacterial proteases are synthesized as precursor molecules with pro regions. In every case where the function of the pro region has been investigated, it has been found to be necessary for folding and secretion (1). One of the most striking and best studied examples of pro-mediated folding is the bacterial enzyme, α-lytic protease (αLP). αLP (EC 3.4.21.12) is a 198aa serine protease secreted by the Gram-negative soil bacterium Lysobacter enzymogenes to degrade other soil microorganisms. The overall three-dimensional fold of αLP clearly places it in the same family as the mammalian digestive serine proteases chymotrypsin, trypsin, and elastase, despite only moderate sequence homology (2). In contrast to these mammalian homologues, whose small Nterminal zymogen peptides simply prevent premature activation, αLP is synthesized with a large 166-aa N-terminal pro region (Pro) that is required for proper folding of its mature protease domain (3). In vivo, coexpression of αLP and Pro, either in cis as the natural precursor molecule or in trans as two separate polypeptide chains results in the secretion of active αLP (4), whereas expression of αLP alone leads to accumulation of the protease in the outer membrane because of apparent misfolding. In vitro energetic studies reveal a novel means of stability for the mature protease arising from kinetics. This not only distinguishes αLP from its mammalian homologues but provides compelling support for the possibility of metastable native conformations in general. Emerging structural and energetic details of pro-mediated folding may define a theme for the folding of a wide range of homologous extracellular proteases that also contain pro regions. In addition, features of αLP’s kinetic barrier may provide insight into other proteins with metastable conformations of biological importance. Here we describe the role of kinetic stability in αLP folding, details of pro-αLP interactions and a possible mechanism and an evolutionary rationale for pro-mediated folding of αLP. Folding Under Kinetic Control. To understand the requirement of the pro region for folding, the folding free-energy landscape of αLP has been mapped in the absence of the pro region through refolding and unfolding experiments. In vitro refolding of chemically denatured αLP in the absence of Pro, by dilution from denaturant, results in an inactive molten globule-like intermediate (5). Designated the “I” state of the protease, this intermediate is monomeric and greatly expanded relative to the native state “N.” Spectroscopic data indicate that I possesses substantial secondary structure but lacks stable tertiary interactions. Urea-denaturation experiments show that I has <1 kcal/mol (1 cal=4.18 J) stability over the unfolded state “U” (6). Under physiological conditions, the αLP I state remains stable for months without any appreciable conversion to mature enzyme. The very small fraction of I that does mature to the active N state can be measured by using a very sensitive enzymatic assay. From this assay, it has been determined that the I state refolds with an extremely slow initial rate of 1.18×10–11 s–1 at 4°C (t1/2=1,800 years), corresponding to a folding barrier height of 30 kcal/mol, as calculated by transition state theory (Fig. 1; ref. 6). This remarkably high barrier prevents the intermediate and native states from being in equilibrium with each other. Therefore, to determine the relative stability of these conformations, it is necessary to compare the ratio of the folding and unfolding rates instead of using the usual equilibrium approaches. To measure the unfolding rate on a reasonable time scale, the N state must be chemically or thermally denatured. To avoid complications of autolysis when studying the rates of αLP unfolding, the active-site serine has been mutated to alanine (S195 → A; chymotrypsin homology numbering from ref. 7). During unfolding, both secondary and tertiary structure (monitored via CD and tryptophan fluorescence, respectively) are lost simultaneously in a single rate-limiting step (6). Extrapolating the data to zero denaturant gives an unfolding rate of 1.8×10–8 s–1 at 4°C or an unfolding barrier of 26 kcal/mol (t1/2=1.2 years). The ratio of this unfolding rate to the slower folding rate results in an equilibrium free energy that favors the I state by 4 kcal/ mol. Over a broad range of temperatures, the I state of αLP, not the N state, is at the
*Present address: Department of Molecular and Cellular Biology, University of California, Berkeley, CA 94720. †To whom reprint requests should be addressed. E-mail:
[email protected]. PNAS is available online at www.pnas.org. Abbreviation: αLP, α-lytic protease.
About this PDF file: This new digital representation of the original work has been recomposed from XML files created from the original paper book, not from the original typesetting files. Page breaks are true to the original; line lengths, word breaks, heading styles, and other typesetting-specific formatting, however, cannot be retained, and some typographic errors may have been accidentally inserted. Please use the print version of this publication as the authoritative version for attribution.
KINETIC STABILITY AS A MECHANISM FOR PROTEASE LONGEVITY
11009
minimum free energy. In fact, because of the marginal stability of I, the N state is actually significantly less thermodynamically stable than either the I or U states.
FIG. 1. Free-energy diagram of αLP folding with and without its pro region at 4°C. In the absence its pro region (P), unfolded αLP (U) spontaneously folds to a molten globule-like intermediate (I), which proceeds at an extremely slow rate to N through a high-energy folding TS. The addition of pro region provides a catalyzed folding pathway (denoted by dashed lines) that lowers the high folding barrier and results in a thermodynamically stable inhibition complex N-P. * indicates measurement at 25°C. (Modified from ref. 6.) To surmount the high barrier to folding and the extraordinary thermodynamic instability of the native state, αLP has coevolved the pro region, which can assist the folding of αLP when supplied in cis or in trans. Addition of Pro to I results in rapid folding to the N state (0.037 s–1) and recovery of functional protease (Fig. 1; ref. 6). Pro acts as a foldase, facilitating αLP folding by binding tightly to the folding transition state of the protease, lowering the barrier by 18.2 kcal/mol. In this manner, Pro serves as a potent catalyst, increasing the rate of αLP folding by 3×109. In addition, Pro is the tightest binding inhibitor known for the native protease (Ki=3×10–10 M; refs. 8 and 9), making Pro a single-turnover catalyst. This tight binding serves a critical function in αLP folding by shifting the thermodynamic equilibrium in favor of folded αLP (Pro·N is 3.4 kcal/mol more stable than Pro-I; Fig. 1). The product of the folding reaction is not active αLP but the inhibitory complex. Release of active αLP requires that the Pro region be removed by proteolysis. Once Pro is degraded, the active protease becomes kinetically trapped in the metastable N state, with the high barrier preventing unfolding to the more thermodynamically favored unfolded states. In this way, promediated folding provides the only efficient means of folding αLP to its metastable native conformation.
FIG. 2. (a) Topology of Pro as described in the text. A disordered loop in the Pro C domain is shown in red. (b) Schematic of primary sequence alignments of pro regions from nine